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Pain is a universal and costly medical health problem. It is estimated that approximately one in 
ten individuals develop chronic pain each year. Chronic pain is among the top 10 complaints 
for which individuals seek help from primary care health professionals. In spite of its 
prevalence, doctors report a lack of confidence in managing chronic painful conditions. 
Moreover, the use of opioids for non-malignant chronic pain has increased recently and has 
become more regulated. Not surprisingly there is a high demand for alternative treatment 
options for managing chronic pain. 
Chronic nonspecific musculoskeletal pain (CNMP) is a type of chronic pain, marked by the 
absence of a clear patho-physiological or anatomical origin. CNMP causes major disruption to 
patients’ lives, relationships, and functionality. A rising prevalence of CNMP is observed in 
the general population but especially in children and adolescents. A diagnosis of CNMP early 
in life is recognized as a predictor for disability later. The limited information on its etiology, 
diagnosis and management perplexes doctors and patients alike. 
There is a growing body of evidence that suggests vitamin D deficiency may play an important 
role in the etiology of CNMP. The discovery of vitamin D receptors in most tissues and cells 
in the human body and the identification of non-classical functions support the potential 
involvement of vitamin D in multiple chronic painful conditions including CNMP. In addition, 
vitamin D deficiency, by itself, is also reported as a major public health concern. Therefore 
because vitamin D supplementation is cheap and safe, it is increasingly being used as a 




The management of CNMP, its perceived relationship with vitamin D deficiency and advice 
about using vitamin D supplementation by GPs has not been described previously.  Nor do we 
know if supplementing vitamin D deficiency might improve symptomatology for patients with 
CNMP. In addition, very little is known about patient’s perspectives, beliefs and views of their 
chronic pain management, especially in relation to vitamin D testing and supplementation, pain 
education and the patient-provider relationship. Patient perspectives are fundamental for  
identifying areas of management which require improvement to achieve better treatment 
outcomes.  
AIM 
The overall aims of this thesis is to provide evidence about, 
1. The diagnosis and management of CNMP in Australian general practice and the role, if 
any, of vitamin D deficiency and supplementation in its etiology and treatment respectively. 
2. The perspectives of patients with chronic pain about their medical management, 
investigations and vitamin D supplementation.  
The research objectives are: 
Objective 1- What management strategies do GPs employ with patients presenting with 
CNMP? 
Objective 2- How effective is vitamin D supplementation in the management of CNMP? 
Objective 3- What demographic and pain-related factors are associated with; testing for vitamin 




Objective 4- What perspectives do patients with chronic pain have about the patient-provider 
relationship, pain education and does it affect their pain intensity and perceived time to 
recovery? 
METHODS 
For the objective 1 focus groups were used to explore and contrast in-depth accounts of GP’s 
experience in Australia. As GPs’ are often the first medical experts to start management for 
CNMP patients, their perspectives are critical for improving diagnosis and management. We 
wanted to understand their approach to managing CNMP and the role, if any, of vitamin D 
testing and supplementation. Ethical approval was granted by the Human Research Ethics 
Committee, University of Adelaide (HS-2013-056). Individual informed consent was collected 
at the beginning of each focus group. Twenty-seven general medical practices of varying size 
and socioeconomic patient mix in Adelaide and surrounding areas were invited to participate. 
Five practices with 23 GP’s consented and participated in the study. The focus groups were 
audio recorded, transcribed using Nvivo 10 and analyzed thematically.  
For the objective 2, a systematic review of the literature and meta-analysis was undertaken of 
studies published up to November 2015. Only randomized controlled trials investigating 
vitamin D supplementation compared with placebo were included. Studies using other designs 
and concurrent interventions along with vitamin D supplementation were excluded in order to 
study the direct effect of vitamin D. Following PRISMA guidelines, PubMed, Embase, Web 
of Science, Cochrane, and Scopus electronic databases were searched for randomized 
controlled trials comparing vitamin D supplementation to a control or placebo in CNMP 
patients; the search was not limited by language or date. All studies were independently 
reviewed using a standardized form.  Jadad score was used to assess the quality of the studies 
included. The main outcome (pain) was measured using visual analogue scale (VAS). The 
mean change in VAS from baseline was considered as the primary pain outcome measure. 
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Meta-analysis was performed using the mean and standardized mean difference which was 
computed with 95% confidence intervals and overall effect size was calculated. Both fixed and 
random effect models were used in meta-analysis to properly account for heterogeneity in the 
studies. metan software in STATA was used for estimating the combined and overall effect. 
For the objectives 3 and 4, a cross-sectional study using Survey Monkey was conducted to 
understand the perspectives of individuals with chronic pain about their pain management. 
Ethical approval was granted by the Human Research Ethics Committee, University of 
Adelaide (HREC-2016-0712) and the University of South Australia (application id- 
0000035791). The survey was completely voluntary and anonymous.  The survey collected 
demographic data and included questions about the following; the participant’s medical 
history, pain-related factors (pain intensity, duration and characteristics of pain), pain 
education, goals from chronic pain management, patient’s perception of recovery time and 
vitamin D supplement intake. The analysis was performed using STATA 14.1 Statistical 
software. A range of statistical approaches were used for analysis these include; descriptive 
analysis for depicting the profiles of patients, logistic regression for estimating odds ratio, and 
least absolute shrinkage and selection operator (LASSO) technique. 
 
RESULTS 
In the first study, five main themes were identified: the ambiguous etiology of CNMP; gender 
differences; developing the “right strategy”; patient centered care; and verifying vitamin D 
levels. GPs adopt a patient-centered approach tailored to individual patients’ medical history, 
physical examination and psychosocial health. GPs’ recommended vitamin D supplements in 
patients with CNMP if indicated by a patients’ history. 
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In study two, 107 articles were identified on initial search, but 77 studies were excluded on 
initial screening of abstract. Thirty full text studies were retrieved for further evaluation, 
however twenty-seven studies did not meet our selection criteria and hence were excluded. 
Data from the remaining three studies was included in the meta-analysis. A forest plot was used 
to present the results from the meta-analysis. Moderate – quality evidence suggested no effect 
of vitamin D supplementation on pain relief (SMD: 0.004; 95% CI: -0.248 to 0.256) in CNMP 
patients. Because only a small number of moderate quality studies were identified, better 
designed, large, double blind RCTs conducted over longer periods of time and capturing short, 
medium and long term effects are called for. 
In study three, the estimated sample size was (n) 384 respondents to the survey to have power 
of 90% and have 5% uncertainty in the effect estimate. A simple prediction model was 
developed from the data collected using the LASSO regression technique. The findings from 
this study showed that older age was consistently associated with testing, vitamin D deficiency 
and intake of vitamin D. Unemployment, being on leave due to pain or in part time employment 
and being resident of Australia were also associated with vitamin D testing. Higher mean pain 
intensity score ≥6 on an 11 point numerical rating scale was associated with vitamin D 
deficiency; and being diagnosed with vitamin D deficiency was associated with intake of 
vitamin D. Being vitamin D deficient and unemployed on leave or part time employed due to 
pain were associated with doctor advised vitamin D supplementation.  
Using the data collected in the survey study, the effect of pain education and patient-provider 
relationship on patient-reported pain intensity and recovery was examined using univariate and 
multivariate logistic regression. The findings from this study showed that individuals aged 40 
years and above and female were more likely to report higher pain intensity and poor perception 
of recovery. Being in part-time employment was also associated with pain intensity and 
recovery. Pain education and patient-provider relationship did not show an association with 
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pain intensity and recovery. A separate regression analysis showed that individuals who 
received pain education were more likely to report changes in pain cognition and management 
of pain. We therefore hypothesize that pain education has an indirect relationship with patient-
reported pain intensity and recovery induced by change in pain cognition and management of 
pain. The findings also show that individuals who reported good patient-provider relationship 
were more likely to report positive changes in pain cognition and management of pain. 
 
CONCLUSION 
General practitioners in Australia adopt a holistic approach to managing patients’ with CNMP. 
They appear recommend vitamin D deficiency based on a person’s history but the role of 
vitamin D deficiency in CNMP is unclear. The literature contains many studies examining the 
relationship between vitamin D deficiency and CNMP but only a few that could be included in 
a meta-analysis.  The results demonstrated no evidence of benefit but more studies should be 
undertaken. Finally, using data from a cross sectional survey, it appears that several 
demographic and pain-related factors available to doctors are associated with vitamin D 
deficiency, testing and supplementation and these could be used in a predictive model for 
patients with chronic pain to rationalize testing and supplementation.  More importantly, the 
pain management strategies for individuals with chronic pain should include education directed 
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According to the National Pain Strategy (1), “One in five Australians, including children and 
adolescents, will suffer chronic pain in their lifetime and up to 80% of people living with 
chronic pain are missing out on treatment that could improve their health and quality of life” 
(p. 7).  
The impact of chronic pain on an individual goes beyond their physical suffering, it causes 
emotional distress, social isolation, and impacts society through the financial burden of disease 
via loss of income, medical expenses, and the monetary cost of the disability pension. The 
economic burden of chronic pain to society is enormous, with current estimates of $150 billion 
and $200 billion per annum in the USA and Europe, respectively (2). Management of chronic 
pain still perplexes health professionals and scientists alike due to its complex presentation and 
multiple co-morbidities (3). For many years chronic pain was considered as either a symptom 
of underlying disease (4) or a secondary consequence of other medical conditions (5, 6). 
However, chronic pain is now widely recognized as a condition in its own right (5). Hence, it 
is warranted to explore the mechanisms that underlie the development of chronic pain 
independent of other conditions.  
The estimated prevalence of chronic pain in Australia is approximately 20% (7) which is 
similar to estimates for adult Europeans (8, 9). However, prevalence estimates of chronic pain 
can often be inaccurate due to differences in the definition of chronic pain (10-13), methods 
used for data collection (8, 10, 14, 15), if the focus is on a body part or function (11, 16) or 
pain being associated with a specific condition (12, 17). 
Musculoskeletal conditions are reported to be the most common cause of chronic pain (7), with 
the reported high prevalence of chronic nonspecific musculoskeletal pain (CNMP) ranging 
between 30-70% (8, 15, 18, 19). According to Pfizer Australia (20), 13% of the Australian 




population who live with chronic pain have no medical explanation for it. An alarming 20% 
have considered suicide with 5% attempting it because of their chronic pain (20).  
Chronic pain management forms a significant part of the workload for general practitioners 
(GPs). GPs are often the primary contact for individuals experiencing pain (21, 22); GPs 
provide referrals to pain clinics and also the ongoing pain management following discharge 
from pain clinics (6). Predictably chronic pain is among the top 10 complaints for which 
individuals seek primary care (7, 23). However, primary care physicians report reduced 
confidence (24-26) in managing non-malignant chronic pain. They report lack of training and 
a perceived risk of side effects, substance misuse and concerns about addiction from opioid 
therapy (24-27). In the past 20 years, the prescription and consumption of opioids for managing 
chronic pain have increased fifteen-fold in Australia (28-30). This increase is attributed to GPs 
prescribing opioids for managing non-malignant chronic pain (31). An analysis of 4666 GP 
visits in Australia (30, 32) found that 43.9% of opioids were prescribed for chronic pain, 3.5% 
for malignant neoplasia and the remainder for non-chronic pain and other causes. This rise in 
opioid prescription by GPs may be due to lack of specialist support, shortage of proven 
therapies (33, 34), a wish to avoid patients going untreated (34) and to the Medicare model of 
funding which limits longer consultations (34) which might allow alternate strategies to be 
discussed and used. The increasing concern about the use of opioids for non-malignant chronic 
pain has led to heightened vigilance (32, 35), with doctors’ failure to comply with the state 
legislative requirements for opioid prescription sometimes resulting in disciplinary action (36).  
For the above reasons, there is a need for alternative therapies which could help relieve chronic 
painful conditions. A growing amount of evidence suggests that vitamin D deficiency may play 
an important role in the pathophysiology of CNMP (37). Vitamin D deficiency is also reported 
as a major public health concern in Australia with nearly one-third of Australians reported to 
have low levels (38). Low vitamin D levels have a direct effect on musculoskeletal health (37, 




39, 40) and may often present as diffuse muscle pain, muscle fatigue, arthralgia, deep bone 
pain and muscle weakness (41-44). These symptoms are nonspecific and fit the criteria for 
CNMP. Vitamin D supplementation could alleviate some nonspecific pain and because it is 
easily available, and inexpensive it could be a safe method of managing CNMP.  
The management of CNMP by GPs’ and its perceived relationship with vitamin D deficiency 
has not been described previously.  Nor do we know if correcting vitamin D deficiency could 
actually improve the pain experienced. This thesis provides evidence about the diagnosis and 
management of patients with CNMP and the effectiveness of vitamin D supplementation, 
which may potentially bridge the knowledge gap and help improve treatment outcomes. 
Moreover an attempt has been made to obtain insights from patients suffering with chronic 
pain, about their current pain management strategies and perceived recovery time. 
 
1.2. Thesis Aim  
 
The overall aims of this thesis are to provide evidence about 
1)  The diagnosis and management of CNMP in Australian general practice and the role, if any, 
of vitamin D deficiency and supplementation in its etiology and treatment. 
2) The perspectives of patients with chronic pain about vitamin D supplementation and their 
medical management and investigations. 
The research objectives are: 
Objective 1- What management strategies do GPs employ with patients presenting with 
CNMP? 
Objective 2- How effective is vitamin D supplementation in the management of CNMP? 




Objective 3- What demographic and pain-related factors are associated with: testing for vitamin 
D levels, vitamin D deficiency and intake of vitamin D supplement among people with chronic 
pain? 
Objective 4- What perspectives do patients with chronic pain have about the patient-provider 
relationship, pain education and does it affect their pain intensity and perceived time to 
recovery? 
 
1.3. Thesis Outline 
 
The remainder of the thesis is organized as follows. Chapter 2 provides the relevant literature 
that describes context of the specific aims, introduced above. The review covers common 
chronic painful musculoskeletal conditions, including CNMP, that are seen in Australian 
general practice. It also examines what role vitamin D deficiency and supplementation may 
have in each of these conditions. Chapter 3 addresses the first research question, which 
describes Australian GPs’ decision-making processes when managing CNMP in practice using 
a focus group study design. This chapter is accepted for publication as a research article in 
peer-reviewed journal Family Medicine and Community Health. 
Chapter 4 addresses the second research question, which examines the effects of vitamin D 
supplementation on CNMP using a systematic review and meta-analysis of randomized 
controlled trials (RCTs). This chapter was published as a research article in a peer-reviewed 
journal (45) (Attached as Appendix). 
Chapter 5 presents the methods for a cross-sectional survey of patients with chronic pain, the 
variables selected to examine patients’ perceptions, views, and beliefs on vitamin D testing, 
deficiency and supplement intake; pain education; patient-provider relationship; pain intensity 
and their perception of recovery. Chapter 5 describes in detail the objectives and methodology 




used in designing and conducting the survey. Chapter 5 is published as a research article in the 
peer-reviewed Journal of Pain Research (Attached as Appendix). 
Chapter 6 addresses the third research question, which examines the patients’ views and beliefs 
about vitamin D testing, deficiency and supplement intake and the factors associated with 
medically advised vitamin D supplementation and patients’ perception of recovery. Chapter 6 
is under review as a research article in a peer-reviewed journal. 
Chapter 7 examines patients’ views and beliefs about patient-provider relationship and pain 
education, and if there is an association between the patient-provider relationship and pain 
education and patient reported pain intensity and perception of recovery. This chapter will be 
prepared for submission to a peer-reviewed journal after completion of the Ph.D.  
Chapter 8 provides a summary from the overall thesis, synthesis of the findings, and a proposed 
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The structure of this chapter is as follows. Section 2.1 describes the background on vitamin D, 
its synthesis, metabolism and guidelines on interpreting vitamin D levels in clinical practice. 
Section 2.2 reviews pain, and the journey from the Biomedical model to the current 
Biopsychosocial model of pain. Section 2.3 describes the effects of vitamin D on chronic pain 
conditions such as osteoarthritis (OA), rheumatoid arthritis (RA), chronic widespread pain 
(CWP), fibromyalgia (FM) and chronic nonspecific musculoskeletal pain (CNMP), and on how 
vitamin D levels might relate to or modulate CNMP. 
 
2.1 Vitamin D 
 
In 1919, Sir Edward Mellanby proposed a deficiency of a fat-soluble vitamin or accessory food 
factor (46) as the cause for the development of rickets in children. He fed a diet consisting only 
of oats to a group of dogs restrained indoors without any sun exposure. He produced rickets in 
these dogs through the restrictive diet. He then fed the dog’s cod-liver oil, which is not present 
in oats, and the dogs were cured of rickets. He attributed the treatment success to vitamin A 
present in the cod liver oil. In 1922, McCollum and associates performed a test of bubbling 
oxygen through cod liver oil, which burned out the vitamin A, leaving behind a “new 
substance” that remained effective in treating rickets. They labelled this new substance in the 
oil - “vitamin D” following sequential alphabetical designations (47). Labelling of this 
substance as a vitamin is often questioned, as vitamin D acts more like a hormone than a 
vitamin. Also unlike any other vitamins, vitamin D can be synthesized in the human body. It is 
acknowledged as a fat-soluble hormone precursor, which is produced by exposure to adequate 
sunlight. In 1928, a German structural chemist Adolf Windus won the Nobel Prize for the 
chemical identification and synthesis of vitamin D (48). Two forms of vitamin D are recognized 
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namely; vitamin D2 [ergocalciferol] found in plants and some fish and vitamin D 3 
[cholecalciferol] synthesized in the skin from direct exposure to the sunlight (49). 
 
2.1.1. Synthesis of Vitamin D 
 
Cutaneous synthesis of vitamin D 
 
On exposure of the skin to sunlight (UV-B rays), pre-vitamin D3 is synthesized in the skin 
from 7-dehyroxycholesterol (see Figure 2.1). Multiple factors such as the amount of UV 
exposure (290-315 nm wavelength), skin pigmentation and thickness, age, latitude, season, and 
level of sun protection used (including clothing, shade, and sunscreen) regulate this step. 
Previtamin D3 is isomerized to vitamin D3, which binds to the vitamin D binding protein 
(DBP) (48) and is transported into the liver. In the liver, it is hydroxylated by the 25-
hydroxylase enzyme to 25-hydroxyvitamin D [25(OH) D] which is the inactive form. 
Subsequently, in the proximal convoluted tubules of the kidneys, 25-hydroxyvitamin D is 
hydroxylated by the enzyme 1 α-hydroxylase to 1,25-dihydroxyvitamin D [1,25 (OH)2D], the 
physiologically active form (50-52). This cutaneous synthesis of vitamin D supplies 80-100% 
of the daily requirement of vitamin D (53). 
 
Exogenous synthesis (synthesis of dietary vitamin D) 
 
Vitamin D can be ingested from food sources such as eggs, oily fish, liver, unfortified butter 
and fortified foods like milk, margarine, cereals, juice, and yoghurt (54). This orally ingested 
vitamin D2 also binds to DBP and is transported to the liver from where it follows the path of 
cutaneous synthesis (48). 






2.1.2.  Vitamin D metabolism 
 
 
Figure II2 Molecular structures of various compounds of vitamin D pathway from 
synthesis to metabolism (55). 
 
The hydroxylation steps in vitamin D metabolism, 25-hydroxylation, 1α-hydroxylation, and 





Figure 2.1 Synthesis of Vitamin D (48) 
 
Both 25 (OH) D and 1, 25(OH) D undergo 24-hydroxylation to form 24, 25 (OH) D and 1, 24, 
25 (OH) D respectively (56), which is the initial stage of biodegradation that ends in the 
formation of water-soluble calcitroic acid (56, 57). The hydroxylation of vitamin D in the liver 
is almost unregulated therefore serum level of 25(OH) D can reflect either cutaneous 
production in the skin or dietary intake and is hence used as the marker for vitamin D status 
(57, 58). The only regulated step in the synthesis of the active form of vitamin D is the 
production of 1, 25(OH) D by the kidney (51). 
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The wide-ranging effects of vitamin D are also attributed to the extra-renal expression of the 
enzyme 1 α-hydroxylase in tissues of skin and brain (50) and also in the cells of osteoclasts, 
macrophages (59), breast, colon, prostate (60) and smooth muscle (61). They can locally 
synthesize the active form of vitamin D (61). This pre-vitamin D3 is biologically inert and 





Figure 2.2 Vitamin D synthesis, activation and catabolism (55). 
 
2.1.2. Calcium homeostasis 
 
A flux of calcium between bone, kidney, intestine and extracellular fluid regulates plasma 
concentration of calcium. This flux is predominantly controlled by 3 major hormones: 
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parathyroid hormone (PTH), calcitonin and 1, 25-dihyroxyvitamin D. These hormones also 
form a negative feedback control for maintaining calcium levels (62). The parathyroid hormone 
(PTH) is regulated by the serum calcium (Ca), phosphorus (P) levels (61), growth hormone 
and prolactin (63). The normal concentration of PTH, phosphate, and calcium regulate the 
central point in vitamin D metabolism - the renal hydroxylation of 25- hydroxyvitamin D to 
1,25- dihydroxyvitamin D. Though decrease in PTH and phosphate levels independently 
increase 1,25-hydroxyvitamin D production, PTH is the most potent stimulus (64). Rising 
levels of 1, 25-dihydroxyvitamin D increases the plasma concentration of calcium and 
phosphate by increasing the absorption of calcium and phosphate from the gastrointestinal tract 
(50-52). It also increases osteoclastic reabsorption of calcium and enhances the effects of PTH 
in the nephron to promote renal tubular calcium reabsorption. Thus, 1,25-dihydroxyvitamin D 
regulates  calcium and phosphate deposition and release from bone (64). 
 
2.1.3. Vitamin D receptors  
 
There are two known forms of the vitamin D receptor (VDR), namely nuclear VDR and 
membrane bound VDR. The most thoroughly described are the nuclear VDR, an intracellular 
polypeptide from the steroid-thyroid-retinoid acid receptor superfamily (65). The discovery of 
the nuclear VDR in 1969 enhanced the knowledge about various functions of vitamin D (66). 
The nuclear VDR gene contains 9 exons and 8 introns and is present on chromosome 12q12-
14 (67, 68). Nuclear VDR initiates biological functions or suppression of gene transcriptions, 
by binding to the DNA of target cells as VDR/VDR homodimers or VDR/RXR heterodimers 
and synthesizing RNA encoding proteins (65).  
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The membrane-bound VDRs are located in the cells of various tissues including parathyroid, 
pancreas, special nerve cells, keratinocytes, macrophages and renal tubular cells (51), brain, 
vascular smooth muscle, prostate, and breast (69). These membrane-bound VDRs induce ‘rapid 
responses’ leading to the formation of second messengers and phosphorylation of intracellular 
proteins and regulating approximately 3% of the human genes (70).  
 
2.1.4. Evaluating Vitamin D status  
 
The circulating levels of 25(OH)D is measured to evaluate vitamin D status- sufficiency, 
insufficiency, deficiency or toxicity in an individual (71, 72). Even though 25(OH) D is not the 
biologically active form of vitamin D, it is used because it gives the sum of both cutaneous and 
exogenous synthesis (71, 72). It also has a half-life of approximately 2-3 weeks, as compared 
to 4-6 hours of 1,25 (OH)D (73). As a consequence, circulating serum levels of 25(OH)D are 
a thousand fold higher than 1,25(OH)D (73). Moreover, in the case of vitamin D deficiency, 
renal production of 1,25(OH)D increases (71, 72) due to PTH regulation of calcium 
metabolism, which can give false positive results for the 1,25(OH) D assay, making it less 
reliable. 
 
2.1.5. Level of Vitamin D in Australian Population 
 
An approximate exposure of 10-15 minutes to a midday sun in summer in Sydney is considered 
equivalent to taking a 15000 IU (375 µg) of vitamin D supplement orally (74). However, due 
to the increased prevalence of skin cancer in Australia, previous public health messages have 
discouraged people from this level of exposure to sun rays when UV radiation is high (75). It 
now appears that almost 1/3 of the Australian population has low serum levels of vitamin D 
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(38). Studies have also observed that nearly 43% of young women and 23% of the general 
population (76, 77) in Australia are vitamin D deficient during winter. Moreover, children and 
adolescents have poor vitamin D status particularly those from the cooler regions of Tasmania 
(78) and New Zealand (79).  
 
2.1.6. Interpretation of circulating vitamin 25 (OH) D levels 
 
Current evidence, based on a working group commissioned by the Australian and New Zealand 
Bone and Mineral Society (ANZBMS) and Osteoporosis Australia, classifies circulating levels 
of serum 25(OH)D as follows (80): 
1. Vitamin D adequacy: > 50 nmol/L at the end of winter (10–20 nmol/L higher at the end of 
summer, to allow for seasonal decrease). 
2. Mild vitamin D deficiency: 30–49 nmol/L 
3. Moderate vitamin deficiency: 12.5–29 nmol/L 
4. Severe vitamin D deficiency: < 12.5 nmol/L 
The working group recommended a target level of 50 or 60 nmol/L for maintaining bone health 
and muscle function. An analogous range between 50 and 62.5 nmol/L was recommended by 
the 14th vitamin D workshop (81) to prevent adverse musculoskeletal outcomes such as 
fractures and falls. However, the serum level of vitamin D necessary for prevention of other 
diseases is still unclear.  
The knowledge of non-classical effects of vitamin D which included immune modulation, 
cellular regulation, apoptosis, anti-inflammatory, anti-microbial, insulin secretion and 
neuroprotection (51, 61) advocated its potential role in multiple conditions. Along with the 
rising prevalence of vitamin D deficiency worldwide (82), vitamin D supplementation is being 
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used in the management of wide range of conditions including chronic pain. The past decade 
has seen an explosion in studies regarding the underlying role of vitamin D deficiency and/or 
supplementation for the management of the chronic musculoskeletal conditions. However, in 
order to understand the potential role of vitamin D deficiency in painful conditions and their 
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2.2. Chronicles of Pain 
 
 
To heal does not necessarily imply to cure. It can simply mean helping to achieve a way of life 
compatible with their individual aspirations—to restore their freedom to make choices—even 
in the presence of continuing disease. 
—Rene Dubos (1978) 
 
Pain is a universal and costly medical health problem (83). Though there has been an explosion 
of research on pain (84), it still remains difficult to diagnose and manage and also difficult to 
explain. Chronic pain is especially demoralizing; its continuous presence limits the individual’s 
personal, social and professional activities, often making them adopt the sick role (85). 
Research has shown that solely tissue-based explanations for symptoms fail to explain chronic 
pain (83). Although physical pathology and pain may be related, physical pathology does not 
predict the severity of pain nor the level of disability. Similarly, the severity of pain cannot 
fully predict the level of psychological distress or the degree of associated disability (83). The 
question that remains to be answered is how to provide an optimal level of management and 
care for the patients suffering from chronic pain.  There are a number of theories that have tried 
to address this complex situation. Earlier theories focused on tissue damage and the associated 
pain. However, recent theories put greater emphasis on the sensitivity of nociceptive system 
(86), non-nociceptive sensory inputs, associative learning (87), and cognitive and behavioral 
processes that link fear of pain, activity avoidance and catastrophizing (88). The biomedical 
concept of chronic pain has given way to the biopsychosocial concept of pain (89, 90), which 
posits that pain, and how people respond to it, is influenced not only by the biological factors 
but also by the belief’s, attitudes and social and cultural environment of the patient (91, 92).  
This Biopsychosocial model supports an integrated multi-disciplinary treatment approach (93). 
Although it is beyond the scope of this thesis to review the theories in depth, a concise 
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discussion allows a framework for evaluating the possible role of vitamin D in the chronic 
painful conditions. 
2.2.1. The Biomedical model of pain 
 
Ever since the revolutionary writings of Descartes, the idea that pain runs along a channel has 
been popular and has guided treatment (94). Descartes viewed the physiology as a “hydraulic 
system” that runs directly from the receptor on the skin to the brain (Figure 2.3). His drawing 
depicted a man with fire near his foot; the fire activates the ‘pain receptor’ stimulating the 
hydraulic system to ring a bell in his head.  This model ruled the management and study of 




Figure 2.3 Descartes model of pain (94)  
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The Biomedical model provides a framework for disease and health based on reductionism, 
which suggests that all diseases occur due to a biological defect or pathogen, and dualism, 
which suggests that mind and body are two separate entities (95). Health was judged by the 
mere presence or absence of symptoms or disease. This Biomedical model was also applied to 
diagnosing and managing painful conditions. It focused solely upon nociception, the sensing 
of a harmful stimulus without essentially taking emotional aspects of pain into consideration 
(96). Thus, overlooking how past experiences, social and cultural background shape the whole 
experience of pain (96). 
The Biomedical model was criticized for promoting an impersonal, cold, technical style of 
clinical practice which overlooked the human dimension of suffering and compassion (89, 97) 
and disregarding the interaction of diverse social and individual factors that form a major part 
of an individual’s experience. Engel recommended a more holistic approach as an extension to 
the Biomedical model known as the Biopsychosocial model (98) which is described in section 
2.2.6. 
 
2.2.2. The Specificity Theory 
 
The Specificity theory of pain was proposed by Max von Frey in1894 (99). He postulated that 
there are four main types of sensations: pain, touch, heat, and cold, and all of the other skin 
sensations are derivatives of these main types. Each of the four sensations was suggested to 
have distinctive receptors and pathways that carry the stimulus from periphery to spinal cord 
and then to specific centers in the brain (Figure 2.4). Thus, each sensation was perceived to 
have a specific central and peripheral set of mechanisms that also determined the intensity and 
nature of the sensation (pain, heat, cold and warmth) generated.  Although the theory aptly 
explained many characteristics of pain such as sensory receptors that respond to specific 
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nociceptive stimuli, for example, the A - delta and c-nerve fibers, it did not account for neurons 
which respond to both non-nociceptive and nociceptive stimulus, nor the many vagaries in the 
relationship between stimulus and response in the nociceptive range (100). The Specificity 
theory also could not explain pain without ongoing tissue injury or stimulus (101), for example 




Figure 2.4 Schematic representation of the Specificity theory (102) 
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2.2.3. The Pattern theory 
 
In 1920 Goldschneider proposed the ‘Pattern theory’ (103) which disregarded the Specificity 
theory and suggested that all senses including pain shared receptors and that there was no 
special system for perceiving pain. The theory advocated that a peripheral sensory input, 
damaging as well as non-damaging both can give rise to painful or non-painful experience 
depending on the difference in the patterns of the signals sent through the nervous system 
(Figure 2.5). For example, being hit hard feels painful because it produces different patterns of 
neural activity but being caressed does not, although they belong to same sense modality. The 
difference in the patterns determined the quality of sensation. The major success for the Pattern 
theory was that it identified the neurophysiological mechanism of encoding and processing 
sensory information thus accounting for painful conditions such as neuralgia (104). However, 
it also had limitations; such that it did not acknowledge any control of the brain over the 
perception of pain and the role of various psychological factors that could affect the perception 











Figure 2.5 Schematic representation of the Pattern theory (102) 
Touch  Warmth Pain Pressure 
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2.2.4. The Gate Control Theory of Pain 
 
The Gate Control theory proposed by Ronald Melzack and Patrick Wall (105) was the first 
theory to postulate the top-down brain influences on the experience of pain and related 
behaviors. This theory postulated that signals produced in primary afferents following 
stimulation of skin are transmitted to three regions within the spinal cord; the substantia 
gelatinosa, the dorsal horn and a group of cells termed as ‘transmission cells’ (Figure 2.6). The 
transmission of sensory information from the primary afferent neurons to transmission cells of 
the spinal cord was moderated by the substantia gelatinosa in the dorsal horn which functions 
like a ‘pain gate’. The activity in the small nerve fibers (A-delta and C fibers) acts to open the 
gate, whereas the activity in large nerve fiber (A- beta) closes the gate, thus limiting the pain 
experience. The gate can also be modulated by input from descending fibers that originate from 
supraspinal centers and project to the dorsal horn; if the nociceptive information exceeds the 
threshold of inhibition it can open the gate and activate pathways that lead to the pain 
experience. As described by Melzack in 1993 (106), the Gate Control theory forced scientists 
to acknowledge the central nervous system as an essential component in pain processes; with 
the brain and dorsal horn capable of modulation, inhibition and excitation of sensory inputs 
and altering the pain processes. The Gate Control theory is the first major theory to recognize 
the close interaction between psychosocial and physiological processes affecting pain (94), 
although its focus was arguably on the influence of non-nociceptive input over nociceptive 
input. More recent development of the Gate Control theory have posited that an individual’s 
thoughts, feelings, and behavior could affect the transmission of the nociceptive signal by 
opening or closing the gate. Negative thinking, focusing on pain and nonconstructive thinking; 
feelings such as sadness, helplessness, anger, hopelessness, and stress; behaviors such as poor 
nutrition, inactivity, smoking, sleep deprivation – could potentially “open” the gate whereas, 
positive thoughts, feelings, and behaviors could prevent the gate from “opening” (94). The 
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wide acceptance of the Gate Control theory led to the development of treatment strategies such 
as transcutaneous electrical nerve stimulation (TENS), which aims to close the gate by 
selectively stimulating A beta (large diameter) nerve fibers (107). However, the inadequacies 
in the Gate Control theory became evident with an improved understanding of the significance 
of higher central nervous system (CNS) levels in the modulation of nociception (108, 109) and 




Figure 2.6 The Gate Control theory (105)  
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2.2.5. The Neuromatrix model of Pain 
 
Although the Gate Control theory mention’s descending influence on the ‘gate’, there was not 
much detail given about this component. Twenty-five years later Melzack proposed the 
Neuromatrix model as an extension of Gate Control theory (110). This theory promotes pain 
as a multidimensional experience, initially produced by the specific pattern of nerve impulses 
generated by neural network or neuromatrix, which is widely distributed and can be activated 
in the presence of peripheral sensory stimulus or centrally without stimulation. According to 
this model, every individual has an exclusive neuromatrix, formed by an individual’s genes, 
sensory and learning experiences (Figure 2.7) which help to understand why individuals 
experience pain differently (111). 
The Neuromatrix model is widely recognized for its contribution to managing chronic pain 
states after resolution of the primary injury or when the pain shifts from the primary site (112). 
The Neuromatrix model was recognized as a clinical breakthrough for its application to 
phantom limb pain and pain after spinal cord resection (113). However, the Neuromatrix model 
was criticized for its lack of specificity, as it did not specify the biological or neurochemical 
substrates for its basis (114). Another criticism of the Neuromatrix model was that it did not 
add more to our understanding of the mechanisms of pain relief from the Gate Control theory 
and was deemed more suitable for understanding brain functioning than pain itself (114).  
 
 





Figure 2.7  The Neuromatrix model of pain (115) 
 
Pain-stress response 
Melzack incorporated the role of the hypothalamic- pituitary-adrenal axis (HPA axis) (111) in 
the maintenance of chronic pain in the Neuromatrix model.  He proposed that an injury or 
painful stimulus disrupts the homeostasis, inducing the HPA axis starting with the secretion of 
Corticotrophin-releasing hormone (CRH) from the hypothalamus (Figure 2.8). CRH activates 
pituitary gland to secrete adrenocorticotropic hormone, which stimulates adrenal cortex to 
secrete cortisol (111). To meet the high demand of cortisol during stress, blood sugar levels 
rise, the breakdown of muscle protein increases and replacement of calcium in bones is also 
inhibited (111). Melzack emphasized that prolonged stress and homeostatic imbalance could 
exhaust this adaptive response also known as Selye’s General Adaptation Syndrome (116).  
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Prolonged stress also activates the limbic system, which is important for emotion, motivation 
and cognitive process (116). In addition, once the pain is established, it could act as a stressor 
itself, maintaining the disruption to homeostasis thereby forming a vicious cycle which 






Figure 2.8 The Hypothalamic Pituitary Adrenal Axis (111)   
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2.2.6 The Biopsychosocial Model 
 
In his criticism of the Biomedical model Engel recommended a more holistic approach as an 
extension to the Biomedical model known as the Biopsychosocial model (98). This model 
accredited equal importance to biological, psychological and social factors (Figure 2.9) in the 
diagnosis, prevention, and management of disease (89).  It prompted clinicians to broaden their 
gaze, support multidisciplinary treatment and disease control and helped to improve the patient 




Figure 2.9  Engel’s conceptual model of illness (117) 
 
In 1982, Loeser applied the Biopsychosocial model to the understanding and management of 
pain. He added four dimensions closely associated with pain (90): a) nociception, b) pain, c) 
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suffering, and d) pain behavior. He defined nociception as stimuli, either: chemical, mechanical 
or thermal that act on peripheral receptors producing activity in the nerve fibers; pain as the 
sensation that results due to the nociception; suffering as the unpleasant emotional response 
and pain behavior as the actions used to communicate about the pain (Figure 2.10). This model 
emphasized how an individual’s past experiences and anticipation of recovery could impact 
their suffering and pain behavior. This model successfully highlighted the intricate nature of 
chronic pain and the complex interactions between the psychological, social and economic 




Figure 2.10 Loeser’s conceptual model of pain (90)  
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The biopsychosocial perspective recognized pain as a complex phenomenon that results from 
interactions between the physiological, psychological and social factors (90). It further 
recognized the interaction of different emotional, psychological, social and economic factors 
and its effect on individual’s experiences of pain, reporting of symptoms and associated 
disability (94). The major strength of the Biopsychosocial model is that it acknowledges the 
role played by psychological and social factors in pain. 
The Biopsychosocial model considers pain to be a physical illness that is influenced by 
physiological, psychological, and social factors that interact and or exacerbate the clinical 
presentation.  Even patients with identical medical diagnosis differ in their psychosocial and 
behavioral characteristics, which influences their treatment outcome.  
 
2.2.7. Current theoretical concept of pain 
 
Today our understanding of pain has further evolved from “being the outcome of nociception” 
to pain being an emotional and sensory experience that serves to protect our body (87, 118). 
Pain is acknowledged as the “output” that can be modulated by an individual’s biological, 
psychological and social factors which explains why every individual experience pain 
differently. While, nociception is defined as the activity in high-threshold primary neurons A-
delta or C fibers most often due to noxious stimulus. Unlike nociception, pain can always be 
sensed and it informs us to protect the body part. It is also the only protective mechanism we 
are necessarily aware of, thus making self-report the best measure of pain.  
 
 








Damage or inflammation of tissue changes the chemical environment of the peripheral 
nociceptors (119). Injury and inflammation release intracellular contents such as  ATP, K+ ions; 
and produce inflammatory cells such as cytokines, chemokines, and growth factors; neutrophils 
which secrete Cox-2 which promotes PGE2 production (119). These factors can directly affect 
the nociceptive terminal and stimulate it (nociceptor activators), while others can sensitize the 
terminal making it hypersensitive to succeeding stimulus (nociceptor sensitizers) (119).  This 
is known as peripheral sensitization (120). Peripheral sensitization decreases the excitation 
threshold of polymodal nociceptors (121) and also increases the responsiveness of peripheral 
end of nociceptors (120), which transfer the input from target tissues via the spinal cord to the 
brainstem (120). Following sensitization, even a harmless stimulus can evoke pain while 
noxious stimulus can evoke an even stronger response (120). For example, primary allodynia 
(120) where previous non-painful stimulus such as hot water (showering) becomes painful after 




A nociceptor input can generate long-lasting excitability of neurons in central nociceptive 
pathways, which is reversible. This phenomenon is known as central sensitization. The concept 
of “central sensitization” was first proposed by Woolf and colleagues in 1983 (122). It is also 
described as activity-dependent plasticity due to increase in the synaptic strength by N-methyl-
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D-aspartic acid glutamatergic receptors. The “conditioning input” can also amplify subsequent 
responses to other non-stimulated non-nociceptor or nociceptor fibers (123). Central 
sensitization can also be elicited by the diminished inhibitory transmission or loss of inhibitory 
neurons (124). Once established it augments nociceptive sensitivity and remains highly plastic 
(125); new nociceptive input aggravates it, however, in the absence of new nociceptive input 
it does not resolve but is sustained (126). Recently Woolf also integrated all forms of pain 
sensitization and reduction in pain threshold beyond the receptor field of spinal nociceptors 
into central sensitization. This new integration promotes that central sensitization can be 
detected in other CNS locations and can have multiple drivers that can change a period of time 
(86).  Thus, psychological, social and biological factors all can influence neuronal activity- 
they can all generate central sensitization. This is central understanding the change in pain 
hypersensitivity seen in clinical syndromes such as fibromyalgia, which does not have clear 
tissue injury (119, 123). 
 
2.2.9. Peripheral nerve injury 
 
In the event of peripheral nerve injury, three additional mechanisms have been suggested which 
are ectopic excitability, disinhibition, and structural reorganization in the dorsal horn of the 
spinal cord.  
Ectopic excitability 
Following a nerve injury, the distribution of sodium and potassium ion channels is altered 
which leads to increase membrane excitability. It can also produce ectopic impulses in the 
absence of peripheral stimulus. This is known as ectopic excitability and is a major contributor 
to spontaneous neuropathic pain seen in diabetic peripheral neuropathy (127).  





The central terminals of nociceptor sensory neurons terminate in the superficial laminae of the 
dorsal horn, while low threshold sensory fibers terminate in the deep laminae of the dorsal 
horn. The physical arrangement of this circuitry is reorganized following a peripheral nerve 
injury. However, although this structural rewiring has been identified in rodents it still remains 
to be observed in patients (128).  
 
Disinhibition 
Peripheral nerve injury causes substantial loss of inhibitory currents especially the ones 
mediated by GABA. This is due to the selective death of GABAergic inhibitory interneurons 
(129). Following the nerve injury, neurons in the dorsal horn begin to undergo apoptosis due 
to excessive glutamate release, failure of glutamate uptake or result from the release of tumour 
necrosis factor from activated microglia (129).  
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2.3. Musculoskeletal conditions and the role of vitamin D 
 




The term “osteoarthritis” (OA) comes from Greek meaning bone and joint inflammation. It is 
a progressive degenerative disorder of synovial joints characterized by gradual loss of cartilage, 
changes in subchondral bone with subsequent development of bony spurs and cysts on the joint 
margins. It may affect a single joint, few joints or can be generalised (130). The main symptoms 
of OA are joint pain, stiffness, locomotor restriction and varying degrees of functional 
impairment (131). The symptoms, especially pain, tend to be worse in the morning and improve 
in 1-2 hours, followed by worsening during late afternoon and evening again to be improved 
after a few hours (132). If night pain is present it often interferes with the sleep pattern causing 
fatigue and enhancing sensitivity to pain (133). 
 
The pathophysiology of pain in OA is not fully understood. The hyaline cartilage covering the 
articular surfaces of bones in the synovial joint is aneural, which means it is not nociceptively 
competent – it cannot generate a nociceptive signal. There are nociceptive fibres and 
mechanoreceptors present in the synovium of the subchondral bone, periosteum, tendons, 
capsule and ligaments (133) and in the OA affected bone marrow lesions and synovitis (134, 
135) so these tissues are obviously more implicated. Both central and peripheral sensitization 
are reported to play a part in the maintenance of the pain (133). 
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Diagnostic guidelines for Osteoarthritis  
 
The American College of Rheumatology (ACR) criteria (68) can be used to diagnose OA of 
hand, hip, and knee. However, a clinical diagnosis of OA can be made without laboratory or 
radiographic investigations in the presence of typical signs and symptoms on clinical grounds 
in patients above the age of 45 years (136).  
 
The ACR criteria for osteoarthritis of the hand (137): 
i) hand pain, aching or stiffness 
ii) Hand tissue enlargement of two or more joints 
iii) Fewer than three swollen metacarpophalangeal joints 
iv) Hand tissue enlargement of two or more distal interphalangeal joints 
v) Deformity of two or more joints 
 
The ACR criteria for osteoarthritis of the hip (137): 
i)  Hip pain plus at least two of the following: 
ii) ESR of less than 20 mm per hour 
iii) Femoral or acetabular osteophytes on radiographs 
iv) Joint space narrowing on radiographs 
 
The ACR criteria for osteoarthritis of knee (137): 
i) Knee pain plus osteophytes on radiographs and at least one of the following; 
ii) Patient age older than 50 years 
iii) Morning stiffness lasting 30 minutes or less 
iv) Crepitus on motion 




Vitamin D and osteoarthritis 
 
OA is often associated with vitamin D deficiency especially in elderly people (138, 139) and 
affects the health-related quality of life in the older population (140). Vitamin D deficiency 
affects bone mineral density, articular cartilage turnover and osteoblastic activity (141) and 
also enhances the activity of metalloproteinase and proteoglycan synthesis (142) which leads 
to cartilage loss and can, therefore, theoretically precipitate OA (143). It is also possible that 
the reduced mobility in OA patients affects the time they spend outdoors and their activity 
levels leading to reduced UV exposure thus causing diminished vitamin D synthesis. 
 
Some studies show a moderate to a strong association between vitamin D levels and knee OA. 
However, it is unclear if this association is applicable across all age groups. An observational 
study (143) separated 80 elderly women with knee OA (diagnosed following ACR criteria) into 
two groups based on their serum vitamin D levels tested by ELISA. Group 1 consisted of 54 
patients with vitamin D level <50nmol/l and group 2 consisted of 26 patients with vitamin D 
level > 50nmol/l. The Kellgren-Lawerence (K/L) grading scale was used for determining the 
clinical grade of knee OA and the Lequesne Algofunctional Index was used to assess the pain 
and physical function, with a total score ranging from 0 to 24. A score of < 7 corresponds to 
mild-moderate, 8-13 severe and > 14 to extremely severe functional impairment. Patients in 
group 1 showed higher K/L grades- 2, 3 and 4 (p<0.001) and also significantly higher score in 
Lequesne test (p<0.001) when compared to group 2. This study showed that vitamin D status 
correlates with disease severity and worsening especially in women aged 65-80 years 
diagnosed with knee osteoarthritis (143). However, contrasting findings were observed in 
another cross-sectional study (144), which compared serum vitamin D levels of 148 patients 
aged 45- 60 years, diagnosed with knee OA with 150 age-matched controls. The study found 
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that the overall mean serum 25(OH) D levels in participants with OA were not significantly 
lower than the controls (p=0.28). However, subgroup analysis showed that the mean 25 (OH)D 
levels in OA patients aged <60 years was significantly lower than the controls (p=0.01) thus, 
suggesting a significant association between serum vitamin D and knee OA in patients aged 
<60 years (144). 
 
Two main symptoms of OA, pain and physical activity, have been widely investigated for the 
effect of vitamin D supplementation. A retrospective cohort study (145), involving 182 OA 
patients scheduled for knee or hip replacement surgery, investigated the role of vitamin D levels 
on pre-operative physical activity. The University of California, Los Angeles (UCLA) activity 
scale was used to measure patients’ physical activity. A score of >3 was considered as mild 
functional disability and a score <3 as a major functional disability. The study found that 
patients with 25(OH)D levels <50 nmol/L compared to patients with 25 (OH)D levels >50 
nmol/L were three times more likely to report UCLA activity scale scores of <3 (Odds ratio 
(OR) 2.79; 95% CI,1.72-9.17) suggesting an association between serum level of vitamin D and 
pre-operative physical activity score (145). These findings are in line with previous studies 
which reported an association between vitamin D levels and muscle strength and performance 
(146, 147) thus affecting overall physical activity in OA patients. The Tasmanian Older Adult 
Cohort (TasOAC) (148) examined, the correlation between vitamin D levels and the difference 
in the knee and hip pain. Radioimmunoassay was used to measure 25(OH)D levels at baseline 
and the Western Ontario and McMaster Universities Arthritis Index (WOMAC) questionnaire 
was used to measure pain at baseline, 2.6 and 5 years, from 769 randomly selected adults aged 
50-80 years. This was the first study to demonstrate that even moderate vitamin D deficiency 
could predict the incidence, anatomical changes and worsening of knee pain over 5 years and 
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hip pain over 2.4 years (148). This suggests that maintenance of vitamin D status may attenuate 
knee or hip pain and the decline in QOL in older populations with knee OA. 
 
In 2012 a cross-sectional study (149) found that inter-racial differences in experimental pain 
are mediated by differences in vitamin D levels. The study compared 45 black Americans and 
49 white Americans diagnosed with symptomatic knee OA. The study used quantitative 
sensory testing, including measures of sensitivity to heat and mechanically induced pain. Black 
Americans showed significantly lower levels of vitamin D, demonstrated a higher level of pain 
and greater sensitivity to heat and mechanically induced pain than the white Americans. This 
suggests that deficiency in vitamin D levels may be a risk factor for increased knee OA pain in 
black Americans (149). 
 
Another widely researched area is structural changes in OA patients (determined by 
radiographs) and the effect of vitamin D. Presence of cartilage loss, osteophytes and narrowing 
of joint space have been shown to be relatively reliable radiographic indicators of progression 
of OA (150). The K/L scale is widely used to classify the progression of OA using the above 
radiographic indicators. The K/L scale ranges from 0 to 4; 0=no osteophytes or joint space 
narrowing, 1=questionable presence of joint-space narrowing or osteophytes or both, 
2=definite presence of either osteophytes or joint space narrowing, 3=definite moderate 
(approximately 50%) joint space narrowing usually with osteophytes present and 4=severe 
joint space narrowing.   
 
Using this technique MacAlindon et al. (150) studied participants from the Framingham Study 
who had been followed for more than 40 years. The participants received anteroposterior 
weight-bearing radiography of the knee at baseline and a follow-up examination. The K/L scale 
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was used, with a score of 2 and above classified as OA. The study found that participants with 
low intake and low serum levels of vitamin D, approximately 75 nmol/L, had 3 fold increased 
risk of radiographic worsening of pre-existing knee OA than participants with high intake and 
serum levels (150). Similar results were replicated in hip OA patients. Lane et al selected 237 
women from the random sample of the Study of Osteoporotic fractures (SOF) (151), who had 
a baseline and follow-up (8 years) data on serum vitamin D levels and hip radiographs and 
performed logistic and linear regression to examine the association between vitamin D levels 
with radiographic changes. The study reported that participants with low serum levels of 
vitamin D (defined as between 19-54 nmol/l) were nearly 3 times more likely to develop 
incident hip OA, defined as the development of definite narrowing of the joint space. Most 
studies consider serum level of vitamin D >50 nmol/l to be sufficient, it is not clear as to the 
reason for defining deficiency even above 50 nmol/l level. This study also did not investigate 
the effects on progression of OA. 
 
Although these studies investigating how radiographic indicators of OA interact with vitamin 
D levels show similar outcomes, only one study supports the effect of vitamin D on disease 
incidence (151) while others support its role only in disease progression and not incidence 
(150). Moreover, MacAllidon et al. used the full extension anteroposterior radiographs which 
have limited accuracy in evaluating the joint space without fluoroscopic positioning  (150). A 
follow-up study in 2007 (152) used data from two longitudinal cohort studies which included 
the Framingham Offspring Cohort (offspring of the original Framingham study participants) 
and Boston Osteoarthritis of the Knee Study (BOKS). They found no association between 
vitamin D status and risk of joint space or cartilage loss in knee OA patients. The study included 
715 and 277 subjects respectively from each cohort with baseline mean vitamin D level of 50 
nmol/L. The study used radiographic assessment for joint space narrowing, MRI for cartilage 
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loss, and radioimmunoassay for measuring vitamin D levels at baselines and follow-up, 9.5 
years for the Framingham Offspring Cohort and 30 months for the BOKS study. The cohort 
studies showed 20.3 % and 23.6% worsening of the knees respectively, with most knees 
showing no evidence of OA at baseline thus negating any association between vitamin D levels 
and incidence or disease progression of OA (152).  
 
These findings are in line with randomized double-blind placebo-controlled clinical trials.  An 
RCT (153) randomised 146 participants diagnosed with symptomatic knee OA to receive either 
oral cholecalciferol 2000 IU/day or placebo for 2 years. The treatment and placebo group 
showed no significant differences in the increase in serum vitamin D levels (p<0.001), knee 
pain (p=0.08), knee function (p=0.04) and cartilage volume loss (p=0.96) indicating that 
vitamin supplementation for 2 years, as compared with placebo, did not reduce knee pain or 
cartilage volume loss in patients with symptomatic knee OA.  
 
Another 2016 multicentre RCT (154) in Tasmania and Victoria randomised 413 participants 
with symptomatic knee OA and low vitamin D levels to receive 50,000 IU vitamin D3 or an 
identical placebo monthly for 2 years. The study found that level of vitamin D increased in the 
treatment group more than in the placebo group (p<0.001).  However, there were no significant 
changes in the tibial cartilage volume (p=0.13) as measured by MRI, or the WOMAC knee 
pain score (p=0.10) over 2 years among participants receiving the supplementation as 
compared to the placebo. Thus, failing to show any association between vitamin D levels and 
progression of OA. However, these RCTs included participants with vitamin D levels between 
12.5 - 60 nmol/L, which is below the optimal vitamin D level of 50 nmol/L in winter and 10-
20 nmol/L higher in summer for musculoskeletal health as described by the Australian and 
New Zealand (AUNZ) position statement (80). This raises the question of how many patients 
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in the treatment group reached optimal vitamin D levels, which could be the reason why the 
group did not benefit from additional vitamin D.  
 
In conclusion, although though there is some evidence supporting the role of vitamin D in the 
development and progression of OA, the heterogeneity of trial outcomes and lack of effect 
shown in prospective RCTs means that at present there is no clear indication for regular use of 
vitamin D in OA patients. A systematic review (138) appraising the evidence regarding the 
effect of vitamin D on OA, identified the lack of evidence regarding the association of vitamin 
D and OA in hip or hand. However, for OA of the knee, there is a moderate level of evidence 
linking vitamin D levels with the progression of knee OA, and strong evidence linking vitamin 
D levels with cartilage loss. This review suggests that vitamin D may have affected the 
structural changes of knee OA rather than the symptoms. 
 
 




Rheumatoid arthritis (RA) is a chronic autoimmune disease of unknown aetiology (155) 
characterized by systemic features and joint involvement (156). It affects nearly 1% of adults 
worldwide (157). RA exhibits periods of flare-ups which are characterised by pain, 
inflammation, and restriction in the movement and remission (158). The inflammation can also 
damage the joints if left untreated (158).  
 




Diagnostic guidelines for Rheumatoid arthritis  
 
Again, the ACR criteria are used for the definitive diagnosis of RA (159). There are 3 main 
criteria: 
i) The confirmed presence of synovitis in at least 1 joint,  
ii) Absence of an alternative diagnosis that better explains the synovitis, 
iii) A total score of 6 or more out of 10 in the categories described below in A-D; 
 
A. Joint involvement (159): 
 1 large joint – score 0 
 2- 10 large joints (shoulders, elbows, hips, knees, and ankles) - score 1 
 3 small joints (metacarpophalangeal joints, proximal interphalangeal joints, second 
through fifth metatarsophalangeal joints, thumb interphalangeal joints, and wrists) with 
or without involvement of large joints - score 2 
 4- 10 small joints with or without involvement of large joints – score 3 
 >10 joints (at least 1 small joint)- score 5 
B. Serology (at least 1 test result is needed for classification) (159) 
 Negative rheumatoid factor and negative anti-citrullinated protein antibody (ACPA) - 
score 0 
 Low-positive RF or low-positive ACPA- score 2 
 High-positive RF or high-positive ACPA – score 3 
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C. Acute-phase reactants (at least 1 test result is needed for classification) (159) 
 Normal CRP and normal ESR- score 0 
 Abnormal CRP or abnormal ESR - score1 
 
D. Duration of symptoms (159) 
 < 6 weeks- score 0 
 > 6 weeks- score 1 
 
Vitamin D and Rheumatoid arthritis 
 
Vitamin D has multiple immunomodulatory actions (160, 161) such as inducing immune 
tolerance (162), decreasing antigen presentation (163), inhibiting pro-inflammatory T helper 
cells (164), producing regulatory T cells and suppressing proliferation and differentiation of B-
cell precursors into plasma cells (165). 1,25-(OH)D inhibits the differentiation of monocytes 
to dendritic cells reducing the number of antigens presenting cells that stimulate the T cells 
which are vital in RA (166). Evidence supports the role of vitamin D deficiency in the 
development and progression of multiple autoimmune conditions, such as RA (167), type 1 
diabetes mellitus, multiple sclerosis (168), polymyositis (169), and systemic lupus 
erythematosus (SLE) (169). 
 
Because vitamin D has immune modulatory actions, its possible role in the development of RA 
and the associated pain have been studied extensively. A systematic review and meta-analysis 
(170) investigated if there was an association between vitamin D intake and the incidence of 
RA and vitamin D levels and RA activity. For the analysis, of the former association, data was 
collected from 3 cohort studies including 215 and 757 participants and 874 incident cases of 
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RA. The study found that individuals in the higher vitamin D intake group had a 24.2% lower 
risk of developing RA than the lower intake group. In the sub-group analysis, the study found 
that vitamin D supplement intake also lowered the risk of developing RA by 23.6%.  The meta-
analysis showed a significant association between vitamin D intake and RA incidence 
(p=0.047). For the second analysis, data was collected from 8 studies, six cross-sectional and 
two case-control studies. Seven of the eight studies indicated that RA activity was inversely 
correlated with serum vitamin D levels. However, as noted by the authors the results of the 
analysis should be interpreted cautiously as the data on vitamin D levels and RA activity from 
all studies could not be combined because of high heterogeneity between the individual study 
designs and outcomes (170). These results are in contrast to another study conducted by Baker 
et al. (171) which found no association between vitamin D intake and risk of RA.  
 
Very few studies investigating the risk of developing RA have actually examined the nutritional 
and dietary intake of the participants prior to the onset of RA. One such study, a prospective 
cohort study (172) who followed participants for 11 years reported that higher intake of vitamin 
D was associated with lower risk of RA, especially in elderly women.  The cohort reported on 
data collected from 29,368 women aged between 55-69 years with no prior history of RA. The 
study followed these participants for 11 years, estimated their dietary and supplemental intake 
of vitamin D as reported from the respondents’ responses to a baseline food frequency 
questionnaire and examined the incidence of RA. The study confirmed 152 cases of RA in the 
11 years follow-up period. The inverse association was evident for dietary and supplementary 
vitamin D intake and risk of development of RA (Relative risk (RR) 0.67, 95% CI, 0.44-1.00, 
p=0.05). Despite the large sample size and long follow-up, only 152 cases were identified 
during the follow-up period of 11 years and as a result, could not establish a statistical 
significance (172). These findings are in contrast to the two cohort studies conducted by 
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Costenbader and colleagues (173) who found no association between vitamin D intake and the 
risk of developing RA. The first cohort included 91,739 women from the Nurses’ Health Study 
(1980-2002) and the second study included 94,650 women from the Nurses’ Health Study II 
(1991-2001). 
 
The relationship between vitamin D and disease activity of RA has been researched 
considerably. A cohort study (167) which compared 44 patients diagnosed with RA to age and 
sex-matched controls (n=44) found that vitamin D deficiency was highly prevalent in patients 
with RA and influenced disease severity. The study measured serum vitamin D levels, 
parathyroid hormone levels, C-reactive protein and erythrocyte sedimentation rate along with 
the 28-joint Disease Activity Score (DAS28) in both the groups. Vitamin D levels were found 
to be negatively correlated to the DAS28 score, CRP and ESR the correlation coefficient being 
-0.084, -0.115 and -0.18 respectively. This suggests that vitamin D has a role in modulating 
disease activity in RA (167). Similar findings of an inverse association between vitamin D 
status and disease activity in RA were observed in studies conducted by Cutolo and colleagues 
(174) who studied the association between serum 25- hydroxyvitamin D levels and the DAS28 
score in female RA patients from Italian and Estonian background during winter and summer. 
The study found that in both IP and EP the variation in 25(OH)D levels between winter and 
summer was significant (p=0.0005). However, a negative correlation between 25(OH)D and 
DAS 28 was found in summer only in IP (r= -0.57, p<0.0001) and in EP in winter (r= -0.40, p 
<0.05). 
 
Similar findings were observed in studies conducted by Rossini and colleagues (175) in 2010 
(p=0.001) and Haque and Bartlett (176) in 2010  (p=0.001). A recent systematic review and 
meta-analysis  also found an inverse association between vitamin D and disease activity as 
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measured by the DAS28 (r=-0.13, 95% CI, -0.16- -0.09). The latitude-stratified subgroup 
analysis showed a relatively stronger negative correlation between vitamin D levels and 
DAS28 in low-latitude areas and also in developing nations (156). The stronger negative 
correlation in low-latitude areas was attributed to the moist weather condition in low-latitude 
areas, which tend to cause higher arthritis pain resulting in higher DAS28 scores. Some of the 
limitations of this meta-analysis is that it has a small sample size (n=3489) and it does not 
address heterogeneity within the selected studies. Some studies have also linked vitamin D 
deficiency with disease activity in RA (177, 178). However, other studies did not find an 
association between vitamin D deficiency and disease activity in RA (171, 179, 180). 
 
Many studies have also proposed that vitamin D deficiency also leads to RA associated 
osteoporosis. This was first suggested by Olezner and colleagues in 1998 (181), who 
investigated 96 RA patients and found that lower levels of serum vitamin D accelerated 
negative calcium balance and inhibition of bone formation which lead to an increase in the 
disease activity and predisposed them to osteoporosis (181). Deal and colleagues (182) have 
also observed that RA patients are more susceptible to osteoporosis (182). Hence, vitamin D 
supplementation along with anti-rheumatic drugs have been proposed for patients with RA not 
only for its effect on disease activity (157) but also for the prevention and treatment of 
osteoporosis (183). 
 
The findings from the above studies provide some support for the role of vitamin D in the 
development and progression of RA suggesting that vitamin D measurement and 
supplementation should be considered as an option in the management of RA patients. 
However, due to the limited number of studies investigating the association between vitamin 
D and RA, there is clear need for well-designed RCTs with long-term follow-up. 
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Chronic widespread pain (CWP), is a global musculoskeletal disorder, with an estimated 
prevalence of 10% to 24% in the general population (184, 185). The pathophysiology of CWP 
is unclear, but it is believed that somatization, altered pain perception, functional changes in 
pain receptors and hyperexcitability of central and peripheral nervous system play important 
roles. Although multiple individual, social, psychological and occupational risk factors 
influence the development and progression of CWP, other potential risk factors for developing 
CWP are  smoking status (186), poor education (187), low physical activity (188), low income 
(189, 190) and poor social life, relationship status- married, divorced or separated (185). CWP 
is characterized by reduced pain threshold, fatigue, disturbed sleep, problems with cognition 
and feelings of stress, depression and anxiety, headaches and irritable bowel syndrome (191). 
 
Chronic widespread pain often overlaps and even resembles other musculoskeletal and pain 
syndromes such as CNMP (192), chronic fatigue syndrome (193), fibromyalgia and irritable 
bowel syndrome (193). These conditions are often grouped as “medically unexplained 
symptoms” (194) and are recognised in specialist clinics (195). However, this often leads to 
the interchangeable use of these terms, especially chronic widespread pain, fibromyalgia and 
CNMP in practice (196-198). FM is now recognised as one of the sub-group of patients who 
have CWP where CWP forms a cardinal feature of FM (191).  
 
The interchangeable use of terms was first observed by Rohrbeck and colleagues (193) who 
discovered that the estimated frequency of fibromyalgia was much higher than the annual 
prevalence of diagnosed fibromyalgia in the primary care setting in UK population. Therefore, 
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they examined the consultation pattern over a 5-year period and identified 148 cases consulting 
for various musculoskeletal pains and 524 controls who had not consulted for musculoskeletal 
pain during the same period. The review showed that patients seeking medical care for multiple 
regional pain syndromes exhibited similar attributes to those associated with CWP and FM. 
Also, the GPs were rarely using the diagnostic label of “fibromyalgia” and were not necessarily 
applying the ACR criteria for fibromyalgia when making the diagnosis (193). Similar findings 
were supported by another UK primary care study (199). The known differences between CWP 
and FM are that patients with CWP do not exhibit tender points (191) and are linked to higher 
consumption of drugs, and use of disability pensions compared to FM patients. Still, there is 
not enough information on other sub-categories of CWP, which could potentially improve 
patient care. 
 
Diagnostic guidelines for chronic widespread pain 
 
According to ACR criteria, CWP is classified as pain persisting for more than 3 months that 
affects both sides of the body, above and below the waist, including some part of the axial 
skeleton (200-203). In 1996 Macfarlane et al. (204) proposed a coding system for classifying 
CWP pain as pain with a strong association with psychological disturbance, fatigue, sleep 
problems and tender points. They named it the “Manchester definition”. Though this definition 
is used in clinical and epidemiological studies it is not clear if this definition is better than the 
ACR criteria. Future research should compare the classification based on these methods, with 
or without tender points.    
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Vitamin D and chronic widespread pain 
 
Multiple studies demonstrate that CWP is associated with low levels of vitamin D (37, 200-
203). This relationship is often attributed to the development of osteomalacia associated with 
low vitamin D levels, of which musculoskeletal pain is a feature. Moreover, CWP and low 
vitamin D levels have common risk factors such as smoking (186), low physical activity (188) 
and depression (187) which may partly explain their association. It is equally possible that 
CWP will affect physical activity and subsequent sun exposure thus affecting vitamin D levels. 
 
Some studies show evidence of low vitamin D levels in women experiencing CWP, while in 
men it is unrelated to vitamin D levels. It is not clear why there was a gender difference, 
however, it is important to note that these studies mostly include participants of Caucasian 
origin which may not translate to non-white ethnic groups (200, 205).  
 
In a large cross-sectional study (202), the European Male Aging Study data from 3075 men 
aged between 40-79 years was collected. The participants with CWP had lower vitamin D 
levels than the pain-free participants (p<0.05). The findings suggest a moderate level of 
association between vitamin D levels and CWP indicating vitamin D levels to be a predictor of 
the onset of CWP. In a follow-up analysis (203), data was collected from the original 
participants of the EMAS study. The study assessed baseline as well as follow-up vitamin D 
levels, the course of pain, and presence of CWP using the ACR criteria. Of the 2313/3369 
respondents, 151 developed new CWP at follow-up and 577 remained pain-free at both time 
points. The participants at the upper quantile of serum 25(OH)D level (≥ 90.6 nmol/l) as 
compared to those in lower quantile (<38.9 nmol/L) were more likely to have developed CWP 
(OR=1.93; 95 % CI,1.0-3.6) at follow-up. These results (203) suggest that men with very low 
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levels of vitamin D (below 38.9nmol/L) at the beginning of the study were at an increased risk 
of developing CWP at follow-up, mediated by depression (OR=1.77; 95 % CI,0.98-3.21), and 
obesity (OR=1.67; 95 % CI,0.93-3.02).  
 
Similar results were observed in various reports which suggest an association between low 
vitamin D and CWP in a specific group (201). These findings contrast with a population-based 
study (200), which observed an association between serum vitamin D levels and CWP, in 
women but not in men, although men reported similar rates of pain (11.4% for men, 12.5% for 
women). This study included 9377 men and women born in the 1st week of 1958 who had a 
biomedical assessment at the age of 45 years. The mean vitamin D levels in women who 
reported CWP were 46.6 nmol/l and men were 53.1 nmol/l respectively (200). The analysis 
showed the interaction between 25(OH) D levels and gender in relation to CWP (p=0.006). 
This interaction was independent of lifestyle and social factors. Similarly, a 2015 meta-analysis 
(205) of data from 12 studies giving a total of 1,854 patients and 7850 controls, found a crude 
association between low levels of vitamin D and CWP. In the unadjusted analysis, CWP 
patients showed higher risk of hypovitaminosis D (OR= 1.63; 95% CI, 1.20–2.23, p=0.117, 
I2=37.8%). The subgroup analysis based on gender did not find a significant difference in the 
ORs. Although the individual studies included in the review suggested a relationship between 
hypovitaminosis D and CWP, the pooled analysis failed to establish any association. 
 
Studies investigating the effect of vitamin D supplementation on pain often separate the pain 
categories with five commonly being used: chronic, widespread, non-specific, persistent or 
musculoskeletal pain. Hence, studies reporting an effect observed with supplementation are 
listed under the section of chronic non-specific musculoskeletal pain. 







In 1904, Sir William Govers first coined the term “fibrositis”, a term commonly used to 
describe muscular pain, tension or psychogenic rheumatism. The current concept of 
fibromyalgia was proposed by Smythe and Moldofsky in 1977-1978 (206), which represents it 
as pain condition (-algia) and not just inflammation of connective tissues (-itis). Fibromyalgia 
(FM) (207) is a major type of non-inflammatory myalgia (208), commonly seen in 
rheumatology clinics (209). The prevalence of CWP and FM in developed countries is reported 
to be 10% - 24% (185, 197) and 0.5%- 4% (210) respectively in the adult population. It is 
characterised by chronic widespread pain and multiple tender points for which no definitive 
cause is identified (211). It is associated with a range of other symptoms, like sleep disorder, 
psychological stress, fatigue and mood disorders (193). The muscle pain and tenderness in FM 
is attributed to central sensitisation and amplification of nociception (208). When fibromyalgia 
was first proposed, it was controversial, however now with extensive research in the area our 
understanding has improved. 
 
Diagnostic guideline for Fibromyalgia 
 
The following criteria are used for the diagnosis of FM.  A patient should satisfy all three 
conditions listed below for a diagnosis of FM (212): 
i) Widespread pain index (WPI) > 7 and symptom severity (SS) scale score >5 or WPI 3-6 and 
SS scale score >9. 
ii) Symptoms should be present at a similar level for at least 3 months. 
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iii) The patient does not have a disorder that would otherwise explain the pain. 
 
Widespread pain index (WPI) - 
WPI is used as a quantitative measure (213) to record the presence of pain in the listed nineteen 
body parts.  The presence of pain in each is scored 1, a score of > 7 is considered diagnostic. 
 
Symptom severity (SS) scale –  
SS is a two-part scale (213) which is used to indicate the level of symptom severity over the 
past week. In part (a) fatigue, waking unrefreshed and cognitive symptoms are scored 0 (no 
problem), 1 (slight/mild problems), 2 (moderate level of the problem) and 3 (severe, life 
disturbing problem) each. In part (b) a list of other symptoms such as muscle pain, muscle 
weakness, headache, dizziness, constipation, diarrhoea, irritable bowel syndrome, insomnia, 
heartburn, nausea, vomiting, loss of appetite, rash etc. are checked. SS scale is scored between 
0 to 12 by adding the scores in the parts (a) and (b). 
 
Vitamin D and Fibromyalgia 
 
According to the 1990 ACR criteria for FM an individual should have a history of CWP and 
presence of 11 out of 18 tender points, which are grouped in 9 paired regions of the body (211). 
Women are 1-2 times more likely to experience CWP, but about 10 times more likely to meet 
criteria for FM (210). This gender difference between CWP and FM is solely attributed to the 
ACR criteria requiring 11/18 tender points, which is observed 11 times more commonly in 
women than in men (214, 215). This tender point criterion made FM more exclusive to females 
as they are more likely to exhibit tender points than men. Therefore, excluding this criteria 
would make it far more generalised in all gender groups (216). This is reflected in studies 
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investigating the incidence of vitamin D insufficiency or deficiency in FM patients. Screening 
40 female patients (217) with FM attending an outpatient department of the Civil Hospital, 
Karachi , showed that 32 were vitamin D deficient (serum vitamin D levels <50nmol/l) and 8 
patients were vitamin D insufficient (serum vitamin D levels between 52.5-72.5 nmol/l). 
Similar, findings were observed in a 2003 case-control study (218) comparing the vitamin D 
levels of 38 pre-menopausal women to age and gender matched controls. The study found that 
17 women from the FM group as compared to 7 women from the control group had a serum 
vitamin D concentration <20 nmol/l. (p<0.015) supporting the observation that there is a higher 
proportion of vitamin D deficiency in FM patients (218). However, another case-control study 
(219) did not observe a significant difference in vitamin D levels between the patient and 
control group (p>0.05), the incidence of vitamin D deficiency was also similar between the two 
groups (67.5% vs 70%). The treatment group included 40 pre-menopausal women diagnosed 
with FM while the control group included 40 age and sex matched healthy controls. But, the 
study observed that in the FM group, vitamin D levels showed significant correlation with the 
intensity of pain (r=-0.653, p=0.001) as reported by the patients, suggesting that 
hypovitaminosis D may play a role in amplifying pain intensity in FM patients (219). These 
findings were similar to a 2010 cross-sectional study (220) which did not observe a significant 
difference in vitamin D levels in 87 fibromyalgia patients compared to 92 age and sex matched 
healthy controls and no association between vitamin D levels and pain intensity. These findings 
were similar to another case-control study conducted in the United States (192) that observed 
no effect on pain with vitamin D supplementation. Altogether, these studies do not make any 
conclusive findings regarding the association between vitamin D and FM, with some studies, 
reporting a positive association (217, 221, 222) and others a negative association (198, 220, 
223). The major limitations of these studies were that most included only female participants 
                                                                                                                                    Chapter 2 
52 
 
and most did not have long enough follow-up periods. There was also a lack of information 
regarding seasonal variations in serum levels of vitamin D and in pain intensity.  
 
Multiple studies have investigated the effect of vitamin D supplementation in FM patients. In 
a case-control study (224), bone mineral density (BMD) and serum vitamin D levels were 
measured to examine the possible association between fibromyalgia and osteoporosis or 
hypovitaminosis D. The study collected data from 205 female patients (224) diagnosed with 
fibromyalgia and 205 gender and age- matched healthy controls. The study found no 
differences in BMD and vitamin D levels in the patients (cases) and controls. However, it was 
recorded that in summer, the patient group showed a lower rise in vitamin D levels than 
controls, indicating a relative vitamin D insufficiency among FM patients. The lower rise in 
vitamin D levels could be due to reduced outdoor time as a result of fatigue and soreness in the 
patient group. However, as the study did not follow these patients further, there are no data to 
show if the reduced vitamin D levels during summer altered the pain intensity of these patients 
(224). Another study (213) screened vitamin D levels and calculated WPI of 30 consecutive 
female patients (both veiled and non-veiled) diagnosed with fibromyalgia. This study found all 
the FM patients had severe vitamin D deficiency (mean level was 11.8+- 3.6 nmol/L) with a 
significant inverse correlation between vitamin D levels and WPI (p=0.08). The study 
supplemented all participants with either single dose (600,000 IU) vitamin D3 intramuscular 
injections or oral vitamin D3 tablets 50,000 IU weekly for 8 weeks. Participants were re-
evaluated by the clinical FM diagnostic criteria at follow-up, 1 month after the treatment with 
vitamin D injection or 2 months after treatment with vitamin D tablets. The study observed 
clinical improvement in all patients following treatment with vitamin D. In a 2014 study (225) 
30 women with fibromyalgia and vitamin D levels <80nmol/L were randomized to receive 
1200-2400 IU cholecalciferol per day. The treatment group observed a reduction in pain 
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irrespective of the dose given as compared to the control group. The major limitation of this 
RCT was its small sample size. Another study (222) found similar results in 139 patients with 
fibromyalgia. One hundred and three patients (74%) had low vitamin D level (38.9nmol/L); 
and were randomized to receive vitamin D3 injections (600, 000 IU i.m. single dose) or oral 
tablets (50,000 IU) for 8 weeks. Ninety percent of the patients in the treatment group reported 
complete resolution or a decrease in myalgia. This study also showed that vitamin D deficiency 
was highly prevalent in Arab (86%) and Pakistani patients (87%) (222) and least prevalent in 
Caucasian patients (8%) suggesting that the diagnosis of FM in Indo-Pakistani women could 
mean low levels of vitamin D. Limitations of this study were the lack of a control group and 
the short follow-up period. The study also did not provide any information regarding recovery 
time or variations for the two methods of supplementation used. The number of studies 
evaluating the effect of vitamin D supplementation on pain intensity in FM patients is limited, 
necessitating more focused research in the area to understand how low vitamin D may generate 
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Chronic non-specific musculoskeletal pain (CNMP) is a complex idiopathic condition, 
characterised by localized or generalised pain and disability. The pathoanatomical and 
pathophysiological explanation for CNMP is unclear which often leads to a non-specific 
diagnostic label based on the presenting symptoms (226). It is a major health problem (227) 
with an increasing number of patients (217, 228), especially in children and adolescents (229, 
230). However, there is a paucity of data on the prevalence of CNMP, mainly because of the 
lack of clear guidelines for identifying patients and different and often overlapping definitions 
of pain used in individual studies. Most of the studies reporting on prevalence use different 
terms of investigation such as, “chronic pain”, “chronic widespread pain” or “nonspecific 
pain”. According to de Vries and colleagues (231), in Western societies a high prevalence of 
CNMP is reported among patients seeking medical care resulting in reduced participation in 
work leading to a high socioeconomic cost. Chronic nonspecific musculoskeletal pain (CNMP) 
is an idiopathic condition with high prevalence reported among patients seeking medical care 
in general practice. The effects of CNMP extends beyond individual’s physical and mental 
health, often affecting their family (232-234) and social life, working ability and performance 
(235) resulting in high levels of health care utilisation (236).  
 
CNMP has a multidimensional biopsychosocial basis (84, 237), with patients exhibiting higher 
levels of anxiety and depression and poor physical activity and gross motor skills (226). 
Multiple factors such as psychological, physical, lifestyle (238) and social factors (84) interact 
to form a vicious cycle of pain (88) with management approaches reflecting this 
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biopsychosocial framework (118, 239). Meyer and colleagues (240) observed that in chronic 
musculoskeletal pain conditions, the sensitivity of central neurons input from unimodal and 
polymodal receptors is intensified. As a result, patients experience generalized or widespread 
hypersensitivity which resembles central sensitization. Management strategies should also put 
greater emphasis on the enhanced sensitivity of the nociceptive system (86), increased 
contribution of non-nociceptive sensory inputs and associative learning (241), cognitive 
mechanisms that emphasise perceived threat to body tissue and behavioural processes linking 
fear of pain, activity avoidance and catastrophizing (88) and de-emphasise ongoing tissue 
pathology or damage (87), with some exceptions, such as seronegative arthropathies.  
 
Diagnosis of chronic non-specific musculoskeletal pain 
 
CNMP is often used interchangeably especially with CWP and FM, because the pain 
presentation and associated co-morbidities such as mood disorders, sleep disturbances, and 
fatigue (211) are similar. However, it often differs from the ACR classification of CWP by 
more commonly affecting a single site rather than multiple sites (185).  Due to the lack of 
diagnostic criteria, CNMP is often a diagnosis of exclusion. We do not know the clinical 
reasoning general practitioners (GPs) apply for diagnosing CNMP. There is a clear need for 
more research to understand the clinical presentations and diagnosis of CNMP in primary care.  
 
Related research objective: To understand the clinical reasoning GPs’ employ when 
diagnosing managing patients with chronic non-specific musculoskeletal pain. 
 




Chapter 3 entitled ‘A qualitative exploration of GPs’ perspectives on managing chronic 
nonspecific musculoskeletal pain in Australian general practice’ aims to address this gap in 
knowledge.  
 
Vitamin D and chronic non-specific musculoskeletal pain 
 
There are mixed findings from studies investigating the role of vitamin D deficiency for 
patients with CNMP. A small number of studies suggest an association between low vitamin 
D levels and incidence of CNMP (37, 200), with one even reporting complete resolution of 
pain (213) on supplementation. However, there are also studies showing no effect of vitamin 
D supplementation (192, 198) and these contributed to the Cochrane systematic review (242) 
appraising evidence regarding the effect of vitamin D supplementation on all chronic painful 
conditions, concluding that there was insufficient evidence of a positive effect of vitamin D 
supplementation on pain. Thus, the link between vitamin D and CNMP remains unclear.  
 
A cross-sectional study conducted by Plotnikoff and Quigley (37), was the first to demonstrate 
an association between vitamin D and nonspecific musculoskeletal pain, with nearly 96% of 
participants found to be vitamin D deficient. This study included 150 patients suffering from 
non-specific musculoskeletal pain with no history of FM, temporomandibular disorder, or 
complex regional pain syndrome. The study observed no differences in the level of vitamin D 
deficiency among the immigrant and non-immigrant groups. The risk of vitamin D deficiency 
was more pronounced in the younger compared to the older participants. Following this study, 
multiple studies were performed to investigate if gender and ethnicity affect vitamin D and 
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CWP. The results from these studies are conflicting. For example, the study by MacFarlane 
and colleagues (201) who conducted two population-based cross-sectional surveys, A and B in 
England, which compared subjects of South Asian origin (India, Pakistan and Bangladesh) 
with white Europeans. Survey A reviewed the occurrence of musculoskeletal pain among 
people aged 18-75 years while survey B was a screening survey of bone density in women aged 
18-36 years using bone density scanning.  The results from Survey A indicated a high incidence 
of widespread pain among South Asians (n=1945, OR=1.6, 95% CI, 1.3-2.1) compared to 
white Europeans (n=932). Survey B similarly showed a higher incidence of widespread pain 
among South Asians (n=137, OR=1.8, 9.5% CI, 0.7-4.7) and found that low levels of vitamin 
D (<10ng/ml) were more common among those with widespread pain (OR=3.5, 95% CI, 0.4-
31.0).  
 
These results not only show Asian ethnicity as a high-risk group but also suggests low levels 
of vitamin D to be a predictor of CWP. These results are consistent with a 2010 study (223) 
performed in an outpatient clinic in Iran. The study compared serum vitamin D levels of 276 
patients referred to the clinic for the nonspecific musculoskeletal pain to 202 matched controls. 
The study (223) found a strong association between vitamin D and nonspecific bone pain, leg 
pain, arthralgia and widespread skeletal pain particularly in females (OR=2.1, 95% CI, 1.1–
4.3, p=0.001). Another prospective observational study (243) performed in 2010 measured 
vitamin D levels in 100 female patients with CNMP of duration greater than 6 months, who 
were unresponsive to analgesic drugs. Eighty-four patients were detected as vitamin D deficient 
(serum vitamin D levels between 24-48 nmol/L) with 42 patients classified as severely deficient 
(serum vitamin D levels between 12- 20 nmol/L). All patients with deficient levels of vitamin 
D were given 1 α hydroxycholecalciferol 0.5-1μg with 800mg of calcium supplements orally 
daily according to the severity of the deficiency for 3 to 4 months. All showed noteworthy 
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improvement in their symptoms. The patients were thereafter given a daily supplement of 
400IU vitamin D3 and 800 mg calcium carbonate along with a recommended 15 minutes of 
daily sun exposure, which maintained their improvement and treatment effect even after a year.  
 
Several cross-sectional studies (244-246) and case reports (247, 248) and large intervention 
studies (192, 249, 250) support the beneficial effect of vitamin D supplementation on 
musculoskeletal diseases or complaints. These case series report on an unusual pain syndrome 
in vitamin D deficient patients, which shows improvement on supplementation (247, 248). 
These cases describe the pain pattern as nonspecific and sometimes localised to lower 
extremities, which may represent CNMP. But, due to limited information, it is difficult to be 
certain that this is the correct diagnosis. One of these reports observed complete resolution of 
symptoms with 50,000IU intake of vitamin D2 (247). However, the pain was reproduced if 
vitamin D deficiency recurred and could again be resolved with normalisation of vitamin D 
status. Another case study reported on wheelchair bound patients who regained their muscle 
strength within 4 to 6 weeks of treatment with vitamin D (248).  
 
A small number of randomized controlled studies have investigated the efficacy of vitamin D 
supplementation on nonspecific pain. In 2012 Schreuder et al (250) performed a semi-crossover 
randomized controlled trial on 84 non-Western immigrants who were vitamin D deficient with 
complaints of persistent nonspecific musculoskeletal pain. The study evaluated the effect of 
high dose vitamin D3 on the pain patterns. Participants were randomized to either placebo or 
oral vitamin D3 150,000 IU single oral dose. At week 6, patients originally in the vitamin D 
group were randomised a second time to receive vitamin D again or switch to placebo, whereas 
patients originally in the placebo group were all switched to vitamin D. The outcomes were 
self-evaluated by patients based on the changes in their pain after the first 6 weeks. Patients in 
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the vitamin D group reported significant pain relief (p=0.04) and improved ability to walk 
upstairs (p=0.008), compared to their counterparts in the placebo group. The study found a 
small positive effect 6 weeks after high-dose vitamin D3 on non-specific musculoskeletal pain. 
This study used only a single strength of vitamin D with some participants receiving only 1 
dose of vitamin D supplementation in 12 weeks which could have affected their outcome 
measures. 
 
Another RCT (249) investigating the effects of a single a dose of 30,000 IU vitamin D 
administered orally or parenteral on nonspecific musculoskeletal pain in community-dwelling 
elderly subjects over 65 years of age observed similar effects. The study used a Visual Analog 
Scale (VAS) for pain assessment, Timed up and go test for measuring functional mobility, and 
SF-36 to measure the quality of life. The study assessed pain, functional mobility, quality of 
life and vitamin D levels before and after 4 weeks of treatment. In both the oral and parenteral 
(intravenous) vitamin D group, the TUG (p=0.0001, 0.0001) and the VAS (p=0.0001, 0.002) 
decreased significantly, whereas the SF-36 subtitles, physical functioning (p=0.0001, 0.0001), 
role physical (p=0.006, 0.001) increased. The single dose of vitamin D significantly improved 
the quality of life, decreased the pain and improved functional mobility in the elderly. This 
study added valuable information to the literature because of its randomized, placebo-
controlled, double-blind study design and power analysis. This study excluded participants 
diagnosed with underlying chronic conditions such as Paget’s disease, renal stones, 
fibromyalgia, thyrotoxicosis etc. that could potentially interfere with the effects of vitamin D 
supplementation.  
 
These findings were not replicated in another RCT (192) including 50 patients with CNMP and 
vitamin D levels <50nmol/L. The study found no effect of 50,000 IU vitamin D 
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supplementations given once weekly for 3 months on the pain. The study used Functional Pain 
Score (FPS), and VAS to measure pain and serum immunoassay to measure vitamin D levels, 
at baseline and 3-month follow-up. There was no difference in, vitamin D levels (p=0.09), VAS 
(p=0.73), FPS (p=0.18) compared to 3-month post-treatment vitamin D levels (p=0.85), VAS 
(p=0.12), FPS (p=0.05). The study also observed no difference in pain scores between the 
treated groups. However, this study lacked proper blinding and randomization and included 
patients diagnosed with osteoarthritis (in whom pain is an integral part of their clinical 
diagnosis) in the control group. The current state of the evidence concerning vitamin D 
supplementation in CNMP pain is still unclear.   
 
Related research objective- - What is the current evidence concerning the effect of vitamin D 
supplementation on pain associated with CNMP? 
 
Chapter 4 – ‘Does vitamin D alleviate chronic nonspecific musculoskeletal pain? A systematic 
review and meta-analysis’ aims to address this gap in knowledge.  
 
 
2.3.6 How vitamin D can affect or modulate chronic nonspecific 
musculoskeletal pain? 
 
The discovery of vitamin D receptors on muscle cells (251-253) led to many studies, as vitamin 
D supplementation could be an inexpensive and effective method to treat nonspecific 
musculoskeletal pain. It would be especially beneficial in non-Western immigrants, who are 
more prone to vitamin D deficiency than resident Caucasian people (201, 254-257). 
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In addition to calcium homeostasis, vitamin D is involved in many regulatory biological 
processes such as anti-inflammatory, anti-apoptotic and anti-fibrotic (51, 61) and it is believed 
to play a role in innate and adaptive immune system function as well (51, 61). People with 
vitamin D deficiency can present with nonspecific muscular pain and bone pain (258). It is 
proposed that the pain associated with hypovitaminosis D may be due to insufficient calcium 
phosphate (259) which affects the collagen matrix mineralisation causing it to become rubbery. 
As a result, the bone is not well supported which causes pressure on the periosteal covering 
innervated by sensory fibres (259). Even a gentle pressure on these bones can elucidate pain 
(259). Supplementation with vitamin D may exert non-genomic influence on the metabolism 
of muscle cells, growth of muscle fibres and nonspecific effect on central and peripheral 
nervous system (250). 
 
Vitamin D deficiency could disturb the neuroimmunological process that subserves pain (260) 
due to the loss of its immune regulatory (51, 61), anti-inflammatory and anti-apoptotic function 
(51, 61). However, it is still unclear if pain associated with vitamin D deficiency is widespread 
or localised to arms, lower back or legs.  
 
2.3.7 Characterising the testing, prescription, and taking of vitamin D 
supplements in people with pain. 
 
Vitamin D supplements are taken by a large number of people, with and without pain. It is also 
considered as cost-effective (261, 262), easily available intervention (262) with minimal side 
effects (262). Remarkably, however, little is known about the demographic and clinical features 
that are associated with the testing, prescription and consumption of vitamin D supplements in 
people with chronic pain. There is a reasonable evidence that older age groups (263), female 
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gender (264), higher body mass index (265) and dark skin pigmentation (266) are associated 
with vitamin D deficiency. 
 
However, one would predict that if the link between vitamin D deficiency and pain is based 
specifically on postulated biological mechanisms, such as the neuroimmunological process, 
then the characteristics of someone’s pain neuropathic or non-neuropathic descriptors and the 
intensity of their pain, should also be considered when testing for, prescribing and taking 
vitamin D supplementation. Moreover, if vitamin D deficiency is suspected on the basis of 
biological mechanisms of effect, then factors such as where one lives should relate only insofar 
as differences in exposure to sunlight or diet exist. 
 
Related research objective- What demographic and pain-related factors are associated with 
testing of vitamin D, vitamin D deficiency, and the prescription and taking of vitamin D 
supplements? 
 
Chapter 6 – “Factors associated with testing, deficiency and supplementation of vitamin D: a 
predictive model” aims to address this gap in knowledge. 
 
2.3.8 Patient’s perspectives on pain education and their patient-provider 
relationship. 
 
The first study of this thesis investigates, using a focus group design, the perspectives of GPs’ 
on management of people with chronic pain. That study revealed certain features of the clinical 
interaction that were felt by GPs’ to be important for the patient such as developing a good 
rapport. The final study of this thesis uses a survey design to compare and contrast the GPs’ 
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perspectives with those of patients on the patient-provider relationship, the implications of pain 
education and their effect on pain intensity and perception of recovery. Patient perspectives on 
care has been studied in other contexts such as quality of care (267), cost of care (268), 
experience of care (269) among others. But it remains unknown as to whether patients with 
chronic pain and GPs are aligned in what they prioritise as important in their clinical 
interactions. 
 
Related research objective- What are the experiences of people with chronic pain, of their 
health care interactions and pain education?  
Chapter 7 – “Effect of pain education and patient-provider relationship on patient-reported pain 




There is some evidence of an association between vitamin D deficiency and musculoskeletal 
weakness and pain. However, it remains unclear if the pain associated with vitamin D 
deficiency is generalized or localized to a specific body part such as arms, lower back, and 
legs. It is also possible that another confounding factor may lead to both increased pain 
perception and lower vitamin D levels, or that they are simply associated but not causative. For 
example, individuals with musculoskeletal pain may have reduced exposure to sunshine 
because they walk less, which would lead to an association but would not necessarily mean 
that low vitamin D levels were causative. This would be applicable for all musculoskeletal pain 
types. It remains to be confirmed whether this association is causative or not. 
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This thesis seeks to identify the magnitude of any effect of vitamin D supplementation on 
nonspecific musculoskeletal pain. We then investigate the clinical understanding currently 
used by general practitioners when managing individuals who present with this complex 
condition. Further, for the first time, we try to understand the perspectives of patients’ who 
experience chronic pain about their pain management. These studies will provide context-
specific evidence that can contribute to the implementation of evidence-based management, to 
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This chapter comprises of the first study of the thesis, which examined objective 1 - What 
management strategies do GPs employ with patients presenting with CNMP? 
In the Australian health care system, general practitioners (GPs)  are usually the primary point 
of contact for medical advice (22). As a result GPs see the widest range of conditions of any 
specialty and are required to have a working knowledge of multiple conditions (270). 
Complaints of chronic pain arise in an estimated 15-20% of GP visits (23, 271). However 
compared to management of other chronic diseases physicians report a high level of 
dissatisfaction when managing chronic pain due to lack of training and resources (24-26). 
This paper has been accepted as an original research article for publication in Family Medicine 
and Community Health. 
 




According to the Australian Bureau of Statistics (ABS) National health Survey (NHS) data in 
2007-2008 (272), 3.2 million people (1.4 million males and 1.7 million females) aged 15 years 
and over reported experiencing pain in the previous four weeks. In comparison to the 1995 
data, the overall rates of body pain in Australia increased from 57% to 68%; and severe/very 
severe pain increased from 7% to 10% (272). It was also observed that 1 in 5 Australians with 
severe/very severe pain suffered from depression or other mood disorders which are 4 times 
the rate for people without pain (5%) and more than twice the national average (9%) (272).  
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The prevalence of chronic pain today is comparable or higher than that of the National Health 
Priority Areas such as cardiovascular disease, cancer, musculoskeletal diseases, injuries, 
mental disorder, asthma and diabetes (273). It is also estimated that the prevalence of chronic 





Figure 3.1 Prevalence Chronic Pain, Australia 2007 (273)  
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Economic Impact  
 
On the Society: 
 
The total cost of chronic pain was estimated in 2007 at $34.3 billion to the economy per year 
or $11,000 per person (273). The highest impact is seen on productivity costs with 
approximately $11.7 billion caused by chronic pain. The next largest share is associated with 
the burden of disease (BoD) at around $11.5 billion, followed by the costs to the health system 
at approximately $7.0 billion which captures the medical costs, the pharmaceuticals, other 
health care services and residential aged care (273). Comparatively, smaller costs are attributed 
to the opportunity cost (e.g. informal care, aids and modification and deadweight losses (DWL) 
(e.g. taxation revenue forgone, welfare payments, disability support pension, and NewStart 
allowance. 
 
Figure 3.2 Total cost of Chronic Pain to society(273)  
DWL: Deadweight loss; BoD: Burden of Disease 
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On the individual 
 
Individuals suffering from chronic pain bear the largest share (55%) of the whole cost 
themselves, primarily due to the large burden of disease, followed by the Federal government 
which bears 22% of the total cost (273). While employers and the State Governments bear 5% 
each, followed by family and friends bearing 3%, and society bearing the remaining 10% of 
the cost (273).  
 
 
Figure 3.3 Total cost of chronic pain at an individual level (273) 
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Chronic nonspecific musculoskeletal pain  
 
Chronic non-specific musculoskeletal pain (CNMP), is a type of chronic pain distinguished by 
the clear absence of pathophysiological or anatomical causes (226). It has a rising prevalence 
among patients seeking medical care in general practice. CNMP causes significant disruption 
to the sufferers’ lives, relationships (226) and working ability (235). Multiple studies suggest 
that symptoms of CNMP in children and adolescent age groups is a predictor of poor quality 
of life and disability in adulthood (226, 274). 
 
The International Classification of Diseases (ICD) does not provide diagnostic codes for an 
array of chronic pain manifestations (275) which includes CNMP. The lack of diagnostic codes 
hinders billing for health care expenses related to pain management and development of new 
therapies (276-278), which further complicates the management of CNMP for doctors. In the 
absence of both an ICD code and guidelines for management, it becomes imperative that we 
better understand how GPs are diagnosing and managing patients with CNMP currently.  
 
As seen in chapter 2.3 CNMP has been linked with vitamin D deficiency, which is a major 
global public health concern (38, 279, 280), even in countries with abundant sunlight (280). It 
has been estimated that nearly one-third of Australians aged > 25 years are vitamin D deficient 
(38). Vitamin D supplementation for CNMP has produced inconsistent results (192, 249, 250, 
281), with the benefits of screening for hypovitaminosis D being questioned (192, 282). 
 
In the literature review, we found little information about how GPs manage CNMP, with no 
published studies undertaken in primary care. To address this, we conducted a qualitative study 
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with Australian GPs, aiming to understand their approach to managing CNMP. Bearing in 
mind, GPs role in primary health care for most individuals in Australia, their experiences and 
views can add valuable information to our understanding about the diagnosis and management 
of CNMP. This article addresses a significant gap in the literature by describing GPs clinical 
reasoning, experiences and views on managing CNMP in primary care setting.  
 
Composition of Australian General Practice Workforce: 
According, to the Australian Institute of Health and Welfare (AIHW) statistics, 102,805 
medical practitioners were registered and 88,040 were employed in 2015. Of the employed 
practitioner’s 27.2% were aged 55 years or older and 40.1% were women. The report also states 























Objective: Chronic nonspecific musculoskeletal pain (CNMP) is a complex idiopathic 
condition which causes significant disruption to patients’ lives, their relationships and 
functionality. The etiology of CNMP is not fully understood which makes diagnosis and 
management challenging.  As general practitioners (GPs) are central to the management of 
chronic pain, their perspectives on managing CNMP is important.  
Purpose: To explore the clinical reasoning GPs employ when diagnosing and managing 
patients with CNMP. 
Methods: A qualitative study design using focus groups was conducted with Australian GPs. 
Five focus groups were conducted across Adelaide. All focus groups were audio recorded and 
transcripts were coded and analyzed thematically using NVivo software. 
Results: The main themes remained consistent across the 5 focus groups: the ambiguous 
etiology of CNMP; gender differences; developing the “right strategy”; patient centred care; 
and verifying vitamin D levels. 
Conclusions: The findings show that GPs use a patient-centered approach tailored to individual 
patients’ medical history, physical examination and psychosocial health. There was general 
concern over low levels of vitamin D in patients with CNMP and vitamin D supplements were 
recommended if indicated by a patients’ history. 
Keywords 









Chronic pain is Australia’s third most costly health condition (273), with one in every five 
Australians experiencing chronic pain at some point in their life (284). Similar numbers are 
reported worldwide (285). Although pain is now recognized as a disease and is highly 
researched, its management perplexes the medical world.  One of the reasons could be a poor 
understanding of the variations in the presentation of chronic pain.  
Chronic nonspecific musculoskeletal pain (CNMP) is an idiopathic condition with high 
prevalence reported among patients seeking medical care in general practice (18) and 
rheumatology clinics (226, 286). CNMP is distinguished by the clear absence of an underlying 
anatomical or pathological cause (226). It is characterized by pain, distress, and disability 
(229). Besides poor physical health, it also causes mental and emotional suffering, social 
isolation (226, 229, 232), and reduced productivity (235). As the pathophysiology of CNMP is 
not fully understood, its management remains a challenge for medical doctors and patients 
alike. 
General practitioners (GPs) are reported to be the preferred health professionals whom patients 
with chronic pain seek for medical care (21). Considering the central role of GPs in the 
management of chronic pain, their experience, perspectives and clinical reasoning about 
CNMP is fundamental to improving our understanding of the different variants of chronic pain. 
However, little is known about how patients with CNMP are currently being managed by GPs. 
To address this, we conducted a qualitative study with Australian GPs.  
 
  





The aim of this study was to explore the clinical reasoning GPs employ when diagnosing and 




Ethics approval for the study was obtained from the University of Adelaide Human Research 
Ethics Committee (approval no: HS- 2013-056). Written consent was obtained from every 




A qualitative methodology was selected for this study in order to enable an in-depth exploration 
of participant experiences, views, and understandings. The synergistic and serendipitous nature 
of focus groups has been well established (287, 288). Given that this is an under researched 
topic where unpredictable accounts or concerns could potentially arise, focus groups were 
considered the appropriate exploratory method. An additional advantage of the focus group 
method was that practitioners could potentially learn from each others’ experiences during the 
discussion and thus explore the nature of best practice during (and potentially after) the focus 
group discussions.  
A set of flexible semi-structured questions developed by the authors (two of whom are 
practicing GPs) to ensure coverage of research objectives across all focus groups was used as 
a guide for exploring GPs’ views on management of patients with CNMP. Participants were 
encouraged to openly discuss the questions presented and any issues raised with the premise 
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of there being 'no right or wrong answers' in order to encourage both shared and contrasted 
contributions to be openly explored. The dynamics of a group were judged to be more likely to 
generate in-depth discussions where participants could also raise their own questions for 
collective consideration. Moreover, this flexible method enabled researcher interpretations to 
be iteratively explored during the group and the opportunity for any apparent emerging themes 
to be summarised for further critical participant input and revision. Emerging themes identified 
through initial thematic analysis of each focus group were introduced for further exploration 
and development in subsequent focus groups (289). 
Twenty-seven practices were invited to participate in the study. Of which five practices agreed 
to participate. Twenty-three GPs were recruited via phone calls and emails to respective 
practice managers. Every participating GP was provided with an information sheet which 
included details about the proposed study and the procedure to be followed, ethics approval 
and consent. Five focus groups were conducted in each of the medical practices in Adelaide, 
providing varying size and socioeconomic mix of patients. 
 
Data collection and analysis 
 
Each focus group session lasting approximately an hour was audiotaped and later transcribed 
using the software Nvivo 10. Thematic analysis was performed on the transcribed data 
following the principles described by Braun and Clarke (290): (i) familiarization with data and 
transcription of verbal data;  (ii) generating initial codes; (iii) searching for themes; (iv) 
reviewing themes; (v) defining and naming themes; and (vi) report production.  
Each focus group discussion was conducted and audiotaped by MG. On completion of each 
focus group, transcription of the data was performed by MG, inserting memos to clarify 
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contextual circumstances where appropriate including intonation of the speaker. The initial 
coding was performed by MG who then ‘fed back’ her impressions to the team at the end for 
further discussion and validation against the transcript. The themes linking codes were initially 
identified by MG and SV, which were then periodically reviewed by PA and NS. Emerging 
themes were introduced to subsequent focus groups for further discussion and review. 
 
Data Trustworthiness and Reflexive analysis 
 
The dynamic and flexible nature of the focus group method allowed the moderator to share and 
iteratively expand upon her interpretations of discussions while they were taking place, both 
with supplementary questions and by providing summaries of issues raised with invitations for 
further contributions to expand and further shape these. This enabled a reflexive practice in 
that the moderator actively sought to question and reconstruct her own interpretations as part 
of the focus group activity. This was further enacted through the collective review of themes 
performed by the whole research team until a definitive consensus, grounded in the original 




In reporting our qualitative findings, we have complied with the Standards for Reporting 
Qualitative Research (SRQR) (291). 
 
Demographic data of participants 
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Five focus groups were conducted consisting of twenty-three GPs. Among the 23 GPs, 4 (17%) 
were female and 19 male (83%). Most GPs were aged 45-55 years (n=17, 74%) with only 2 
(8.6%) being aged less than 40.  The mean age was 50 years ± 8.7 and their years in general 
practice ranged between 3 - 43 years, with mean of 17.5.  
 
Thematic Analysis Findings 
 
Following thematic analysis, five themes were identified: ambiguous aetiology, gender 
differences, developing the “right strategy”; patient centered care; and verifying vitamin D 
levels.  
Theme 1: Ambiguous aetiology 
 
GPs reflected on the uncertainty of diagnosing and managing CNMP patients, particularly in 
the absence of any guidelines. CNMP was believed to have multifactorial etiology and 
pathophysiology which may often precede untreated injuries, falls, sprains, infections, and 
autoimmune disease. Uncertainty about the underlying etiology was a common theme. Some 
GPs linked the long-term use of medications like statins, benzodiazepines, and opioids to 
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Table 3.1 Exemplar quotes for Theme 1 
Theme Quotes 
 





“Usually patients with past medical history of untreated falls or 
fractures present nonspecific musculoskeletal pain” 
 
“Patients with previously undiagnosed conditions like 
autoimmune disease, fibromyalgia often report chronic 
nonspecific musculoskeletal pain” 
 
“Many patients with old injuries related to sports, work later show 
nonspecific musculoskeletal pain symptoms” 
 
“Patients using statins long term can also develop nonspecific 
musculoskeletal pain.” 
 
“Opioids, benzodiazepines dependency can often lead to chronic 
nonspecific musculoskeletal pain.” 
 
 
Theme 2: Gender differences 
One of the topics discussed was the presence of gender bias.  In general, there was consensus 
that more female patients are likely to be diagnosed with CNMP. This however, was attributed 
to their generally higher uptake of medical services. On the other hand, male patients were 
believed to seek medical advice for specific issues such as functional impairment due to pain. 
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Theme 2 : Gender differences 
 
 
“Though more females present with non-
specific variant, the reason could be that 
males rarely visit GPs.” 
 
“Females to males ratio is 2:1, but then 
again females in general seek medical advice 
more frequently than males.” 
 
“Males put a name to their pain, usually 
joints and muscle pain. They focus on the 




Theme 3: Developing the “right strategy” 
GPs emphasized that it was important to change the approach of diagnosis based on individual 
patient complaints, as patients with CNMP have diverse clinical presentations and needs. The 
“right strategy” was described as the process of identifying what would work best for an 
individual patient. The standard modus operandi – history taking, physical examination, and 
investigation was used, but tailored to the individual patient.  Strong emphasis was placed on 
longer consultations as it helped to take a detailed medical history and also provided GPs an 
opportunity to develop a good patient-provider relationship. Arranging longer consults, 
however, was considered difficult due to financial and time constraints. Most GPs did not 
encourage repeating specialized investigations such as x-rays or CT scans as it was believed to 
add little or no value to the management, but instead drew patients’ attention to general signs 
of wear and tear. Some exemplar quotes for theme 3 are presented in Table 3.3. 
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Table 3.3 Exemplar quotes for Theme 3 
Theme Quotes 
 
Theme 3 : Developing the right strategy 
 
 
“Patients come with very different 
complaints hence it’s difficult to have one 
approach” 
 
“Patient has an expectation of a thorough 
examination which needs to be matched. 
They need to be assured that the doctor cares 
and wants to help them”. 
 
“Ideally longer consult would be perfect to 
build trust and confidence, but often not 
possible due to time and financial 
constraint.”  
 
“Doing X-ray or ultrasound scan may make 
a patient feel great for doing it but adds little 
value to the diagnosis while increasing the 
costs and morbidity.” 
 
“X-rays show signs of wear and tear. This is 
detrimental for patients, shifts their focus 
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Theme 4: Patient-centered care 
 
Similar to diagnosis, management was also reported to be tailored to the individual patient. 
Setting realistic goals and managing the psychosocial health of patients’ was reported as the 
framework for patient care. An important aspect for setting realistic goals was shifting patients’ 
focus from complete recovery to improving their functional capacity, mood and overall quality 
of life. Managing psycho-social wellbeing (mood, stress, signs of depression) of patients was, 
at times, reported to be more pertinent to recovery than pharmacological therapy. Some GPs 
also reported limited or no improvement in patients if their psychological well-being was 
overlooked. However, most GPs observed a general resistance from patients in seeking 
psychological help, such as counseling or therapy, as this was attributed to the stigma attached 
to such treatments. Judging an appropriate time to introduce patients to these treatment options 
was considered crucial for their acceptance and continuity.  
GPs also endorsed a multidisciplinary approach to management to increase the support network 
for the patients. This approach involved psychologists, exercise physiologists, nutritionists, 
physiotherapists, and massage therapists. In addition, some GPs advocated the use of relaxation 
techniques and meditation because they were thought to be beneficial to treatment outcomes. 
Some exemplar quotes for theme 4 are presented in Table 3.4. 
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Table 3.4 Exemplar quotes for Theme 4 
Theme Quotes 
 
Theme 4: Patient-centred care 
 
 
“Patients are looking for quick fix need to set 
realistic goals.” 
 
“It is important to set goals for your patient’s 
especially functional goals.” 
 
“There is always a psychological component 
with CNMP patients. Predominantly 
psychological support is important and often 
is more beneficial than drugs.” 
 
 “Increased stress or anxiety disorder makes 
CNMP worse and causes a bigger impact but 
patients are often resistant to diagnosis and 




Theme 5: Verifying vitamin D levels 
 
There was a general concern among GPs over vitamin D levels in chronic pain patients, mainly 
due to lower physical capacity and high body mass index.  Although concerned over vitamin 
D levels, most GPs thought routine testing as avoidable. Instead GPs advised vitamin D 
supplements if indicated by a patients’ history, activity levels, ethnicity, and diet. Vitamin D 
testing was also recommended for patients with a high-risk of developing deficiency, such as 
the elderly living in residential care or previously vitamin D deficient patients. Use of vitamin 
D supplements was reported to enhance the overall bone and musculoskeletal health, lessening 
of aches and pains and improving a general sense of well-being and mood in patients with 
CNMP. Vitamin D was also regarded as an economical, readily available adjunct therapy with 
minimal side effects. Some exemplar quotes for theme 5 are presented in Table 3.5. 
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Table 3.5 Exemplar quotes for Theme 5 
Theme Quotes 
 
Theme 5 : Verifying vitamin D levels 
 
 
“Chronic pain patients are often at risk of 
vitamin D deficiency due to a sedentary 
lifestyle.” 
 
“Patients are usually inactive with little to no 
outdoor activities, so the risk of deficiency 
increases.” 
 
“It is cyclic  they are not very active, spend 
less time in the sun, have lower levels of 
vitamin D end up having more aches and 






In this preliminary qualitative study, almost all participating GPs reported on the ambiguous 
etiology and variability in clinical presentations of patients with CNMP. It was believed that 
CNMP had a multidimensional biopsychosocial basis with patients exhibiting higher levels of 
anxiety and depression and poor physical activity. Despite its multidimensionality and 
unknown etiology, findings from our study show that GPs adopt a patient-centered approach 
to management tailored to individual patient needs. These findings, are similar to another study 
reporting on GPs management of medically unexplained symptoms. This study described that 
GPs applied similar strategies of tailoring treatments to patients for managing medically 
unexplained symptoms in the absence of guidelines (292). 
GPs from our study also put special emphasis on spending more time with patients, developing 
a good patient-provider relationship, providing support systems and setting realistic goals for 
successful management which was consistent with other study findings (293, 294). Similar 
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strategies were also employed by Canadian clinical practitioners’ (295), Dutch GPs (296) and 
Slovenian family physicians (297) when managing medically unexplained symptoms. 
In addition GPs in our study were also concerned over low vitamin D levels in patients with 
CNMP and supported use of vitamin D supplements based on patients’ history and lifestyle. 
Though, the underlying mechanism by which vitamin D levels might interact with chronic pain 
is not fully understood, literature suggests that vitamin D deficiency can often presents as non-
specific bone and muscle pain (258). It is quite possible that vitamin D deficiency may closely 
resemble CNMP and could be overlooked. Therefore it is not surprising that there are many 
studies examining the role of vitamin D and supporting its potential use in various chronic 
painful conditions (298, 299). 
Special emphasis was put on spending more time with patients, developing a good patient-
provider relationship, providing support systems and setting realistic goals for successful 
management which was consistent with previous study findings (293, 294). In addition GPs in 
our study also reported concern over low vitamin D levels in patients with CNMP and 
supported use of vitamin D supplements based on patients’ history and lifestyle. These views 
are not surprising given the number of studies examining the role of vitamin D and supporting 
its potential use in chronic painful conditions (298, 299). 
It is reassuring that GPs in our study report similar strategies as Dutch GPs who, in an 
independent study, were asked about their approach to the treatment of patients with 
unexplained symptoms (296). Treatment strategies common to both these studies were 
developing a doctor-patient relationship and explaining to the patients the significant impact 
that their psychosocial health can have on their symptoms (296).  
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Strengths and weaknesses 
This study is the first to qualitatively explore the management of CNMP in Australia.  Being a 
qualitative study the number of participants was characteristically small. However, practices 
from various areas in Adelaide were selected in order to cover a diversity of patient populations 
and to subsequently obtain a spread of GP perspectives.  
 It is possible that the views and experiences shared by the GPs may have been influenced by 
their practice years, age or gender; it is noteworthy that younger female GPs did not participate 
in this study. While the GPs interviewed were not representative of the broader population of 
Australian GPs in a quantitative sense, the diversity of participating GPs in this study broadly 




To our knowledge, this is the first qualitative study to examine the clinical reasoning GPs 
employ when diagnosing and managing patients with CNMP. Our key thematic findings were 
that GPs use a patient-centered approach to managing CNMP patients which is tailored to a 
patient's individual clinical presentation, needs, and psychological well-being. Besides, GPs 
may recommend vitamin D supplements depending on a patient’s history and lifestyle. All GPs 
who advised vitamin D supplements perceived them as beneficial with none reporting side 
effects. 
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Does vitamin D supplementation alleviate 
chronic nonspecific musculoskeletal pain? 
A systematic review and meta-analysis. 
 
  






This chapter address the second objective of this thesis- How effective is vitamin D 
supplementation in the management of CNMP? 
Findings from focus group discussions, Chapter 3, demonstrate that GPs consider vitamin D 
supplementation to be a potentially safe and effective method of management for patients with 
CNMP. In addition, findings from observational studies, as described in chapter 2 section 2.3, 
also indicate that low levels of vitamin D seem to be associated with several musculoskeletal 
disorders such as OA, RA, CWP, and FM. However, randomized controlled trials (RCTs), 
which are considered to be level II evidence by the National Health and Medical Research 
Council (NHMRC) provide mixed findings. RCTs are considered as level II evidence as they 
allow to make causal inference in the presence of unmeasured confounding and allow 
accounting for selection bias (300). In order to identify if the association (301) between vitamin 
D and CNMP is causal or otherwise conducting a systematic review was essential.  
A Cochrane review (242) investigated vitamin D supplementation for the treatment of a range 
of chronic musculoskeletal conditions and concluded no substantial effect. Given the different 
pathophysiological origins of these conditions, such a finding was perhaps not surprising. The 
authors of the review suggested that specific conditions should be investigated individually. 
We contend that another aspect of that review may have contributed to its null findings: there 
was no attempt to confine source literature to direct comparisons between vitamin D and a 
control or placebo. This is important in this field because it is arguably very difficult to isolate 
the treatment effect attributable to vitamin D supplementation when it is instigated as a part of 
the multimodal intervention. 
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To address this gap in literature we conducted a systematic review of RCTs examining the 
effects of vitamin D supplementation on CNMP. Meta-analysis was conducted using the data 
from the systematic reviews, to estimate the “effect size” of vitamin D supplementation on 
CNMP. This chapter addresses the second aim of the thesis and has been published in the 
Clinical Rheumatology Journal (45) (Attached as Appendix). 
 
What is already known on this topic? 
 
Multiple studies report a strong association between low vitamin D levels and CNMP (302-
304). However, these are mostly observational studies, which may not be able to fully control 
for all the confounding factors such as season, diet, age, latitude, body mass index, smoking, 
and physical activity. Moreover, they do not account for biases such as selection bias, 
unmeasured confounding bias, and measurement error (300). To reach conclusive outcomes, it 
is important that these findings are supported by evidence from RCTs.  
Currently, only three RCTs satisfying our selection criteria, have examined the effect of 
vitamin D supplementation on CNMP symptoms. Results from these few studies are mixed, 
that is, some indicate a large effect and others show no effect (“statistically significant”) of 
vitamin D supplementation on CNMP.  
Although the best evidence synthesis of the effect of vitamin D supplementation on this 
condition is still not conclusive, there has been an exponential rise in vitamin D testing and 
supplementation worldwide (305-307). This has raised justifiable concerns about the evidence 
for vitamin D measurements and supplementation. In Australia alone, the use of vitamin D 
testing increased 94 fold between 2000 and 2010 (308). According to the current MBS reviews 
the number of claims and benefits paid for item numbers relating to vitamin D testing has 
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increased by 3587% in Australia over the last 10 years (282). Analysis of MBS data has raised 
concern about the unnecessary testing of vitamin D or repeated testing of vitamin D in the 
general population (282). The review noted that 98% of the vitamin D tests were requested for 
the purpose of screening/testing rather than monitoring. In order to promote quality use of 
testing, Medicare deleted the previous vitamin D testing item numbers 66608 and 66609 and 
split the testing into two types: i) 25-hydroxyvitamin D testing for high-risk patient groups, ii) 
1,25- dihydroxyvitamin D testing for patients with severe conditions such as renal failure or 
hypercalcemia. Under the new rules, 25-hydroxyvitamin D testing is now restricted only 
to high-risk groups and cannot be used as a screening tool. The high risk patient groups were 
defined as the elderly or disabled people living residential care, house bound/ hospitalized 
geriatric patients, immigrants and people with dark complexion of either sex, people with 
chronic disease, obese people, people who avoid sun exposure and people who work in 
enclosed environment such as office, warehouses, taxi, night shift workers and factory. The 
testing of vitamin D outside this criteria is deemed to be private and requires the patient to bear 
the cost (282).   
 
What this study adds? 
 
To our knowledge, this is the only published systematic review and meta-analysis on the role 
of vitamin D supplementation on CNMP. This study was needed as it may help to answer the 
question, whether CNMP could be treated with vitamin D supplementation. Moreover, it is 
important to study if the low levels of vitamin D found in people with CNMP are causal or 
correlational. Meta-analysis of the collected data provides an opportunity to evaluate the 
treatment effect of vitamin D supplementation. We chose conducting a systematic review as it 
is considered Level I evidence by the NHMRC, Australia (282) (NHMRC Evidence Hierarchy 
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Table Attached as Appendix). This is because systematic reviews provide more data than the 
individual studies and meta-analyses increase the precision of the overall results, reducing the 




This review was designed following PRISMA statement (310). The PRISMA checklist for our 
study is attached below. Only studies using randomized controlled or randomized double-blind 
controlled trial design were included as randomization and double blinding are known to 
minimize selection and confounding bias to a large extent thus allowing causal inference (311). 
Studies that combined vitamin D with other concurrent interventions were excluded, the reason 
for this being to isolate the unmediated treatment effect of vitamin D. This otherwise would be 
difficult if instigated as a part of multimodal intervention as there can be both direct and indirect 
effects of vitamin D. No restriction regarding the type, route, dose or frequency of vitamin D 
supplementation was enforced.  
 
How the intervention might be useful?  
 
Vitamin D supplementation increases blood levels of 25OHD (306) thereby correcting vitamin 
D deficiency. The details of how this might work (molecular mechanism, time to effect, and 
extent of reversibility of pain associated with vitamin D deficiency) are unclear at present 
(312). However, we propose that vitamin D deficiency is found to cause defects in bone 
mineralization causing widespread or localized bone pain or discomfort along with aches and 
pain in muscles and joints (313, 314) treating vitamin D deficiency may help relieve some of 
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the unexplained non-specific musculoskeletal pain. As there are vitamin D receptors in the 
central nervous system (315, 316), it is possible that they may modify pain perception. Vitamin 
D supplementation may also alleviate some of the nonspecific pain via its anti-inflammatory, 
anti-apoptotic and anti-fibrotic effects and restoration of calcium homeostasis (51, 61). 
 
Interpreting the results 
 
The results from the meta-analysis suggest that vitamin D has no effect on CNMP. However, 
it is necessary to interpret these results cautiously keeping in mind the heterogeneity within the 
study design and participant population and the relatively small sample size. There are paucity 
of RCTs comparing vitamin D supplementation to placebo. Moreover, within the studies 
selected there was heterogeneity because of differences in the dose and dose regimes of vitamin 
D supplementation used. It is also important for studies to have a long follow-up period as 
vitamin D levels show fluctuations based on seasonal variations. Future studies should try to 
improve the design of RCTs, including- increasing their sample size, to ensure clinically and 
statistically significant findings. 
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PRISMA checklist for the study 
 















Chronic nonspecific musculoskeletal pain (CNMP) is an idiopathic condition often seen in 
general practice and rheumatology clinics, the aetiology of which may include vitamin D 
deficiency. The objective of the present study is to evaluate the effectiveness of vitamin D 
supplementation in the management of CNMP through a systematic review and meta-analysis. 
According to PRISMA guidelines, PubMed, Embase, Web of Science, Cochrane and Scopus 
electronic databases were searched for randomized controlled trails comparing vitamin D 
supplementation to a control or placebo in CNMP patients; the search was not limited by 
language or date. Meta-analysis was performed using the mean and standardized mean 
difference which was computed with 95% confidence intervals, and overall effect size was 
calculated. Both fixed and random effects models were used in meta-analysis to account for 
heterogeneity in the studies. The initial search identified 107 studies, of which 10 were 
potentially relevant, with 7 studies excluded because they did not meet selection criteria. Three 
studies were included in the meta-analysis. We found no effect of vitamin D supplementation 
(standardized mean difference (SMD) 0.004; 95% confidence interval (CI) -0.248 to 0.256) on 
pain in CNMP patients. Forest plot is used to present the results from meta-analysis. Contrary 
to widespread clinical view, there is moderate level of evidence that vitamin D supplementation 
is not helpful for treating CNMP patients. 
Keywords  
Chronic nonspecific musculoskeletal pain, Meta-analysis, Systematic review, Vitamin D, 
Vitamin D supplementation  





Chronic non-specific musculoskeletal pain (CNMP) is an idiopathic condition which is a 
common presentation to rheumatology clinics (226, 286). CNMP is associated with decreased 
physical health, mental wellbeing, social life (18, 233), workability (234) and disability (235). 
Many sufferers become stuck in a descending spiral of economic, social, emotional and 
physical disadvantage (84, 230). CNMP is a significant burden to the economy (236). The 
aetiology of CNMP is not well understood and although many potential contributors have been 
identified (317), a clear nociceptive source has not, and empirical data concerning other 
contributors are lacking. As a result, CNMP is difficult to diagnose, prevent or treat. One 
potential contributor that receives substantial attention clinically and has been investigated in 
a range of clinical studies is vitamin D deficiency (37, 318). 
Vitamin D is involved in many regulatory biological processes. In addition to calcium 
homeostasis, vitamin D is thought to have anti-inflammatory, anti-apoptotic and anti-fibrotic 
effects; it is thought to play a role in regulating blood pressure and in innate and adaptive 
immune system function (51, 61). This range of biological effects highlights the potential role 
of vitamin D deficiency in the development of symptoms associated with acute and chronic 
rheumatic diseases and it is biologically plausible that vitamin D deficiency contributes to the 
development and maintenance of CNMP. That people with vitamin D deficiency can present 
with nonspecific muscular pain and bone pain has been reported (258) and several studies have 
suggested a causative role (207, 303, 304). However, a recent Cochrane review (242) 
investigated vitamin D supplementation for the treatment of a range of chronic painful 
conditions and concluded no substantial effect. Given the different pathophysiological origins 
of the condition included, such as osteoarthritis, rheumatoid arthritis, and fibromyalgia, such a 
finding was perhaps not surprising. The authors of that review suggested that specific 
                                                                                                                                    Chapter 4 
96 
 
conditions should be investigated individually. We contend that another aspect of that review 
may have contributed to its null findings: there was no attempt to confine source literature to 
direct comparisons between vitamin D and a control or placebo. This is important in this field 
because it is arguably very difficult to isolate the treatment effect attributable to vitamin D 
supplementation when it is instigated as a part of the multimodal intervention. 
Despite the clinically topical nature of the issue and the substantial literature, no attempt has 
been made to conduct meta-analyses. Meta-analyses provide the obvious advantage of 
increasing power and estimating effect sizes, which can then be re-tested in subsequent studies 
(319). We aimed to fill these substantial gaps in the literature by using gold standard systematic 
review and meta-analysis methodology to evaluate the evidence concerning the effect of 
vitamin D supplementation, when compared in a randomized controlled trial to a placebo, on 
pain in people with CNMP. 
 
4.5 Methods  
 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses Statement (310) was 
followed for this review. 
Inclusion criteria: 
 
Only randomized controlled trial (RCT) or randomized double blind control study designs were 
eligible. For inclusion, RCTs had to compare vitamin D supplementation to a control or placebo 
and measure the pain outcome using Visual Analogue Scale (VAS). No restrictions were 
applied for the language but restricted the studies to those conducted on “humans”.  
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Exclusion Criteria:  
 
Studies including patients previously diagnosed with an inflammatory joint disease, post-




An electronic search was performed on 5 databases - PubMed, Embase, Web of Science, 
Cochrane, and Scopus. The search period was set from the time of commencement of these 
databases up to 3rd November 2015. The search strategies for each database are listed in Table 
4.1. MG and SV independently searched for potentially eligible studies based on the study title 
and then read the abstracts and selected potentially relevant studies, from which studies not 
matching the selection criteria were excluded. Full articles of the remaining studies were 
reviewed for inclusion. The reference lists of selected studies were manually searched to find 
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Table 4.1 Electronic search strategy tailored to each database 
 












l  [ALL] 
OR  
Musculoskeleta







vitamin D*[ALL] OR 
Cholecalciferol [ALL] OR 
Hydroxycholecalciferol* [ALL] 
OR 
Hydroxyvitamin  D* [ALL] OR 
Ergocalciferol* [ALL] 









“vitamin D” OR “vitamin d2” OR 
“vitamin d3” OR Cholecalciferol 
OR Hydroxycholecalciferol* OR 
“Hydroxyvitamin D” OR 
“hydroxyvitamin d2” OR 













“vitamin D” OR “vitamin d2” OR 
“vitamin d3” OR Cholecalciferol 
OR Ergocalciferol* OR 
Hydroxycholecalciferol* OR 
“Hydroxyvitamin D” OR 











Musculoskeletal  AND  
pain* 
“vitamin D” OR “vitamin d2” OR 
“vitamin d3” OR Cholecalciferol 
OR Hydroxycholecalciferol* OR 
“Hydroxyvitamin D” OR 
“hydroxyvitamin d2” OR 
“Hydroxyvitamin D3” OR 
Ergocalciferol* 







Musculoskeletal  W/3  
pain* 
“vitamin D” OR “vitamin d2” OR 
“vitamin d3” OR Cholecalciferol 
OR Hydroxycholecalciferol* OR 
Ergocalciferol* 
OR“Hydroxyvitamin D” OR 
“hydroxyvitamin d2” OR 
“Hydroxyvitamin D3” OR  
 
  





The final selection of the studies was collectively made by the group. Data extraction was 
performed by MG and MM using a standardized data extraction form similar to Table 4.2 
highlighting the characteristics of selected studies. Data was extracted on sample size, 
characteristics of participants, intervention type; control group, main outcome, and adverse 
events. The review team was never blinded to authors’ names or institutions, journal of 
publication and study results. MM provided the statistical support and help in performing the 




                                                                                                                                    Chapter 4 
100 
 





























































































msk pain or 
pain lasting 













U in 7.5 
ml oil OR 
placebo in 











pain 6 weeks 
after high 






















































                                                                                                                                    Chapter 4 
101 
 
Quality assessment of selected studies 
 
The 5-point Jadad score was used to assess the methodological quality of studies. Following, 
questionnaire formed the basis of scoring (320): 
i) Was the study described as randomized? 
ii) Was the study described as double blind? 
iii) Was there a description of withdrawals and dropouts? 
Each question is answered either yes or no, with each yes, the study is scored 1 point and no 
scored 0 points. For the well described method of randomization and blinding additional points 
are given respectively. However, 1 point each was deducted if the described method of 
randomization and blinding was incorrect. Clinical trials scoring more than 3 are considered as 
high quality (refer Table 4.3).  





(max points 2) 
 
Blinding  





























et al 2012 
1 1 1 1 1 5 
Sakalli et al 
2012 
1 1 1 1 0 4 
Warner et 
al 2008 
1 1 1 1 1 5 





Meta- analysis of the standardized mean differences (SMD), and their standard errors, in VAS 
scores, was performed between vitamin D treated and placebo treated groups. SMD has several 
versions such as, Cohen’s d (321), Glass’s∆ (322) and Hedges’ g (323), however, we have used 
the simple SMD which is the ratio of the mean difference and the standard deviations. The 
value SMD less than 0.5 is considered to be a small effect, from 0.5 to 0.8 medium effect and 
greater than 0.8 large effect (324). Summary effect estimates were calculated with the fixed-
effects models. Analysis was performed in Stata, version 12.1, software (StataCorp LP, College 
Station, Texas) using the metan commands (325). The heterogeneity between studies was 
assessed by computing the I2 statistics. A value of 0 inferred no heterogeneity and value above 
50% is recognized as substantial heterogeneity (324). Following, Bailey (326) we used fixed 
effect model as the objective of this study is to test whether the intervention has produced an 
effect in a set of homogenous studies. In the fixed effects model we weighted the data by the 




The initial search located 101 studies from the databases (PubMed 14, Embase 20, Web of 
Science 19, Cochrane library 45 and Scopus 9). After reviewing the title, the abstract and 
removal of the duplicates, 10 studies were identified for potential inclusion (Figure 4.1). Full 
text of these articles was reviewed and assessed. Of these 10 articles, 7 were excluded because 
they did not meet our selection criteria of study design. Thus leaving us with only 3 studies, 
for conducting the systematic review (192, 249, 250). These three studies used an RCT study 
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design to investigate the effect of vitamin D supplementation (treatment group) compared to a 
placebo (control group) in CNMP patients.  
 









Studies excluded after: 
Initial screening of title and abstract (n=77) 
Studies identified from literature search (n=107) 
 
Full text of studies retrieved for further evaluation (n= 30) 
 
 Duplicate studies excluded (n= 20) 
 
Full text of studies retrieved for further evaluation (n= 10) 
Studies excluded: 
Not RCT (n= 4), patient criteria unfulfilled (n = 3)  
 
Total number of RCTs included (n=3) 




The characteristics of the selected studies are described in Table 4.2. The three studies included 
in the meta-analysis evaluated 492 participants in total. The participants were generally adults 
with their mean ages ranging from 41 to 76 years. The majority of participants in all studies 
were females. All studies measured pain, 1 study also measured functional mobility and quality 
of life. Study sample sizes ranged from 84 - 288 subjects. All 3 studies used VAS to measure 
changes in pain (outcome), in addition, studies also used the timed up and go test (249) 
functional pain scores (FPS) (192) and Likert scales (250). All studies used the oral route for 
administering vitamin D, except Sakalli et al study, which in addition also used the 
intramuscular route for administering vitamin D. This is reflected in Fig 2 which shows 4 
studies namely: Study A- Schreuder et al. study, Study B1 - Sakalli et al. oral vitamin D 
supplementation group, Study B2- Sakalli et al. intramuscular vitamin D supplementation 
group and Study C- Warner et al. study. We did this to test if the mode of administration 
influenced the strength of the clinical effect. The trial period of selected studies was 4 weeks 
(249) and 12 weeks (192, 250). Of the 3 included studies, only 1 study reported that none of 
the participants experienced adverse events during the trial or in the follow-up period (250). In 
general, all studies scored highly on methodological quality with two studies scoring 5 and one 
study scoring 4 (Table 2).  
Out of the three selected studies, two showed reduction in pain, following treatment with single 
mega-dose vitamin D supplementation (249, 250), and one showed no effect on pain following 
vitamin D supplementation (192).  
 
  





The results from meta-analysis are presented in the forest plot (Figure 4.2). The horizontal lines 
depict the length of confidence intervals, which for Study A and Study B1 are on the treatment 
side, indicating a modest effect of the intervention on pain in CNMP patients. For Study B2 
and Study C the lines are on the control side, representing no effect of the intervention. The 
overall effect (represented by black diamond in Figure 4.2) lies on the line of no effect, 
indicating that the average effect size of the pooled analysis is 0. The I2 statistic is 62.4% 
indicating a moderate level of heterogeneity in the pooled analysis, which confirms that the 
variation is not due to chance. The overall pooled SMD was 0 with CI ranging between -0.25 
to 0.26, p-value = 0.97 indicating that the intervention has no clinical effect on the CNMP 
(Figure 4.2). The test for overall effect is not statistically significant.   
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To split the variance as within and between study variance, we also analyzed data using random 
effects model (Figure 4.3). The overall pooled SMD was 0.05 with CI ranging from -0.37 to 
0.46, I2 = 61.4 and p-value = 0.05 reiterating no statistical significance. 
 






We aimed to evaluate the evidence concerning the effect of vitamin D supplementation when 
compared in a randomized controlled trial to a placebo, on pain in people with CNMP.  Our 
results are in contrast to the prevailing clinical opinion (286, 303, 327) insofar as they suggest 
that vitamin D supplementation does not decrease pain in CNMP when compared to a placebo. 
Our results also show, however, that robust randomized controlled trial data are perhaps more 
limited than would be assumed: despite a comprehensive search strategy, only three 
randomized controlled trials, with a total of 492 participants, satisfied our priori criteria. The 
included trials comprised of participants aged between 41-76 years with vitamin D levels of 
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20nmol/L or less. A range of doses of vitamin D were administered in each included trial, but 
there was no evidence of a dose-response relationship.  
The current study raises new questions for the investigation of CNMP. Our results clearly 
suggest that vitamin D supplementation is not helpful for CNMP. According to the Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) (328), we suggest 
there is low to moderate evidence (one high-quality study or several studies with some 
limitations but consistent results) (328) that vitamin D supplementation is not helpful for people 
with CNMP.  
It is notable that the proposed mechanisms by which vitamin D deficiency might contribute to 
CNMP – disruption of calcium homeostasis, a loss of anti-inflammatory, anti-apoptotic or anti-
fibrotic effects (51, 61) imply that the primary cause of CNMP lies within the tissues of the 
body. Although such mechanisms seem intuitive, they are not necessarily consistent with 
modern models of CNMP and other chronic pain conditions. Although vitamin D deficiency, 
through disruption of immune regulation (51, 61) could disrupt the neuroimmunological 
processes that subserve pain (260), the assumption that this would increase pain rather than 
decrease it remains to be properly tested. The prevailing theories with regard to chronic pain 
place greater emphasis on enhanced sensitivity within the nociceptive system (86), increased 
contribution of non-nociceptive sensory inputs and associative learning (241), cognitive 
mechanisms that emphasize perceived threat to body tissue and behavioral processes linking 
fear of pain, activity avoidance and catastrophizing (88) and de-emphasize ongoing tissue 
pathology or damage (with some exceptions, for example seronegative arthropathies) (87). 
Indeed, CNMP is widely considered to be influenced by a wide range of biological, physical, 
psychological and social factors (84) and management approaches reflect this biopsychosocial 
framework (118, 239). Perhaps vitamin D supplementation might play a more important role 
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in painful conditions that more obviously relate to tissue inflammation, for example, 
rheumatoid arthritis, although this remains to be determined. 
The biological complexity of vitamin D effects leaves open the possibility that supplementation 
could offer benefit for people with CNMP and that the current research base is not sufficient 
to detect it. That is, protocols of the RCTs may have led to an inadequate rise in serum vitamin 
D levels post supplementation (329) due to non-compliance, although one might argue that 
such interventions are really ‘advice to take a particular action’ rather than the action itself 
(330). Different effects may also relate to the heterogeneity of body-mass index (BMI) between 
participants. Alternatively, standard doses of vitamin D supplementation may not always 
produce predictable increases in the vitamin D levels (329) or predictable rates at which 
vitamin D level changes (302), potentially masking positive effects. That other study designs, 
for example, clinical (286),observational (304), cross-sectional and case report studies (303), 
have demonstrated moderate benefit following supplementation, may reflect an advantage of 
tailored supplementation regimes (although considering the findings of such studies one should 
remember that these study designs are highly vulnerable and may overestimate true effects) 
(331). 
The relative paucity of RCTs comparing vitamin D supplementation to placebo is surprising, 
considering the widespread clinical endorsement of the idea. The available data are also not 
very generalizable to all ages because most studies have investigated primarily postmenopausal 
women, and compared nonstandard doses for which there is little justification. Estradiol is 
recognized as a physiological predictor of vitamin D binding protein (332) and post-
menopausal women show a higher natural decline in vitamin D levels than pre-menopausal 
women (333), suggesting that it would be important to investigate the variance in vitamin D 
levels in pre-menopausal women with depleting estradiol levels as well as in younger women 
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with normal estradiol levels. Furthermore, CNMP is highly prevalent in children and 
adolescents, but this group has not been investigated with regard to vitamin D. 
There are several considerations, strengths, and limitations of the current study. We included 
the Warner et al study (192) even though they diagnosed participants with primary 
fibromyalgia, not CNMP. On closer appraisal, the participants in their study did not satisfy the 
ACR criteria for fibromyalgia but did satisfy criteria for CNMP. The strengths of this study are 
its focus on CNMP and inclusion of meta-analysis, as was recommended in a recent Cochrane 
review (242); the absence of language or publication restrictions, giving confidence that we 
did not miss important studies; the confinement of included studies to those that used a RCT 
design, because they provide the most rigorous method of verifying if a cause-effect 
relationship exists between the intervention and outcome (334). We used SMD score to 
evaluate the clinical relevance and CI for inference because it focuses on the probability and 
significance of the intervention and helps to establish the clinical and statistical significance of 
the findings (335). There are also limitations: the forest plot shows variability between the 
studies and broad 95% CIs shows the imprecision of the results, a common problem with small 
sample sizes (335). The most significant limitation is indeed the lack of source literature, which 
is particularly pertinent to the field because it contrasts with popular clinical belief.  
This study shows that there is no proven effect of vitamin D supplementation on pain in people 
with CNMP when compared to a placebo. We conclude that there is GRADE C (96) to level B 
(moderate) evidence that vitamin D supplementation is not helpful for people with CNMP. 
Clearly, more robust and nuanced RCTs might have an important impact on our confidence in 











Understanding patient perspectives on 
management of their chronic pain – an 
online survey protocol  
  







This chapter describes the study protocol and questionnaire used for conducting the final study 
of this thesis, which examined the perspectives of patients with chronic pain on their pain 
management. This chapter provides an overview of the study design, the process of data 
collection, and the methodological and the statistical approach used in the cross-sectional 










                                                                        
  





5.3 Abstract  
 
Background:  
It is widely recognized that both doctors and patients report discontent regarding “pain 
management” provided and received respectively. The impact of chronic pain on an 
individual’s life resonates beyond physical and mental suffering; equal or at times even greater 
impact is observed on an individual’s personal relationships, ability to work and social 
interactions. The degree of these effects in each individual varies, mainly because of 
differences in biological factors, social environment, past experiences, support, and belief 
systems. Therefore, it is equally possible that these individual patient characteristics could 
influence their treatment outcome.  
Research shows that meeting patient expectations is a major challenge for health care systems 
attempting to provide optimal treatment strategies. However, patient perspectives and 
expectations in chronic pain management have not been studied extensively. The aim of this 
study is to investigate the views, perceptions, beliefs and expectations of individuals who 
experience chronic pain on a daily basis, and the strategies used by them in managing chronic 
pain. This paper describes the study protocol to be used in a cross- sectional survey of chronic 
pain patients. 
Methods and analysis:  
The study population will comprise of individuals aged ≥18 years, who have experienced pain 
for ≥3 months with no restrictions of gender, ethnicity, or country of residence. Ethics approval 
for the study was obtained from Humans Research Ethics Committees, University of Adelaide 
and University of South Australia. 





Multinomial logistic regression will be used to estimate the effect of duration and character of 
pain, on patient’s perception of time to recovery and supplement intake. Similar analysis will 
be conducted for estimating the effect of health professional support, pain education to family 
and employer on pain intensity and perception of time to recovery. 
Discussion:  
Knowledge about the perceptions and beliefs of patients with chronic pain could inform future 






















The International Association for the Study of Pain (IASP defines chronic pain as “pain that 
persists beyond the normal tissue healing time, usually ≥ 3months”, in the absence of an 
obvious underlying biological cause (337). With nearly 20% of the population affected 
worldwide, chronic pain has become a disease in its own right, rather than just being considered 
a symptom (7-9, 284). Furthermore, chronic pain is often associated with numerous physical 
and psychological complications such as disability, sleep disturbances, fatigue, depression and 
social isolation. The traditional approach for managing an injury or other illness of diagnosis 
and treatment offers little hope to individuals experiencing chronic pain by trapping patients 
with chronic pain in a vicious cycle of trial and error treatments. Both patients and their doctors 
struggle with “pain management” with studies reporting a feeling of inadequacy about 
providing optimal treatment among physicians (338-340) and dissatisfaction among patients 
concerning the treatments provided (341).  
Studies show that between 40%-60% of the general population use dietary supplements to 
promote health and manage conditions (342-344). Approximately 33% of those who use 
supplements quote pain as the primary reason (343). However little is known about their 
benefits as perceived by patients with chronic pain. Moreover, pain is a subjective sensory 
emotional experience (337), which may be influenced by an individual’s biological, 
environmental, social and psychological factors. Together with belief systems and 
expectations, these factors may also guide individual experiences, and influence treatment 
outcome(s). Even though studies (345, 346) report factors which predict chronic pain, their 
association with patients’ perspectives of chronic pain and its management has not been studied 
extensively. In addition, meeting patients’ expectations is an important objective for health care 
systems (347) as it appears to improve treatment satisfaction between 8% to 25% (348, 349). 





Aligning patient expectations with a management plan can enhance treatment outcome and 
benefits. 
Best practice insight recommends publishing a protocol prior to undertaking the study as it 
facilitates awareness of the research in progress (350). It also helps to maintain the transparency 
in reporting of the study (351, 352). This paper describes the protocol and the questionnaire 
used in a cross-sectional survey of individuals who experience pain for ≥ 3 months.  
 
5.5 Aim & Objectives 
 
The aim of this study is to investigate the views, perceptions, beliefs and expectations of 
individuals who experience chronic pain on a daily basis, and the strategies used by them in 
managing this pain. The objectives of this study are to investigate if duration and character of 
pain, education about pain affects chronic pain patients’ perception of time to recovery and 
supplement intake. This study will also examine if health professionals support, pain education 
to family and employer is related to pain intensity and perception of time to recovery in patients 
with chronic pain. 
 
  









An online survey method was selected for this study as it is cost-effective and easy to 
administer; unlike face-to-face interviewing, a survey provides a standardized approach 
allowing uniformity of questions asked to all participants. It also provides access to individuals 
without geographical dependency thus allowing the collection of rich data (353). Although 
online surveys may limit participation from individuals without access to the internet (354) the 
advantages of this method have been shown to outweigh the disadvantages in terms of external 
validity (355). 
A questionnaire was designed specifically for the study following the Checklist for Reporting 
Results of Internet E-Surveys (CHERRIES) protocol (356) for the ethical reporting of surveys 
and will be administered online using Survey Monkey. Ethics approval for this study has been 
obtained from Human Research Ethics Committee of the University of Adelaide (approval no- 




The survey will be advertised on multiple educational, basic and clinical science websites and 
on social media in different countries, including Australia, Ireland, India, New Zealand and 
The United States of America. Individuals accessing these websites will be invited to 
participate in the study if they met the inclusion criteria. The survey will be open for 
participants from all ethnicities and country of residence. It is anticipated that data collection 





will cease by the end of October 2016.  All participants activated an electronic consent prior to 




Individuals for inclusion in the survey should be: 
1. Currently aged 18 years and above. 




Individuals are not eligible to participate in the survey if: 
1. Their current age is below 18 years of age. 
2. They suffer from acute pain of ≤ 3 months’ duration 
3. They do not consent to be a part of the survey study. 
 
Consent & Confidentiality 
 
Individuals who click the link provided to participate in the study are first taken to an 
information page. The information page describes the proposed study, its relevance and also 
outlines what type of information will be asked from the participants and the time required to 





complete the survey. The information page notifies the participants that the survey is voluntary 
and their choice of participating or not participating will have no effect on their own pain 
management in any way. It also provides the participants with information regarding whom to 
contact in case of distress or if they have a complaint. The information page also explains that 
the survey is completely anonymous - information that could disclose the participant’s identity 
will not be asked at any stage during the survey. 
 
Data- storage & handling 
 
The data will be stored on a secure computer owned by University of Adelaide, with password-
controlled access. Only the research team (all authors listed above) will have access to the data.  
 
Sample Size  
 
Sample size calculations for estimation are based on three parameters, the variance or spread 





Where n= sample size, P = estimated population proportion, δ = precision of the estimate.  
For this sample size estimation the values chosen were, P = 0.5 and δ = 0.05. Thus, giving us 
a sample size of 384 with 95% confidence interval and 80% power. This is the simple random 
sampling approach (357). 
 







Currently, there are very few studies examining the perspectives and the expectations of 
individuals who experience chronic pain regarding their pain management. Due to the 
unavailability of validated scales of chronic pain patients’ perspectives, this questionnaire was 
developed by the team of authors through discussions and literature search. The questionnaire 
(358) (Attached as Appendix) comprises of 5 sections and 39 items in total. A pilot study to 





Statistical analysis plan 
 
All analysis analyses will be performed using   STATA 14.1 Statistical software (325). 
Multinominal logistic regression will be performed to estimate the effect of duration and 
character of pain; education about pain and variation in supplement intake on chronic pain 
patient’s perception of time to recovery. Univariate logistic regression will be used to examine 
the effect of support received from health professionals, family and employers on chronic pain 
patients pain levels, quality of life and physical goals. The analysis will be adjusted for 
confounding factors such as age, sex, education, employment and marital status. 
Simple descriptive statistics such as mean, proportions and variances will be described for the 
entire sample. Participants will be described in terms of pain duration, average length of their 





consulting time and frequency of visits, and satisfaction about their education and involvement 






1. Patients’ perception of time to recovery  
Information regarding participants’ perceived time to recovery from their current pain problem 
will be collected.    
2.  Supplement intake 
Information regarding each participant’s intake of complementary medicines or dietary 
supplements (e.g. calcium, magnesium, fish oil) and alternative medicines (Chinese, herbal, 
Ayurvedic) will be collected, in addition to information regarding testing of vitamin D, vitamin 




1.  Demographic data 
Information regarding each participant’s age, sex, country of residence, education, employment 
and marital status will be collected. 
 
2. Pain history 





Information pertaining to each participant’s history of current pain problem such as diagnosis 
received, duration, character and intensity of pain will be collected. 
 
3.   Pain education 
Information regarding method of education received, provider of education and influence of 
education on understanding and management of pain will be collected. 
 
4.  Goals from pain management 
The goals from pain management are classified into pain related outcomes; quality of life and 
physical functioning. Information pertaining to each classification will be collected. 
 
5.  Other variables.  
Information regarding each participant’s most recent health care consultation, as well as 
information regarding provision of pain education to their family and employers, and its 




The results from this survey analysis will be included as a chapter in MG’s thesis and published 
in peer-reviewed scientific journals as well as used for conference presentations. The results of 
the study will be made available to the public on the University of Adelaide and the Body in 
Mind website. 







To our knowledge, this is the first study to examine if patients’ perspectives, views, and beliefs 
about their chronic pain management are associated, with perception of time to recovery and 
particularly with reference to testing and prescription of supplements. Moreover, the study has 
been promoted internationally and it is anticipated that the analysis will capture the variability 
of patients’ perceptions and beliefs across countries (if the distribution of the sample obtained 
allows sub-group analysis). It is also expected that the results from the survey study will 
provide insight about what patients with chronic pain expect from their pain management and 
how these expectations are challenged by the duration of pain, the character of the pain, the 
quality of pain education, and support of health professionals. A deeper understanding of 
patients’ perceptions with regards to their pain management will enable researchers, policy 
makers, and health professionals to design policies, interventions and prevention strategies 
which are tailored to individual patient needs and are intended to improve the treatment 
outcome.  
This study will also provide information on intake of complementary and alternatives 
medicines, dietary supplements, non-pharmacological therapies, and educational sources most 
frequently used by the chronic pain patients for managing their pain. It is also anticipated that 
this evidence based knowledge will describe the self-management strategies most frequently 
implemented by chronic pain patients.  
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Factors associated with vitamin testing, 
deficiency, intake and supplementation 
in patients with chronic pain  







This chapter address the third objective of this thesis- What demographic and pain-related 
factors are associated with; testing for vitamin D levels, vitamin D deficiency and intake of 
vitamin D supplement among people with chronic pain? 
This chapter presents the results from the analysis of data collected from the cross-sectional 
survey (Chapter 5). This chapter investigates the factors associated with vitamin D testing, 
deficiency and intake. As outlined in Chapter 3, findings from study 1 show that vitamin D 
supplementation is clinically endorsed by GPs for patients with CNMP. GPs considered 
vitamin D as improving the overall sense of wellbeing, musculoskeletal health and mood in 
patients with CNMP. It is also considered as a cost-effective (261, 262) and readily available 
intervention (262), with minimal side effects (262). Chapter 2 (literature review) describes in 
detail studies investigating the role of vitamin D in the etiology and management of chronic 
musculoskeletal conditions such as osteoarthritis, rheumatoid arthritis, fibromyalgia, chronic 
widespread pain and chronic nonspecific musculoskeletal pain. However the factors associated 
with vitamin D testing, deficiency and intake in patients experiencing chronic pain are not yet 
widely researched. Hence the current study aimed to explore the demographic and pain-related 
factors associated with vitamin D testing, deficiency and supplement intake. Furthermore, we 
also examined the demographic and pain-related factors associated with vitamin D 





















Vitamin D deficiency is a public health issue, with reports of six to twenty-five fold rise in 
vitamin D testing. It has been linked to many chronic diseases such as diabetes mellitus, 
cardiovascular disease, depression and chronic pain. Identifying factors associated with risk of 
deficiency in individuals with chronic pain will help minimize time and cost. This study aims 
to examine the factors associated with vitamin D testing, intake and doctor advised 
supplementation in individuals with chronic pain. Using a cross-sectional design, data was 
collected from 465 individuals with chronic pain. This data was analyzed using penalized 
logistic regression with the LASSO technique. 57% reported been tested for vitamin D, about 
40% reported been diagnosed with vitamin D deficiency, and of those who had been tested, 
60%, reported taking vitamin D supplementation. The findings suggest older age (OR 3.12,CI 
1.02-9.50) and higher mean pain intensity score (OR 2.02,CI 1.13-3.59) increased an 
individual's chance of being vitamin D deficient. Unemployment or on leave due to pain (OR 
1.79,CI 1.03-3.11), part-time employment (OR 1.86,CI 1.02-3.39), and being resident of 
Australia (OR 2.32,CI 1.13-4.72) increased chances of being tested for vitamin D. While, 
diagnosed vitamin D deficiency (OR 6.67,CI 2.75-16.19), unemployment or on leave due to 
pain (OR 3.71,CI 1.25-11.00) and in part-time employment (OR 2.69,CI 0.86-8.38) were 
associated with doctor advised vitamin D supplementation. Our results may have practical 
implications as identifying pre-test risk factors may assist, in identifying who is at risk of 
vitamin D deficiency, whom to test and treat.   
 
Keywords  
Vitamin D, Vitamin D supplementation, Chronic Pain, Supplements  







Vitamin D is unique compared to other vitamins as it is the only vitamin the human body can 
manufacture on its own with adequate exposure of the skin to sun (UVB rays) (360). Other 
vitamins need to be ingested via foods, for example vitamin C from fruits and vegetables. 
During synthesis in the skin it undergoes conversion into an “active form” known as 1,25-
dihydroxyvitamin D which reaches target tissues (360, 361). For many years vitamin D was 
known as an essential compound important for strong bone and skeletal system. Promoting 
bone remodelling and maintaining calcium homeostasis (361) was believed to be its sole 
function in the human body. More than thirty years ago studies uncovered the presence of 
vitamin D receptors on almost every cell and tissue, which lead to the discovery of various 
genomic and non-genomic functions of vitamin D (362, 363). This also established the role of 
vitamin D in various chronic conditions such as diabetes mellitus, cardiovascular disease, 
depression, multiple sclerosis, many cancers (364, 365) and also chronic pain (37, 366, 367). 
 
Vitamin D deficiency has been reported as a major public health problem worldwide (368, 369) 
with reports of increased vitamin D testing globally (370-372). In Australia, the Medicare 
Benefits Schedule expenditure on vitamin D testing was reported to be approximately $143.1 
million in the year 2013-2014 (370). Similar figures are reported in Ontario, Canada (371) and 
the UK (372). Not surprisingly, a large increase in vitamin D supplementation has also been 
reported. 
Vitamin D deficiency has been linked to chronic pain (37, 366, 367) which is the most 
burdensome non-fatal health condition in terms of years lived with disability (373) and the 
third most common health complaint presenting to Australian general practitioners (374). We 





undertook a cross-sectional survey of patients with chronic pain to examine the factors 
associated with vitamin D deficiency, testing and supplementation. It is anticipated that the 
findings from this study will be beneficial for patients with chronic pain and physicians to guide 







The study protocol was published prior to collecting data (336). The cross-sectional study was 
an online survey of individuals aged 18 years and above who had experienced pain for more 
than 3 months with no restrictions on gender, ethnicity, or country of residence. Individual’s 
aged less than 18 years, experiencing pain for less than 3 months and not providing consent for 
the study were excluded.  The survey was advertised on multiple patient forum websites and 
linked social media in countries like Australia, New Zealand and the United States. The 
primary aim of the survey was to investigate the perceptions, beliefs and expectations of 
individuals who experience chronic pain on a daily basis, and the strategies used by them to 
help manage this pain. All participants gave electronic consent prior to beginning the survey.  
Ethical Statement 
This study was approved by the Human Research Ethics Committee of the University of 
Adelaide (approval no- HREC-2016-0712) and the University of South Australia (application 
id- 0000035791).   







A specialized questionnaire was built in accordance with the Checklist for Reporting Results 
of Internet E-Surveys (CHERRIES) (356). A review of literature was performed a priori to 
identify potential factors associated with vitamin D deficiency, information from this review 
was used for developing the questionnaire. The draft questionnaire was reviewed by two 
general practitioners (NS and SV), who approved the original draft with minor amendments to 
wording only. The survey was also piloted on three individuals diagnosed with chronic painful 
conditions to determine whether questions were easily understood and interpreted in the way 
intended by the researcher. The primary change following their feedback was simplifying some 
of the technical terms used in health research and making it more generalized to appeal a wider 




Sample size calculations for estimation were based on how wide a confidence interval (CI) we 
considered appropriate. This estimation depended on three parameters, the variance or spread 







Where n= sample size, P = estimated population proportion, δ = precision of the estimate. 





As the estimated population proportion (P), was unknown we set P = 0.5 and δ, was set as 0.05 
for the probability of type-I error = α=0.05.  Using, this formula a sample size of 384 was 





To study the best predictors of described outcomes a common practice is to use a statistical 
model depending on the type of the variable (for example a linear model if the outcome is 
continuous). In case of binary outcomes univariate or multivariate logistic regression is used 
for estimating odds ratio (375). The multivariate logistic regression allows simultaneous 
identification of possible risk factors in one model, after adjusting for all predictors. Regular 
logistic regression estimation is carried out by maximizing the likelihood function. However, 
when we have many potential predictors and the sample size is small, then there may not be a 
meaningful way to estimate the coefficients. In order to overcome this, the usual practice is to 
use step wise regression. The trouble with stepwise regressions is that it uses unconstrained 
least-square estimation processes which either over/underestimate the effect sizes. To solve 
this issue, we used LASSO (Least absolute shrinkage and selection operator). LASSO is a 
regression technique that allows the selection of variables and estimation simultaneously in 
order to enhance the accuracy of the prediction and its interpretability (376). LASSO was 
initially designed for simple linear regression, but was extended for general linear models such 
as logistic regression (377). Estimation in LASSO is based on penalizing the likelihood  
𝛽(𝜆) ̂ = argmax
𝛽










Where 𝜷, is the effect size estimate using maximum likelihood, 𝝀  is the penalty parameter and 
p is the number of covariates in the model. The parameter 𝝀  controls the complexity of the 
model. In cases where 𝝀 is zero, the estimate will be same as the simple logistic regression. To 
obtain an optimal value of the penalty parameter we looked at the convergence of the 
likelihood. For some of the models the penalty value was 0.5, and for others the penalty was 2. 
The other benefit of using LASSO is it actually specifies the covariates whose effect sizes are 
exactly zero, thus allowing selection of variables. All the statistical analysis was done in 
STATA 14.1 (325). The LASSO logits regression were fitted using a special user written 
program in STATA [http://www.homepages.ucl.ac.uk/~ucakgam/stata.html]. 
 
Outcome measures  
 
The outcomes were related to patient reported testing, prescription and consumption of vitamin 
D supplements. The following information was collected from the participants: i) had they been 
tested for vitamin D levels; ii) were their test results for vitamin D reported as deficient; iii) did 
they use vitamin D supplements for their pain; and iv) was the supplement advised by their 




The independent variables were the demographic factors of the participants’ which included 
age, gender, country of residence, marital status, education level and employment status. 





Information regarding participants’ pain experience was also collected. Participants were asked 
‘which of the following describe the characteristics of your pain? The choices given were 
aching, burning, sharp, pins and needles, throbbing and others. Participants were also asked if 
their pain was triggered by an injury, options provided were Yes and No. Participants also 
completed a numerical rating scale (NRS) anchored at left with 0 = no pain and at right with 




The survey was conducted online from 29th August to 24th October 2016.  573 people in total 
participated however, 108 of these had incomplete information and hence were excluded from 
the analysis thus giving us a complete sample of 465 participants. All analyses were conducted 
presuming no participants completed the survey multiple times.  Distributions of the 
demographic characteristics of 465 participants are presented in Table 6.1. 
 
  













18-30 95 20 
31-40 101 22 
41-50 100 22 
51-60 95 20 
60+ 74 16 
Gender 
Female 403 87 
Male 61 13 
Prefer not to say 1 <1 
Education Level 
primary and secondary 93 20 
tertiary 174 38 
post-graduate 177 38 
others 19 4 
Employment status 
Full-time employed 136 29 
Unemployed/on leave because of pain 126 27 
Part-time employment 93 20 
Home duties 46 10 
Student 53 11 
Prefer not to say 11 3 
Country of residence 
Australia 293 63 
Europe 68 15 
New Zealand 64 14 
Others 40 9 
Marital Status 
Married 216 46 
Single 129 28 
Partnered 88 19 
Unmarried 27 6 
Prefer not to say 5 2 
Vitamin D deficiency 
Yes 191 41 
No 84 18 
Not applicable 190 41 
Vitamin D testing 
Yes  267 57 
No 198 43 
Vitamin D intake 
Yes 204 44 
No 261 56 
Characteristics of pain 
1-4 128 28 
5-8 173 37 
>9  164 35 
Is your pain triggered by an injury? 
Yes  152 33 
No 313 67 
How long have you had your pain problem? 
< 1 year 33 7 
> 1 year 432 93 





The age of participants ranged from 18 to 90 years, with almost equal number of participants 
from the age groups between 31- 40 years (22%) and 41-50 years (22%). Most participants 
were female and about two thirds were from Australia. Other countries which participated in 
the study were New Zealand, Europe, United States and India. Among the 465 participants, 57 
% (n=267 /465) reported that they had been tested for vitamin D and about 40% were aware 
that they had been diagnosed with vitamin D deficiency. Of those who had been tested for 
vitamin D, 60% (n= 162/267) were in fact taking vitamin D supplementation. 
To identify significant predictors of each outcome a simple logistic regression analysis was 
performed. In each of these, individual logistic regressions all the observed factors 
hypothesized, a priori, to be clinically useful for predicting the outcome, were entered 
simultaneously. In the simple logistic regression the factors significant for vitamin D testing 
were education, country of residence, employment status and gender. Similarly, the factors 
which were significant for predicting vitamin D deficiency were gender and mean pain 
intensity. Correspondingly the factors significant for vitamin D intake were age, gender, 
employment status, marital status, education and country of residence. All these factors which 
were entered in logistic regressions were re-entered into the LASSO model. Results from the 
penalized logistic regression with LASSO suggest that some of the predictors that initially 
showed association in simple logistic regression did not show association after penalizing.  
The final model for the prediction of vitamin D deficiency consisted of six predictors: age, 
gender, country of residence, employment status, mean pain intensity and diagnosis for pain 
problem. For vitamin D testing additional predictors considered were: education level, pain 
related to injury, and duration of pain. For, vitamin D intake and doctor advised vitamin D 
supplementation, characteristics of pain, vitamin D deficiency, and vitamin D testing were 
considered.  





The predictor’s gender (gender 0= females, 1= males), pain related to injury (No= 0, Yes =1), 
mean pain intensity (0 = ≤ 5 or 1= ≥ 6 on 11 point numerical scale), duration of pain (0 = <1 
year or 1 = > 1 year), vitamin D tested (No= 0, Yes =1) and vitamin D deficient (No= 0, Yes 
=1) were treated as binary variables. Due to fewer number of cases in each individual category 
the characteristics of pain were categorized into 3 groups; 0= 1-4 characteristics, 1= 5-8 
characteristics and 2= >9 characteristics, which is used as the base category for LASSO. The 
categorical predictors were re-coded as dummy variables before submitting in the regression.  





Outcomes –  
Table 6.2 presents a summary of factors associated with vitamin D testing. The odds ratios and 
their CIs suggest that males (OR 0.50, CI 0.58-2.25) are half as likely as females to be tested 
for vitamin D. Similarly, the odds of an individual with chronic pain being tested for vitamin 
D are 2.3 times higher if they were from Australia (OR 2.32, CI 1.13-4.72), and 0.3 times less 
likely if they were from New Zealand (OR 0.27, CI 0.10-0.70), than if they were from other 
countries. In addition, chronic pain patients who were unemployed or on leave due to pain (OR 
1.79, CI 1.03-3.11) and in part-time employment (OR 1.86, CI 1.02-3.39) were twice as likely 
to be tested for vitamin D. Age, education level, pain related to injury, mean pain intensity of 
pain and duration of pain were not associated with vitamin D testing.  
Table 6.2 Summary of LASSO for factors associated with vitamin D testing. 
 
Vitamin D Testing 
 






31-40  1.12 0.68 0.64     1.93 
41-50 1 1.00 0.99     1.00 
51-60 1.17 0.58 0.66     2.08 
60+ 1.14 0.69 0.58     2.25 
Gender 
Male 0.50 0.02 .278      0.92 
Country of residence 
Australia 2.32 0.02 1.13      4.72 
Europe 0.71 0.42 0.30      1.64 
New Zealand 0.27 0.00 0.10      0.70 
Employment status 
Unemployed/on leave because of pain 1.79 0.03 1.03      3.11 
Part-time employment 1.86 0.04 1.02      3.39 
Home duties 1.43 0.38 0.63      3.22 
Student 0.79 0.52 0.38      1.63 
Education level 
Tertiary 1.67 0.08 0.93      3.00 
Post-graduate 1.44 0.22 0.80      2.59 
Others 1.45 0.52 0.45      4.63 
Pain related to injury  
Yes 1.06 0.78 0.67      1.66 
Mean Pain intensity  
≥ 6  1 1.00 0.99      1.00 
Duration of pain 
>1 year 1.13 0.75 0.49      2.60 





Table 6.3 presents a summary of factors associated with vitamin D deficiency. The ORs and 
CIs suggest that for individuals with chronic pain the odds of being vitamin D deficient are 
approximately three times higher if they are older than 60 than if they are not (OR 3.12 , CI 
1.02-9.50). Similarly, the individual with chronic pain who has a mean pain intensity ≥6 (OR 
2.02, CI 1.13-3.59) on an 11 point NRS are twice as likely to be vitamin D deficient then an 
individual with chronic pain who has a mean pain intensity ≤5. Gender, country of residence 
and employment status were not associated with patient reported vitamin D deficiency.  
Table 6.3 Summary of LASSO for factors associated with vitamin D deficiency. 
 








31-40 2.62 0.03 1.06      6.45 
41-50 2.28 0.07 0.93      5.59 
51-60 2.94 0.02 1.15      7.51 
60+ 3.12 0.04 1.02      9.50 
Gender 
Male 0.44 0.05 0.19      1.02 
Country of residence 
Australia 1 1.00 0.98      1.01 
Europe 1 1.00 0.98      1.01 
New Zealand 0.64 0.49 0.18      2.26 
Employment status 
Unemployed/on leave because of 
pain 
1.24 0.51 0.63      2.42 
Part-time employment 1 1.00 0.98      1.01 
Home duties 1.23 0.68 0.44      3.41 
Student 1.48 0.46 0.51      4.32 
Mean Pain intensity  
≥ 6 2.02 0.01 1.13      3.59 
Diagnosis for pain 
OA 0.76 0.50 0.35      1.67 
FM 1.53 0.14 0.86      2.74 
CNMP 1.96 0.07 0.92      4.15 
 
Table 6.4 presents a summary of factors associated with taking vitamin D supplements. The 
ORs and CIs suggest that individuals with chronic pain aged between 51-60 years (OR 2.59, 
CI 1.00-6.71) are three times more likely to be taking vitamin D supplements  than those aged 





50 years or younger, and those older than 60 (OR 6.08, CI 2.10-17.60) are six times more likely. 
Not surprisingly, those who had been vitamin D deficient (OR 6.63, CI 3.41-12.89) were six 
times more likely to take vitamin D supplements than those who were not. Gender, country of 
residence, education level, mean pain intensity, characteristics of pain, duration of pain, pain 
related to injury and tested for vitamin D were not associated with vitamin D supplement intake.   
Table 6.4 Summary of LASSO for factors associated with intake of vitamin D supplement. 
 








31-40 0.93 0.89 0.36      2.40 
41-50 2.18 0.11 0.82      5.75 
51-60 2.59 0.04 1.00      6.71 
60+ 6.08 0.00 2.10      17.60 
Gender 
Male 0.62 0.32 0.24      1.58 
Vitamin D testing 
Yes 1.07 0.93 0.19      5.78 
Vitamin D deficiency 
Yes 6.63 0.00 3.41     12.89 
Country of residence 
Australia 0.65 0.45 0.21      2.01 
Europe 1.03 0.96 0.25      4.21 
New Zealand 0.98 0.98 0.18      5.12 
Education level 
Tertiary 1.63 0.23 0.72      3.68 
Post-graduate 1.53 0.30 0.67      3.46 
Others 0.76 0.73 0.15      3.76 
Pain related to injury 
Yes 0.67 0.20 0.36      1.24 
Mean Pain Intensity  
≥ 6 1.32 0.36 0.72      2.41 
Characteristics of pain  
1- 4  1.45 0.32 0.68      3.08 
5-8  1.16 0.64 0.59      2.27 
Duration of pain 
>1 year 1.02 0.96 0.33      3.17 





Table 6.5 presents a summary of factors associated with doctor advised vitamin D 
supplementation. Individuals with chronic pain who were unemployed or on leave due to pain 
(OR 3.71, CI 1.25-11.00) and in part-time employment (OR 2.69, CI 0.86-8.38) were 4 times 
more likely than full-time employed participants to be prescribed vitamin D supplements by 
their doctor. Not surprisingly, being vitamin D deficient (OR 6.67, CI 2.75-16.19) had the 
largest influence on whether doctors would prescribe vitamin D. Age, gender, country of 
residence, education level, mean pain intensity, duration of pain and whether pain related to 
injury were not associated with being prescribed vitamin D supplement.  Finally, and 
surprisingly, whether or not someone had been tested for vitamin D levels (OR 1.49, CI 0.13-
17.24) was not associated with being prescribed vitamin D supplement. 
 
  
















    95% CI 
Age (years) 
31-40 0.95 0.95 0.24          3.76 
41-50 2.08 0.31 0.49          8.78 
51-60 1.17 0.82 0.29          4.69 
60+ 3.12 0.18 0.59          16.48 
Gender 
Male 1 1.00 0.97          1.02 
Country of residence 
Australia 1 1.00 0.98          1.01 
Europe 0.45 0.19 0.13          1.51 
New Zealand 1.13 0.91 0.10          11.80 
Employment Status 
Unemployed/on leave because of pain 3.71 0.01 1.25          11.00 
Part time employment 2.69 0.08 0.86          8.38 
Home duties 3.68 0.12 0.69          19.56 
Student 3.96 0.14 0.63          24.85 
Education level 
Tertiary 0.61 0.43 0.18          2.08 
Post-graduate 0.94 0.92   0.27          3.23 
Others 0.48 0.59 0.03          7.10 
Vitamin D Deficiency 
Yes 6.67 0.00 2.75          16.19 
Vitamin D tested 
Yes 1.49 0.74 0.13          17.24 
Pain related to injury 
Yes 0.93 0.88 0.40          2.20 
Mean Pain Intensity  
≥ 6 1.33 0.49 0.57          3.07 
Duration of pain 




Data from this cross-sectional survey suggests that gender, country of residence and 
employment status were associated with being tested for vitamin D. Our study findings suggest 
that Australians were much more likely to be tested for vitamin D than other nationalities. 
However, this finding could be influenced by the fact that majority of our study participants 
were from Australia. These findings resonate with reports that demonstrate a remarkable 





3587% rise in vitamin D testing in Australia over last 10 years (282) and in the United States 
(378).  
Older people and individuals who reported a mean pain intensity score ≥ 6 on an 11 point NRS 
were more likely to report vitamin D deficiency. To our knowledge, this is the first time that 
intensity of self-reported pain has been identified as being associated with vitamin D 
deficiency. That older people were more likely to report vitamin D deficiency is in line with 
the association between age and risk of developing vitamin D deficiency (379, 380), which has 
been attributed to insufficient sun exposure time (381) and decline in the capacity to synthesize 
vitamin D (263). Not surprisingly then, along with diagnosis of vitamin D deficiency, age was 
associated with taking vitamin D supplements. Supplement usage in general is reported to 
increase with age (382-384) but not to the levels observed here for vitamin D. Not surprisingly, 
doctors advised vitamin D supplementation to individuals who were vitamin D deficient, 
unemployed or on leave due to chronic pain and in part time employment. Although, doctor 
advised vitamin D supplementation was not associated with being tested for vitamin D. 
To the best of our knowledge, most previous studies have investigated vitamin D deficiency 
and insufficiency among healthy populations in Australia (385) Europe (386) and America 
(387). These are findings are important as it highlights factors associated with deficiency, 
testing, intake and doctor advised supplementation of vitamin D in patients with chronic pain. 
That vitamin D deficiency has been proposed as a cause of nonspecific muscular and bone pain 
(258) would predict that pain characteristics, intensity and duration would relate to testing, 
prescribing or taking vitamin D supplementation. We found only a relationship between pain 
intensity and vitamin D deficiency. Our design does not allow causal attribution, but it is 
notable that there are biological pathways that could lead from vitamin D deficiency to pain. 
For example, it is thought that vitamin D deficiency reduces calcium phosphate, which then 





makes the collagen matrix surrounding the bone rubbery. This can cause pressure on the 
periosteal covering, which is innervated by sensory fibers  (258). Even slight pressure on the 
bone can produce pain. In view of this mechanistic plausibility of vitamin D deficiency to 
modulate pain levels in patients experiencing chronic pain, it is plausible that it could be one 
of the reasons for higher mean pain intensity being reported by patients who were vitamin D 
deficient. Clearly, longitudinal data are required to investigate this possibility. 
Our results may have practical implications, as identifying factors associated with a risk of 
vitamin D deficiency could assist to minimize the concern of over diagnosis and over treatment 
of vitamin D deficiency (370). It may assist doctors to identify early on chronic pain patients 
who would more likely benefit from vitamin D supplementation for their chronic pain problem. 
About 25% of adults worldwide have persistent pain – to test everyone would be expensive 
and perhaps of limited return. There is clearly merit in identifying pre-test risk factors in those 
with chronic pain, so as to minimize unnecessary testing.  
 
Study Limitations  
 
Our adherence to CHERRIES recommendations (356) gives us confidence in minimizing bias 
and our online approach allowed us to reach the a priori sample size and diversity that was 
required to fulfil our aims. However, this approach also has clear limitations. We relied on 
word of mouth, social media networks and promotion through consumer advocates to recruit 
our sample, a process that might introduce a bias towards sampling within established social 
media networks and diagnostic groups. That the survey was online clearly limits our sample to 
those with internet connectivity and engagement, and computer skills. We were also bound by 
considerations of participant burden (388), which meant that we decided a priori on the basis 
of pilot testing, to not collect information on participants’ pain medicines, their outdoor 





activities, sun exposure time and safe sun practices and the type and dosage of vitamin D 
supplement preferred by the participants.  These data might have offered important insights. 
Finally, any survey is dependent on self-report and little is known about the validity of 




Among the 465 participants, 57% reported that they had been tested for vitamin D and about 
40% were aware that they had been diagnosed with vitamin D deficiency. Of those who had 
been tested for vitamin D, 60% were in fact taking vitamin D supplementation. The findings 
show that older age and higher mean pain intensity score increased an individual's chance of 
being vitamin D deficient. Unemployment or on leave due to pain, part-time employment, and 
being resident of Australia increased chances of being tested for vitamin D. While, diagnosed 
vitamin D deficiency and unemployment or on leave due to pain and in part-time employment 
were associated with doctor advised vitamin D supplementation. 
In summary, the results from the present study examine the associations between vitamin D 
testing, deficiency, intake and doctor advised vitamin D supplementation in individuals with 
chronic pain. The simple demographic and pain-related factors, could be used as a guide to 
identify who may be at risk of vitamin D deficiency, whom to test and when to treat. 
The authors would like to acknowledge all of the study participants who completed the study 
and the organizations and societies who promoted our survey on their websites. 
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Effect of pain education and patient-
provider relationship on patient-reported 
pain intensity and recovery. 
  







This chapter address the fourth objective of the thesis- What perspectives do patients with 
chronic pain have about the patient-provider relationship, pain education and does it affect their 
pain intensity and perceived time to recovery? 
This chapter presents the results from the analysis conducted on the data collected from the 
cross-sectional survey (Chapter 5). It investigates the association between pain education and 
patient-provider relationship on patient-reported pain intensity and recovery.  
The findings of study 1, outlined in Chapter 3 (Theme 3: Developing the right strategy) show 
that, for diagnosis, GPs emphasize spending more time during consultation with patients which 
was regarded important for taking detailed medical history but was also considered as an 
opportunity for building good patient-provider relationship. Further, in Chapter 3 (Theme 4: 
Patient centered care) educating patients with CNMP for setting realistic goals was regarded 
as an important part of the framework for management. However, little is known about how 
pain education and patient-provider relationship affects patient-reported pain intensity and 
perception of recovery in individuals experiencing chronic pain. Hence the current study aimed 
at exploring patients’ views on the patient-provider relationship and pain education, and their 
associations with; the patient-reported pain intensity, and perception of recovery.  
  








Chronic pain is a global health problem. Its management perplexes patients and doctors alike. 
Various factors influence management of chronic pain. Two factors which have been 
recognized to significantly influence patient satisfaction and pain management are pain 
education and patient-provider relationship. But little is known about the association between 
patient-reported pain intensity and perception of recovery, especially among chronic pain 
patients who receive pain education and patient-provider relationship. 
Aim:  
To explore patients’ views on the patient-provider relationship and pain education and their 
association with self-reported pain intensity and perception of recovery. 
Design and Methods:  
Data was collected from a cross-sectional survey of 465 individuals, with chronic pain after 
excluding “not applicable” cases from all covariates, the sample size obtained was 448. 
Univariate and multiple logistic regression was used to assess the effect of pain education and 
patient-provider relation on self-reported pain intensity and recovery. 
Results:  
Self-reported pain intensity was reported higher by individuals aged 40 years and above and 
by females. Positive self-reported recovery was higher in individuals aged between 18-40 years 
and by males. However, pain education and patient-provider relationship did not show 
associations with self-reported pain intensity and recovery. Interestingly, changes in pain 
cognition and management of pain following pain education showed significant associations 





with self-reported pain intensity and positive perception of recovery. A separate regression 
analysis showed that changes in pain cognition and management of pain were strongly 
associated with pain education and patient-provider relationship. These findings suggest that 
pain education and self-reported pain intensity and recovery have an indirect relation, which is 
induced through changes in pain cognition and management of pain following pain education. 
Conclusion: 
Pain education and patient-provider relationship may not be effective in isolation but should 
be considered jointly with education prompted changes in pain cognition and management of 
pain. 
  







Pain has emerged as a major social, economic, clinical, and global health problem (389). It can 
affect anyone regardless of age, gender, ethnicity, income or geography. Pain that exists beyond 
what is regarded as the healing time (>3 months) is defined as chronic pain (337). Chronic pain 
causes not only physical suffering, but also affects individual’s ability to work, their social life, 
sleep disturbances, depression, suicidal thoughts, and poor quality of life (390). An estimated 
1 in 10 adults is diagnosed with chronic pain globally every year (391).  
Due to a lack of training in pain management, doctors report that they feel inadequate in 
providing care to patients with non-malignant chronic pain (25, 26). However, their role in 
management is not limited to only providing treatment (392). It is reported that patients who 
share a good relationship with their doctor often have better treatment compliance (393) and 
outcomes (394, 395). Not surprisingly, patients who have a good patient-provider relationship 
report high levels of satisfaction, even when receiving less than optimal management and 
experiencing pain. This is famously known as the “paradox of patient satisfaction” (392). 
Although, the association between patient-provider relationship is known for general ailments, 
we still do not know if the patient-provider relationship shows any association with the patient-
reported pain intensity and their time to recovery. 
Management of any long term condition such as chronic pain, requires active participation from 
the patient. To promote self-management, research suggests empowering patients by providing 
education about their pain (396). Pain education has been rated higher than physical and 
medical therapy for chronic pain management (397). Moreover, it shows a positive effect on 
catastrophizing (398, 399), disability (398), pain inhibitory mechanisms (400), physical 
performance (398, 401, 402) and pain itself (398, 399, 401). To the author’s knowledge no 
previous studies have focused on testing the association between patient-reported pain intensity 





and their time to recovery, especially among patients receiving pain education and patient-
provider relationship, in real-world conditions. By real-world conditions we mean 
environments uninfluenced by the researchers or the experiment.  
Keeping this in view we conducted a cross-sectional study using an online survey design that 
explored patients’ perceptions, views and beliefs about their chronic pain management and 
recovery. Patients’ perspectives and views on their management and outcome are central to 
identifying areas which require improvement (403). Findings from this study may help to 
improve the process of care which in turn may improve treatment outcomes.  
 
7.4 Aim and Objectives 
 
The aim of this chapter is to explore patients’ views on the patient-provider relationship and 
pain education and their associations with; self-reported pain intensity and perception of 
recovery. The key three objectives of this study are: i) To examine if self-reported pain 
education affects self-reported pain intensity and perception of recovery; ii) To examine if the 
patient-provider relationship affects self-reported pain intensity and perception of recovery; 
and iii) To determine the type of education material most referred to by health care 
professionals and if the same was perceived helpful by the patients. 
 
  









The data used in this study was collected as part of a cross-sectional study conducted to 
understand patients’ perspectives on their chronic pain management. The study protocol and 
questionnaire for this study has been published in the Journal of Pain Research. This study 
was approved by Human Research Ethics Committee of University of Adelaide (approval no- 
HREC-2016-0712) and University of South Australia (application id- 0000035791). Electronic 
consent was collected from all individuals participating in the survey. The survey questionnaire 
was developed according to a review of the literature and was built in accordance with the 
Checklist for Reporting Results of Internet E-Surveys (CHERRIES) (356). 
 
Study Sample  
 
The study sample consisted of individuals aged 18 years and above with no limitation on 




The sample size was estimated using the expected population proportion (P), the precision of 
the estimate δ and the type-I error. As the value of P was unknown we set it to 0.5 and δ, was 





set as 0.05 for the probability of type-I error = α=0.05. Using these parameters the estimated 




The outcomes used in this study were; self-reported pain intensity and perceived recovery. 
Information on pain intensity was collected from the participants using the question: i) what is 
the average severity of your pain in the last 2 days? Participants were asked to complete a 
numerical rating scale (NRS). Starting with “0” on left side defined as no pain and “10” on the 
right side defined as severe or worst pain; and (23) how long do you think it will take you to 
recover from the current pain problem? The choices provided were “3-6 months”, “6-12 
months”, “up to 1 year”, “more than 1 year” and “never”.  
Due to fewer number of cases in each individual category the pain intensity reporting in the 
last 2 days; was dichotomised at the median as ≤ 5 and ≥ 6. Similarly, patient perceived 
recovery was dichotomised as “recovery” and “never”. All those individuals who selected a 
defined time frame, described above, were grouped as those who perceived recovery and those 




The independent variables used in this study were pain education and patient-provider 
relationship along with demographic characteristics.  
Pain education 





Participants were asked if they had received any form of education about their pain. The 
responses were coded as “1” if yes and “0” if no. The following information was also collected: 
i) did the pain education received change how you think about your pain? ii) Did the education 
received change your management? Response to both these questions was collected using 
simple “yes”, “no” dichotomization. Information regarding who had provided them the 
education on pain was also collected. The choices given were general practitioner, pain 
physician, nurse practitioner, physiotherapist, chiropractor, massage therapist, pharmacist, self-
education and other. Information collected also included the type of education material 
individuals were most referred to and which of them did they consider to be most helpful?  
 
Patient-provider relationship 
Patient-provider relationship was not a direct question but it is a manifest variable. This was 
created using  information from six different questions which were; frequency of their 
consultation; the duration of their consultation; how they felt at their most recent consultation; 
were they informed about the treatment options; how helpful was this information and how 
satisfied they were with their involvement in the decisions about their pain management.  
Responses to these questions were simply summed together. The score was then re-categorised 
into binary variable- “good” patient-provider relationship (if the score was above the median 
value) and “not good” patient-provider relationship (if the score was below the median value). 
This was dichotomised for the reason that there were fewer cases in each of the categories. 
 













This included basic univariate descriptive statistics such as percentages to describe the simple 
distributions of patients receiving pain education, patient-provider relationship, pain intensity 
and recovery status. Cross-tabulation was used to describe self-reported pain intensity and 
recovery in groups defined by age, gender, education level, employment status, marital status, 
patient-provider relationship, pain education, pain cognition and management of pain. As the 
prevalence of chronic pain was reported higher among older age groups we performed cross-
tabulation on two separate age groups: 18-40 years and 41+ years. This was done to assess the 
impact of age on self-reported recovery and pain intensity. Individuals with self-reported pain 
intensity ≤ 5 were compared with individuals reporting pain intensity ≥ 6. Univariate and 
multiple logistic regression were used to study the effect of pain education and patient provider 
relation on pain intensity and patient perceived recovery before and after controlling for the 
potential confounders. Odds ratio (OR) and likelihood ratio test were used to test the model. In 
order to compare the regression models and maintain uniformity of sample size, “not 
applicable” cases from all the covariates were removed. This reduced the sample size from 465 
to 448. Even though our estimated sample size was 384 we received responses from 573 
individuals, within the allocated time period for which the survey was open, of which 465 










All outcome measures were adjusted for confounding factors such as age, gender, education 
level, employment status and marital status. 
Pain intensity was reported by all 465 individuals. Of these 465 individuals 40% (185/465) 
reported their pain intensity to be ≤ 5 and 60% (280/465) reported their pain intensity to be ≥ 
6. The age-adjusted reporting of pain intensity ≤ 5 was 43% (84/196) in younger (18-40) 
compared to their counterparts aged +41 (38%, 101/269). Higher pain intensity (≥6) was 
reported among older age groups (62.45%=168/269) compared to their younger counterparts, 
57% (112/196). 
Table 7.1 shows the self-reported pain intensity in different groups. The prevalence rates of 
pain intensity ≥ 6 increased relatively more among older individuals with chronic pain than 
younger participants. With the exception of individuals aged between 18- 40 years, who were 
students, unemployed or partnered. Women rated their pain intensity higher than men. 
Individuals with primary education rated their pain intensity higher compared to individuals 
with other education. This association was more significant in individuals aged 41 years and 
above. Being unemployed or on leave because of pain was associated with higher pain intensity 
in both the age groups (18-40, +41 years).  
Compared to their younger counterparts individuals aged 41 years and above reported higher 
pain intensity if they did not receive pain education and did not report a good patient-provider 
relationship. Individuals aged 41 years and above reported higher pain intensity if their duration 





of pain was greater than 1 year. The association between higher pain intensity was also stronger 
among individuals aged 41 years and above who received pain education but did not change 
their pain cognition and management of pain. 
Table 7.1 Self-reported pain intensity by participants aged 18 years and above. 
                            Age 18-40 years 
 
                          Age 41 + years 
   
Pain intensity ≥6     Pain intensity ≤5 Pain intensity ≥6 Pain intensity ≤5 
Variable   No   %     No    %  Total   No   %  No     % Total 
Sex                   
Female 100 59% 70 41% 170 149 64% 84 36% 233 
Male 12 46% 14 54% 26 18 51% 17 49% 35 
Education level                   
Primary 26 60% 17 40% 43 32 64% 18 36% 50 
Others 86 56% 67 44% 153 134 62% 83 38% 217 
Employment status                   
Full time employed 36 58% 26 42% 62 47 64% 27 36% 74 
Unemployed/ on leave 
because of pain 
37 82% 8 18% 45 58 72% 23 28% 81 
Part time employment 15 39% 23 61% 38 27 49% 28 51% 55 
Home duties 5 63% 3 38% 8 22 58% 16 42% 38 
Student 17 43% 23 58% 40 7 54% 6 46% 13 
Marital status                   
Married 34 52% 31 48% 65 88 58% 63 42% 151 
Single/unmarried 47 63% 28 37% 75 56 69% 25 31% 81 
Partnered 31 56% 24 44% 55 21 64% 12 36% 33 
Pain education                   
No 9 47% 10 53% 19 24 71% 10 29% 34 
Yes 103 58% 74 42% 177 144 61% 91 39% 235 
Patient-provider 
relationship 
                  
Not good 39 52% 36 48% 75 67 63% 40 37% 107 
Good 73 60% 48 40% 121 101 62% 61 38% 162 
Duration of pain                   
< 1 year 7 50% 7 50% 14 8 42% 11 58% 19 
> 1 year 105 58% 77 42% 182 160 64% 90 36% 250 
Change in pain 
management 
                  
No 41 56% 32 44% 73 84 74% 29 26% 113 
Yes 71 58% 52 42% 123 84 54% 72 46% 156 
Change in pain cognition                   
No 46 59% 32 41% 78 72 72% 28 28% 100 
Yes 66 56% 52 44% 11 96 57% 73 43% 169 
 
  





Table 7.2 shows the unadjusted and adjusted ORs obtained from logistic regression analysis 
on reported pain intensity, with the base category being pain intensity ≤ 5. The unadjusted 
association between pain intensity and gender (unadjusted OR,1.69; 95% confidence interval 
(CI) 0.98-2.92), being unemployed or on leave because of pain (unadjusted OR, 0.50; 95% CI, 
0.29-0.85), part-time employed (unadjusted OR, 1.81; 95% CI, 1.06-3.11), change in 
management of pain (unadjusted OR, 1.59; 95% CI, 1.07-2.36) and change in pain cognition 
(unadjusted OR, 1.53; 95% 95% CI, 1.03-2.27) on receiving pain education had strong 
unadjusted associations. In the adjusted analysis the association between pain intensity and 
gender increased, the adjusted OR was two times higher (adjusted OR, 2.03; 95% CI, 1.12-
3.67) in male compared to female. However, the adjusted associations between pain intensity 
and being unemployed or on leave because of pain (adjusted OR, 0.49; 95% CI, 0.28-0.85) and 
part time employed (adjusted OR, 1.86; 95% CI, 1.06-3.25) did not change much. In addition, 
in the adjusted analysis being a student or unemployed showed an association with pain 
intensity, the adjusted OR was two times higher (adjusted OR, 2.03; 95% CI, 1.03-4.00) 
compared to full time employment status. There was collinearity between employment status 
and changes in management of pain and pain cognition on receiving pain education and hence 















Table 7.2 Unadjusted and Adjusted Odds Ratios for Pain Intensity among individuals with 
chronic pain aged 18 years and above 
 
                                              Pain intensity   
                   Unadjusted                      Adjusted 
 OR (95% CI)  P value OR (95% CI)  P value 
Age     
18-40 years 1  1  
+41 years 0.84 (0.57-1.23) 0.38 0.92 (0.59-1.41) 0.71 
Gender     
Male 1.69 (0.98-2.92) 0.05 2.03 (1.12-3.67) 0.01 
Female 1  1  
Marital status     
Married 1  1  
Single/unmarried 0.68 (0.44-1.05) 0.08 0.75 (0.46-1.20) 0.23 
Partnered 0.87 (0.52-1.44) 0.59 0.85 (0.49-1.49) 0.58 
Education level     
Primary 1  1  
Others 1.09 (0.67-1.76) 0.70 0.92 (0.55-1.54) 0.76 
Employment status     
Full time employment 1  1  
Unemployed/on leave because 
of pain 
0.50 (0.29-0.85) 0.01 0.49 (0.28-0.85) 0.01 
Part time employment 1.81 (1.06-3.11) 0.02 1.86 (1.06-3.25) 0.02 
Home duties 1.11 (0.56- 2.21) 0.75 1.21 (0.58-2.52) 0.60 
Student 1.78 (0.93-3.40) 0.07 2.03 (1.03-4.00) 0.04 
pain education     
Yes 0.94 (0.51-1.73) 0.85 0.79 (0.40-1.56) 0.51 
Patient-provider relationship     
good 0.83 (0.56-1.22) 0.35 0.77 (0.50-1.20) 0.26 
Change in pain management     
Yes 1.59 (1.07-2.36) 0.01 1.65 (0.99-2.74) 0.05 
Change in pain cognition     
Yes 1.53 (1.03-2.27) 0.03 1.27 (0.76-2.12) 0.34 
 
  





Table 7.3 shows self-rated recovery in different groups among individuals with chronic pain. 
The prevalence rates of reporting positive recovery was higher in younger individuals (37% = 
72/196) compared to older individuals (30% = 80/269) with chronic pain. A higher proportion 
(46% and 49%) of men in both age groups perceived that they could recover compared to 
women. Similarly, individuals with higher education and married were more likely to report 
their perception of recovery as “recover”. Individuals who reported receiving pain education 
and changes in management of pain or pain cognition on receiving education rated their 
recovery to be positive, this association was more significant in individuals aged 41+ years. 
Similarly, individuals who had reported patient-provider relationship to be “good” also 
reported a positive recovery. However, being unemployed or on leave because of pain and 
duration of pain was inversely associated with self-reported recovery.  
  





Table 7.3 Self-reported recovery according to age among individuals with chronic pain aged 
18 years and above (n=448) 
 
                  Age    18-40 years 
 













Variable No %  No %  Total No %  No %  Total 
Sex                     
Female 110 65% 60 35% 170 170 73% 63 27% 233 
Male 14 54% 12 46% 26 18 51% 17 49% 35 
Education                      
Primary 25 58% 18 42% 43 41 82% 9 18% 50 
Others 99 65% 54 35% 153 147 68% 70 32% 217 
Employment status                     
Full time employed 44 71% 18 29% 62 47 64% 27 36% 74 
Unemployed/ on 
leave because of pain 
25 56% 20 44% 45 60 74% 21 26% 81 
Part time employment 21 55% 17 45% 38 41 75% 14 25% 54 
Home duties 6 75% 2 25% 8 26 68% 12 32% 38 
Student 25 63% 15 38% 40 8 62% 5 38% 13 
Marital status                     
Married 39 60% 26 40% 65 100 66% 51 34% 151 
Single/unmarried 47 63% 28 37% 75 65 80% 16 20% 81 
Partnered 37 67% 18 33% 55 22 67% 11 33% 33 
Pain education                     
No 14 74% 5 26% 19 22 65% 12 35% 34 
Yes 110 62% 67 38% 177 167 71% 68 29% 235 
Patient-provider 
relationship 
                    
Not good 48 64% 27 36% 75 76 71% 31 29% 107 
Good 76 63% 45 37%  121 113 65% 61 35% 174 
Duration of pain                     
< 1 year 4 29% 10 71% 14 2 11% 17 89% 19 
> 1 year 120 66% 62 34% 182 187 75% 63 25% 250 
Change in pain 
management 
                    
No 54 74% 19 26% 73 86 76% 27 24% 113 
Yes 70 57% 53 43% 123 103 66% 53 34% 156 
Change in pain 
cognition 
        
 
          
No 58 74% 20 26% 78 78 78% 22 22% 100 
Yes 66 56% 52 44% 118 111 66% 58 34% 169 
 





Table 7.4 shows unadjusted and adjusted ORs obtained from logistic regression analysis on 
self-reported recovery, with the reference category being “recover”. With positive perception 
of recovery, gender (unadjusted OR, 2.11; 95% CI, 1.21-3.66), change in pain cognition 
(unadjusted OR, 2.06; 95% CI, 1.34-3.16) and management of pain (unadjusted OR, 1.90; 95% 
CI, 1.25-2.90) had the strongest associations. The association between gender and positive 
recovery remained unchanged in the adjusted analysis (adjusted OR, 2.10; 95% CI 1.17-3.77). 
However the association between positive recovery and change in management of pain 
(adjusted OR, 1.58; 95% CI, 0.93-2.69) and change in pain cognition (adjusted OR, 1.73; 95% 
CI 1.01-2.96) reduced slightly in the adjusted analysis.  
Table 7.4 Unadjusted and Adjusted Odds Ratios for Self-reported recovery among individuals 
with chronic pain aged 18 years and above 
                       Self-reported recovery (“recover”) (n=448) 
            Unadjusted                    Adjusted 
 OR (95% CI)  P value OR (95% CI)  P value 
Age     
18-40 years 1  1  
+41 years 0.70 (0.47-1.04) 0.08 0.67 (0.43-1.04) 0.08 
Gender     
Female 1  1  
Male 2.11 (1.21-3.66) 0.00 2.10 (1.17-3.77) 0.01 
Marital status     
Single/unmarried 0.74 (0.47-1.16) 0.20 0.73(0.45-1.19) 0.21 
Partnered 0.92 (0.54-1.56) 0.76 0.86 (0.49-1.53) 0.62 
Education level     
Primary 1  1  
Others 1.22 (0.73-2.03) 0.43 1.20 (0.70-2.04) 0.49 
Employment status     
Full time employed 1  1  
Unemployed/on leave because of 
pain 
0.99 (0.59-1.67) 0.99 1.02 (0.58-1.77) 0.93 
Part time employment 0.98 (0.56-1.74) 0.97 0.96 (0.53-1.74) 0.91 
Home duties 0.83(0.39- 1.73) 0.62 1.00 (0.45-2.23) 0.98 
Student 1.27 (0.65-2.48) 0.46 1.33 (0.66-2.68) 0.42 
Pain education     
Yes 0.98 (0.52-1.85) 0.96 0.77 (0.38-1.54) 0.46 
Patient-provider relationship     
good 1.06 (0.71-1.59) 0.76 0.91 (0.58-1.44) 0.70 
Changes in pain management     
Yes 1.90 (1.25-2.90) 0.00 1.58 (0.93-2.69) 0.08 
Changes in pain cognition     
Yes 2.06 (1.34-3.16) 0.00 1.73 (1.01-2.96) 0.04 





In an analysis conducted separately, receiving pain education and having a good patient 
provider relationship showed an association with the change in pain cognition (Table 7.5) and 
change in management of pain (Table 7.6). Surprisingly, individuals who were employed part- 
time were also twice as likely to report changes in pain cognition as compared to full-time 
employees. In the adjusted analysis the association between pain cognition and management 
of pain with pain education and patient-provider relationship reduced slightly. 
 
Table 7.5 Unadjusted and Adjusted Odds Ratios for Self-reported changes in pain cognition 
among individuals with chronic pain aged 18 years and above 
        Pain education changed pain cognition (n=448) 
 
          Unadjusted        Adjusted 
 OR (95% CI)  P value OR (95% CI)  P value 
Age     
+41 years 1.12(0.76-1.65) 0.53 1.08 (0.69-1.68) 0.71 
Gender     
Male 1.15 (0.65-2.04) 0.61 1.50(0.80-2.83) 0.19 
Marital status     
Single/unmarried 0.77 (0.50-1.19) 0.24 0.73 (0.45-1.17) 0.19 
Partnered 0.82 (0.49-1.38) 0.46 0.75 (0.42-1.34) 0.33 
Education level     
Primary 1  1  
Others 1.16 (0.72-1.87) 0.52 1.16(0.69-1.94) 0.56 
Employment status     
Unemployed/on leave because of 
pain 
1.40 (0.85-2.31) 0.18 1.29 (0.75-2.21) 0.34 
Part time employment 2.42 (1.34-4.37) 0.00 2.31 (1.24-4.28) 0.00 
Home duties 0.87 (0.44-1.71) 0.69 0.65 (0.31-1.37) 0.26 
Student 0.82 (0.43-1.56) 0.55 0.85 (0.42-1.71) 0.65 
Pain education     
Yes 3.30 (1.66-6.55) 0.00 3.33 (1.67-6.61) 0.00 
Patient-provider relationship     









Table 7.6 Unadjusted and Adjusted Odds Ratios for Self-reported changes in management of 
pain among individuals with chronic pain aged 18 years and above 
                 Changes in pain management (n=448) 
 Unadjusted                 Adjusted 
 OR (95% CI)  P value OR (95% CI)  P value 
Age     
+41 years 0.84 (0.57-1.24) 0.40 0.66 (0.39-1.11) 0.12 
Gender     
Male 0.66 (0.38-1.15) 0.14 0.57 (0.28-1.16) 0.12 
Marital status     
Single/unmarried 0.87 (0.56-1.33) 0.52 0.88 (0.50-1.53) 0.66 
Partnered 0.95  (0.57-1.59) 0.85 0.92 (0.46-1.81) 0.81 
Education level     
Primary 1  1  
Others 1.12 (0.70-1.80) 0.62 1.15 (0.63-2.12) 0.63 
Employment status     
Unemployed/on leave because of 
pain 
0.97 (0.59-1.60) 0.93 0.71 (0.37-1.34) 0.29 
Part time employed 1.26 (0.72-2.19) 0.40 0.67 (0.33-1.35) 0.26 
Home duties 1.11 (0.55-2.22) 0.76 1.16 (0.47-2.86) 0.74 
Student 0.78 (0.41-1.50) 0.46 0.66 (0.28-1.57) 0.35 
Pain education     
Yes 4.83 (2.47-9.44) 0.00 2.44 (1.06-5.60) 0.03 
Patient-provider relationship     









Figure 7.1 shows the top five most referred education material. Results from the survey show 
that individuals with chronic pain were more likely to be referred to the following type of 
education material in the order of preference; website (53%), book (47%), handouts (33%), 
YouTube (16%) and video (11%). 












Website Book Handouts Youtube Video
Most referred type of education material 





Figure 7.2 shows the type of education materials reported most helpful by the individuals 
experiencing chronic pain. The most useful type of education material were, in the order of 
preference; website (46%), book (36%), smart phone app (11%), YouTube (10%) and video 
(7%). Of the referred material only handouts were not preferred by participants. 
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Self-reported Pain intensity 
 
In this study, pain intensity was reported as being higher in individuals aged 40 years and 
above. The findings also show that women were twice as likely to report higher pain intensity 
as men. Our results show an agreement with previous studies which also reported a higher 
prevalence of pain in older age groups, and females (284, 345). However, the participation rate 
of individuals in this study, was slightly higher by individuals aged 40 years and above (58%) 
and considerably higher by females (87%) which may have also contributed to the age and sex 
differentials. 
Individuals unemployed or on leave because of pain were equally (50%) likely to report lower 
pain intensity compared to individuals who were full time employed. Surprisingly, part-time 
employment showed a strong association with lower pain intensity. Though, pain education 
and patient-provider relationship did not show an association, the findings suggest that 
individuals who reported receiving pain education and good patient-provider relationship were 
twice as likely to report lower pain intensity. These findings are in contrast to the popular belief 
that pain education improves pain intensity (398, 399). However, what is new in our findings 
is that education induced changes in thought processes and management led to a reduction in 
pain intensity. Separate regression analysis results presented in Tables 7.5 and 7.6 also show 
the statistically significant effect of pain education on pain cognition and management of pain. 
Which leads to the hypothesis that the effects of pain education may not be direct but indirect, 
prompted by changes in management and pain cognition through pain education. 
 







Self-reported recovery is often tested in post-surgical cases, however to our understanding 
factors associated with patient-reported recovery in individuals with chronic pain have not been 
investigated before, especially in chronic pain sufferers. The findings suggest that self-reported 
positive recovery was higher in younger individuals aged between 18-40 years compared to 
individuals aged 40 years and above. Men were more likely to report positive perception of 
recovery compared to females. It is possible that as the prevalence of chronic pain is less in 
younger adults and males are more likely to report positive recovery. Moreover, studies show 
that older individuals often report more than one chronic disease including chronic pain which 
may also affect their perception of recovery (404). Age, marital status, education level and 
employment status showed no association with self-reported good recovery. Once again, 
similar to the results from the pain intensity study (reported in Table 7.3), pain education and 
patient-provider relationship showed no direct association with recovery. However, changes in 
pain cognition and management of pain showed an association with patient-reported recovery. 
Thus once again supporting the previously stated hypothesis. 
To confirm our suggested new hypothesis we conducted separate regressions between changes 
in pain cognition and management of pain and pain education. Interestingly we found that pain 
education was a predictor of these two factors. The results from this analysis showed that 
individuals who received pain education were three times more likely to report changes in pain 
cognition (Table 7.5) and were four times more likely to report changes in management of pain. 
These findings are in line with studies which report that pain education assists patients to re-
conceptualize pain (398, 400, 405). 





Additionally we also conducted separate regressions between changes in pain cognition and 
management of pain and patient-provider relationship. Not surprisingly, the patient-provider 
relationship also showed a strong association with changes in pain cognition and management 
of pain. The results also suggest that individuals who had a good patient-provider relationship 
with their health care professional were more likely to report positive changes in pain cognition 
and pain management. 
It may be that pain education and patient-reported pain intensity and recovery show an indirect 




The study results also indicate that handouts, though used widely for pain education are not 
rated useful by patients. Website, book, smart phone app, YouTube and videos were rated as 
the top 5 most useful pain education tools. This is an important finding as todays’ patients 
increasingly have access to the internet, which opens a plethora of information sources on 
various diseases including chronic pain. Sadly, though some of this information comes from 
non-certified health experts. It is important to consider these modern options such as apps and 
YouTube videos for providing pain education.  
  
Pain Education Changes in pain cognition Changes in management of pain  Patient-
reported pain intensity and similar for recovery 
 







Data from the self-report internet survey shows that pain education may have an indirect effect 
on patient-reported pain intensity and recovery through change in pain cognition and 
management of pain. Pain education and patient-provider relationship may not be effective in 
isolation. However they must be considered jointly with education prompted change in 
management and pain cognition. 
These findings are important for future research and practice as they give a new direction for 
employing pain education towards enhancing patients’ overall understanding of their pain. 
Additionally, strategies should include education directed towards improving individual pain 




This was a pragmatic study where data was collected from individuals experiencing chronic 
pain in a real world scenario. Low or no participation from individuals who have lower 
education and no internet access is a limitation. We may have also missed assessing areas of 
importance such as the number of education session individuals received. However to avoid 
participation burden and fatigue, it was considered best to limit the length of the study. Finally, 
the accuracy of the data was dependent on participants self-reporting and subjective assessment 
of their experiences. No objective assessment strategies were used to verify the quality of 








Discussion & Conclusion’s 
  





This thesis investigated the role of vitamin D deficiency in patients with chronic nonspecific 
musculoskeletal pain (CNMP). This research examined two very distinct elements – CNMP 
and vitamin D which have previously not been studied extensively. The current research is 
timely as the use of opioids for non-malignant chronic pain has recently become more regulated 
(36). More than ever before there is now a high demand for alternative treatment options to 
manage chronic pain. Moreover, vitamin D deficiency has been described as a pandemic (82), 
which has been associated with many chronic painful conditions (37-39). 
CNMP is a type of chronic pain characterized by the clear absence of anatomical or 
pathological source (226), with a high prevalence reported in individuals seeking medical care 
(217, 228). Currently there are no International Classification of Diseases (ICD) diagnostic 
codes (275) or guidelines for the management of CNMP, as a result it is often a diagnosis of 
exclusion. Moreover, as described in Chapter 2, due to the limited knowledge about its 
presentation and symptoms, the label of CNMP can often be used interchangeably with 
fibromyalgia and chronic widespread pain. But, we do not know how CNMP is currently 
managed in general practice, especially in the absence of guidelines and information regarding 
its aetiology and presentations. GPs are central to management of patients with pain in 
Australia (21, 22). We therefore, conducted a qualitative study, using focus groups, of GPs 
practicing in various medical practices in Adelaide. 
Many studies report a high prevalence of vitamin D deficiency in patients with CNMP (37, 
200). The discovery of non-classical effects of vitamin D such as immune modulation, anti-
inflammatory, cell regulation and neuroprotection (51, 61) has led to an increase in research 
about the involvement of vitamin D in various chronic painful conditions. As detailed in section 
2.2 (chronicles of pain) in the literature review, the evolution of pain models from the 
biomedical model to the relatively new biopsychosocial model allows us to understand how 





and why vitamin D deficiency, its supplementation, and vitamin D associated co-morbidities 
such as stress, anxiety and depression can affect chronic painful conditions. This model 
provides a basis for how diverse aspects of an individual’s life such as body weight, nutrition, 
supplement intake, lifestyle, attitude, belief, family support, employment, psychological 
factors and even interaction with their doctor can potentially influence and change their pain 
experience and thereby health outcomes.  
 
8.1 Summary of the findings 
 
A qualitative exploration of GPs’ perspectives on managing chronic non-
specific musculoskeletal pain in Australian general practice 
 
The first study in this thesis investigated the clinical reasoning GPs’ employ when diagnosing 
and managing patients with CNMP. Using a qualitative study design, data was collected from 
GPs practicing in Adelaide. The results showed that GPs employed an individual patient-
centered approach for both the diagnosis and management of CNMP.  GPs believe CNMP to 
be preceded by a range of factors including injuries, falls, sprains, infections, autoimmune 
disease; and long-term use of medications like statins, benzodiazepines and opioids. There was 
general consensus among GPs that more female patients are diagnosed with CNMP which was 
attributed to their general higher uptake of medical services. Though, management was also 
tailored to the individual patient, more emphasis was put on building a strong patient-provider 
relationship and managing the psychosocial health of the patient. 





The findings also showed that GPs’ were concerned about vitamin D levels in chronic pain 
patients and recommended vitamin D supplementation if indicated by a patient’s medical 
history and lifestyle. Testing for vitamin D levels was widely discouraged by the participating 
GPs. This is consistent with current Australian guidelines for vitamin D testing which 
recommend testing only in people at risk of moderate to severe deficiency defined as 25(OH)D 
level <25nmol/L (406). Our findings are consistent with another study, investigating strategies 
applied by Dutch GPs for managing unexplained symptoms (296). 
 
Does vitamin D supplementation alleviate chronic nonspecific musculoskeletal 
pain? A systematic review and meta-analysis. 
 
Studies reporting a strong association between vitamin D and CNMP are more commonly 
observational studies (described in Chapter 2). Very few randomized controlled trials (RCT’s) 
were found in the literature search, and the results from these studies varied from demonstrating 
a “high effect” to “no effect”. To understand why these RCT’s were unable to replicate the 
findings of the observational studies, a systematic review was performed. Further, a meta-
analysis was used to investigate the association between vitamin D and CNMP. This was the 
first study to use the quantitative technique of meta-analysis to determine if vitamin D 
supplementation is a useful treatment for CNMP. Only studies using an RCT design, comparing 
vitamin D supplementation to placebo in patients with CNMP were included. The initial search 
identified 107 studies, however on systematic appraisal of these studies 104 were excluded for 
the following reasons; i) they did not meet our study selection criteria of an RCT design, ii) the 
investigators had experimentally induced pain or iii) they had included participants 





experiencing more than one type of chronic pain. Finally 3 RCTs with total 492 participants 
were selected and included in the meta-analysis. The smaller number and size of the included 
studies highlights the need for more well-designed RCTs to be conducted. The findings from 
the meta-analysis suggested no effect of vitamin D supplementation on pain in patients with 
CNMP. However, it is important to interpret this results cautiously because the number of 
studies and total number of participants were small. Moreover, there was heterogeneity within 
the studies selected because of differences in the dose and dose regimes of supplementation 
used. In part this may be due to the absence of universal supplementation guidelines for 
replenishing vitamin D levels. 
 
Factors associated with vitamin D deficiency, testing and supplementation in 
patients with chronic pain. 
 
As described in Chapter 2 certain factors (such as age, gender, skin pigmentation, reduced sun 
exposure time) are associated with a higher risk for developing vitamin D deficiency in the 
general population. However, no studies have examined the factors associated with vitamin D 
deficiency, it’s testing and intake in patients with chronic pain.  As described in Chapter 3, GPs 
involved in our study were concerned about vitamin D levels in patients with chronic pain 
which was associated with reduced sun exposure and physical activity in these patients. The 
GPs also recommended supplementation based on a patients’ medical history and lifestyle. 
Therefore, we performed a cross-sectional study to examine what factors, as described by 
patients with chronic pain, were associated with testing, deficiency and intake of vitamin D as 
detailed in Chapter 6. We also examined factors associated with vitamin D supplementation as 





advised by doctors for patients with chronic pain. We developed a simple prediction model 
from data collected using the LASSO regression technique. The findings from this study 
showed that older age was consistently associated with testing, deficiency and intake of vitamin 
D. As, older age is widely recognized as a risk factor for vitamin D deficiency (379, 380) it 
may be the reason why elderly people have higher rates of not only deficiency but also testing 
and intake of vitamin D. 
In addition, being unemployed or on leave due to pain or in part-time employment and being 
resident of Australia was associated with vitamin D testing. This result reflects the increase in 
testing for vitamin D reported by Medicare Australia (370). Higher mean pain intensity score 
≤6 on an 11 point numerical rating scale was associated with vitamin D deficiency; and being 
diagnosed with vitamin D deficiency was associated with intake of vitamin D.  Being vitamin 
D deficient and unemployed or on leave due to pain or in part-time employment were 
associated with doctor advised vitamin D supplementation. To our knowledge this is the first 
study that has successfully developed a model to predict vitamin D testing, deficiency, intake 
and doctor advised vitamin D supplementation in individuals with chronic pain. These findings 
have clinical implications and the model could be useful for identifying patients with chronic 
pain who are at risk of deficiency and therefore benefit from testing or supplementation.  By 
using simple demographic and self-reported pain related factors, which are readily accessible 
by GPs, more rationale and cost-effective management of chronic pain could be achieved.  
 
  





Effect of pain education and patient-provider relationship on patient-reported 
pain intensity and recovery 
 
The focus groups with GPs (detailed in Chapter 3) stressed the importance of educating patients 
about their pain and helping them set realistic goals (Theme 3). In addition, building a good 
relationship with the patients (Theme 4) was also considered fundamental for management of 
patients with chronic nonspecific musculoskeletal pain. Previous studies have rated the patient-
provider relationship and pain education as an important aspect of management for patients 
with chronic pain. However, to our knowledge no previous studies have tested the association 
between patients receiving pain education and patient-provider relationship and patient-
reported pain intensity and their perception of recovery. 
Therefore, we performed a cross-sectional survey to examine if patient-reported pain intensity 
and recovery were associated with receiving pain education and patient-provider relationship 
in patients with chronic pain as detailed in Chapter 7. We used univariate and multiple logistic 
regression to study the effect on pain education and patient-provider relationship on pain 
intensity and recovery before and after controlling for the potential confounders.  
The findings from this study show that individuals aged 40 years and above, and female were 
more likely to report higher pain intensity and poor perception of recovery compared to young 
individuals and males. These findings are in line with previous studies which report higher 
prevalence of pain in older age groups and females (284, 345). 
In addition, being in part-time employment also showed association with higher pain intensity 
compared to individuals who were employed full-time. However, pain education and patient-
provider relationship did not show a association with pain intensity and recovery. These 





findings are in contrast to other studies which report that pain education improves pain intensity 
(398, 399). 
But, education induced changes in pain cognition and management do lead to a reduction in 
pain intensity and positive recovery. We therefore, hypothesized that the effects of pain 
education were induced by changes in pain cognition and management on pain intensity and 
recovery.  Therefore, we tested this hypothesis by a separate regression between changes in 
pain cognition and management of pain and pain education. The results from this analysis 
showed that individuals who received pain education were more likely to report changes in 
pain cognition and management of pain. Thus confirming our hypothesis that pain education 
has an indirect relationship with patient-reported pain intensity and recovery mediated by 
change in pain cognition and management of pain. We also conducted a separate regression 
between changes in pain cognition and management of pain and patient-provider relationship. 
The findings showed that individuals who reported good patient-provider relationship were 
more likely to report positive changes in pain cognition and management of pain. The study 
results also show that individuals with chronic pain rate website, book, smart phone app, 
YouTube and videos as the most preferred material for obtaining pain education.  
These findings have implications for future research and practice. It informs two key corollaries 
of pain education which have potential for altering pain intensity and recovery of individuals 
experiencing chronic pain. It also illustrates the need to integrate modern technology into pain 
education and management.  
 
  





8.2 Synthesis of the findings  
 
GPs in the focus group study (chapter 3) reported that it was challenging if not impossible to 
isolate the effect of vitamin D supplementation on CNMP. They did not believe that vitamin D 
supplementation alone could reduce the pain. But they still recommended vitamin D 
supplementation in patients if indicated by their history. Similar findings were observed in the 
second study of systematic review and meta-analysis (chapter 4). The meta-analysis showed 
that vitamin D may not directly reduce the pain, but it was theoretically plausible that it could 
alleviate some of the associated pain. This raises the question that though vitamin D deficiency 
may not be able to cause pain, it could certainly exacerbate the pain. Suggesting that it may not 
be enough to just evaluate vitamin D alone, but sun exposure levels, physical activity, body-
mass index, diet, sun-protection used which can influence vitamin D levels should also be 
monitored. This is reflected from the focus group study findings were GPs’ prefer a holistic 
approach to management tailored to individual patient needs. This finding was further 
supported by the results of the patient survey that highlighted the importance of educating 
patients to improve their understanding of pain. Also, results from the survey data analysis 
suggest that patients with higher mean pain intensity score (>5) or presentations of CNMP 
should also be considered for screening of vitamin D deficiency.  
 
8.3 Limitations  
 
The limitations of each study were discussed in the relevant chapters. This section discusses 
the limitations of this thesis in general and potential future research. 
The primary limitation of the study reported in Chapter 3 was the focus group methodology 
used. Due to the nature of the study design, in depth information could not be collected. 





However, as discussed in Chapter 3, CNMP is a poorly researched topic which required a 
setting that could facilitate interaction between participants and encourage sharing of 
encounters and experiences to allow refinement during the discussion. The second limitation 
of the study was moderator bias which could inject personal biases into participants’ exchange 
of experiences and can also lead participants to certain conclusion. In order to minimize 
moderator bias, a loosely structured questionnaire was followed for each focus group 
discussion to maintain uniformity in the topics discussed.  
The major limitation of Chapter 4, systematic review and meta-analysis was the paucity of high 
quality RCT’s.  However, unlike the Cochrane review (242) of chronic painful conditions, our 
systematic review included a meta-analysis and focused only on patients with the same clinical 
condition (CNMP) as combining multiple conditions, as done in the Cochrane review, that have 
distinct pathophysiological aetiologies, does not make clinical sense and could lead to 
erroneous conclusions.  
The study described in Chapters 6 and 7 used data collected from a cross-sectional survey 
described in Chapter 5. The primary aim of this study was to investigate the views, beliefs and 
perceptions of individuals with chronic pain on their pain management, with a special focus on 
vitamin D supplement intake, pain education and the patient-provider relationship. It was the 
first study to explore these factors which form an integral part of pain management in 
individuals with chronic pain. Cross-sectional study designs are often used for this type of 
research because of their ability to cross geographical barriers, however it could be argued that 
a longitudinal design would have enabled a more thorough collection of data. Finally, the data 
was a subjective assessment of patients’ views and beliefs, no objective assessment was used 
to verify or validate the participant responses.  






8.4 Concluding remarks 
 
This thesis explores the management of chronic pain, with special focus on CNMP. Although 
previous studies have reported an increasing prevalence of CNMP in clinical practice, research 
on this condition is limited and currently there are no guidelines for managing it. This thesis 
used qualitative and quantitative methods considered applicable to provide detailed findings. 
This thesis helps to fill a significant gap in knowledge about how CNMP is identified, 
diagnosed and managed in by GPs and the effect of vitamin D supplementation on patients 
with CNMP. This thesis also provides a simple predictive model using demographic and pain-
related factors for identifying patients with chronic pain who are at risk of vitamin D deficiency 
and who therefore may benefit from testing or supplementation. In addition, the thesis shows 
how pain education may have an indirect effect on patient-reported pain intensity and recovery 
through education induced changes in pain cognition and management.  The study describes 
the importance of the patient-provider relationship on pain intensity and recovery as described 
by individuals with chronic pain. The study also indicates that individuals with chronic pain 
rate use of website, book, smart phone app, YouTube and videos as the most preferred material 
for obtaining pain education.  
This thesis began with a literature review on vitamin D and its potential role in different 
musculoskeletal conditions. This was followed by examining the clinical reasoning GPs 
employ when diagnosing and managing patients with CNMP. These findings were then 
followed by synthesizing evidence for role of vitamin D supplementation on pain in patients 
with CNMP, using systematic review and meta-analysis. A cross-sectional survey study was 
conducted. The analysis conducted on the data collected from the survey allowed us to develop 





a simple prediction model and identify factors associated with testing, deficiency, intake and 
doctor advised supplementation of vitamin D in individuals with chronic pain. The analysis on 
data collected from the survey also showed that pain education and patient-provider 
relationship should be considered jointly with education prompted change in management and 
pain cognition.  
 
8.5 Directions for Future studies 
 
 
Both the results from the GP focus group and the meta-analysis suggest that Vitamin D 
supplementation is unlikely on its own to improve pain in patients with CNMP, however both 
studies support its use and report alleviation of some of the associated pain. Future research 
should therefore focus not only patients confirmed with the diagnosis of vitamin D deficiency 
but also on patients with comorbidities associated with vitamin D deficiency and pain such as 
obesity, mood disorders and stress. In addition, future studies should focus on investigating 
holistic outcomes such as quality of life, physical activity, fatigue/vitality and mental health. 
Moreover vitamin D functions more like a hormone than a vitamin and therefore it is necessary 
that future studies measure pre and post supplementation vitamin D levels and their correlation 
with primary and secondary outcomes.  
These results could inform future research, medical practice and policy makers, to enhance the 
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Abstract Chronic nonspecific musculoskeletal pain (CNMP)
is an idiopathic condition often seen in general practice and
rheumatology clinics, the aetiology of which may include vi-
tamin D deficiency. The objective of the present study is to
evaluate the effectiveness of vitamin D supplementation in the
management of CNMP through a systematic review andmeta-
analysis. According to PRISMA guidelines, PubMed,
Embase, Web of Science, Cochrane and Scopus electronic
databases were searched for randomised controlled trials com-
paring vitamin D supplementation to a control or placebo in
CNMP patients; the search was not limited by language or
date. Meta-analysis was performed using the mean and
standardised mean difference which was computed with
95 % confidence intervals, and overall effect size was calcu-
lated. Both fixed and random effects models were used in
meta-analysis to account for heterogeneity in the studies.
The initial search identified 107 studies, of which 10 were
potentially relevant, with 7 studies excluded because they
did not meet selection criteria. Three studies were included
in the meta-analysis. We found no effect of vitamin D
supplementation (standardised mean difference (SMD)
0.004; 95 % confidence interval (CI) −0.248 to 0.256) on pain
in CNMP patients. Forest plot is used to present the results
from meta-analysis. Contrary to a widespread clinical view,
there is a moderate level of evidence that vitamin D supple-
mentation is not helpful for treating CNMP patients.
Keywords Chronic nonspecific musculoskeletal pain .
Meta-analysis . Systematic review . VitaminD . VitaminD
supplementation
Introduction
Chronic nonspecific musculoskeletal pain (CNMP) is an idio-
pathic condition which is a common presentation to rheumatol-
ogy clinics [1, 2]. CNMP is associated with decreased physical
health, mental well-being, social life [3, 4], work ability [5] and
disability [6]. Many sufferers become stuck on a descending
spiral of economic, social, emotional and physical disadvantage
[7, 8]. CNMP is a significant burden to the economy [9]. The
aetiology of CNMP is not well understood, and although many
potential contributors have been identified [10], a clear nocicep-
tive source has not, and empirical data concerning other contrib-
utors are lacking. As a result, CNMP is difficult to diagnose,
prevent or treat. One potential contributor that receives substan-
tial attention clinically and has been investigated in a range of
clinical studies is vitamin D deficiency [11, 12].
Vitamin D is involved in many regulatory biological process-
es. In addition to calcium homeostasis, vitamin D is thought to
have anti-inflammatory, anti-apoptotic and anti-fibrotic effects; it
is thought to play a role in regulating blood pressure and in innate
and adaptive immune system function [13, 14]. This range of
biological effects highlights the potential role of vitamin D defi-
ciency in the development of symptoms associated with acute
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and chronic rheumatic diseases, and it is biologically plausible
that vitamin D deficiency contributes to the development and
maintenance of CNMP. That people with vitamin D deficiency
can present with nonspecific muscular pain and bone pain has
been reported [15], and several studies have suggested a causa-
tive role [16–18]. However, a recent Cochrane review [19] in-
vestigated vitamin D supplementation for the treatment of a
range of chronic painful conditions and concluded no substantial
effect. Given the different pathophysiological origins of the con-
dition included, such as osteoarthritis, rheumatoid arthritis and
fibromyalgia, such a finding was perhaps not surprising. The
authors of that review suggested that specific conditions should
be investigated individually. We contend that another aspect of
that review may have contributed to its null findings: there was
no attempt to confine source literature to direct comparisons
between vitamin D and a control or placebo. This is important
in this field because it is arguably very difficult to isolate the
treatment effect attributable to vitamin D supplementation when
it is instigated as a part of multimodal intervention.
Despite the clinically topical nature of the issue and the
substantial literature, no attempt has been made to conduct
meta-analyses. Meta-analyses provide the obvious advantage
of increasing power and estimating effect sizes, which can
then be re-tested in subsequent studies [20]. We aimed to fill
these substantial gaps in the literature by using gold standard
systematic review and meta-analysis methodology to evaluate
the evidence concerning the effect of vitamin D
supplementation, when compared in a randomised controlled
trial to a placebo, on pain in people with CNMP.
Methods
Preferred Reporting Items for Systematic Reviews and Meta-
Analyses Statement [21] was followed for this review.
Inclusion criteria
Only randomised controlled trial (RCT) or randomised
double-blind control study designs were eligible. For inclu-
sion, RCTs had to compare vitamin D supplementation to a
control or placebo and measure the pain outcome using Visual
Analogue Scale (VAS). No restrictions were applied for lan-
guage but restricted the studies to those conducted on
Bhumans^.
Exclusion criteria
Studies including patients previously diagnosed with an in-
flammatory joint disease, postsurgical patients or patients with
experimentally induced pain were excluded.
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Search strategy
An electronic search was performed on five databases—
PubMed, Embase, Web of Science, Cochrane and Scopus.
The search period was set from the time of commencement
of these databases up to 3 November 2015. The search strat-
egies for each database are listed in Table 1. MG and SV
independently searched for potentially eligible studies based
on the study title and then read the abstracts and selected
potentially relevant studies, from which studies not matching
the selection criteria were excluded. Full articles of the re-
maining studies were reviewed for inclusion. The reference
lists of selected studies were manually searched to find addi-
tional potential papers.
Data extraction
The final selection of the studies was collectively made by the
group. Data extraction was performed by MG and MM using
a standardised data extraction form similar to Table 2
highlighting the characteristics of selected studies. Data was
extracted on sample size, characteristics of participants, inter-
vention type and control group, main outcome and adverse
events. The review team was never blinded to authors’ names
or institutions, journal of publication and study results. MM
provided the statistical support and help in performing the
analysis. The manuscript was collectively written by the team,
and all authors approved the final draft.
Quality assessment of selected studies
The five-point Jadad score was used to assess the methodo-
logical quality of studies. Following, questionnaire formed the
basis of scoring [22]
1. Was the study described as randomised?
2. Was the study described as double blind?
3. Was there a description of withdrawals and dropouts?
Each question is answered either yes or no; with each yes,
the study is scored 1 point and no scored 0 points. For well-
described method of randomisation and blinding, additional
Table 2 Characteristics of included studies
Author/
year
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Age 18 to 60 years.






















6 A small positive effect on








group n = 50
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n = 104










12 Vit D deficiency
correction did not
improve msk pain.
Table 3 Jadad scores of included studies
Study Randomization (max points 2) Blinding (max points 2) Account of all patients












Schreuder et al. (2012) 1 1 1 1 1 5
Sakalli et al. (2012) 1 1 1 1 0 4
Warner et al. (2008) 1 1 1 1 1 5
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points are given respectively. However, 1 point each was
deducted if the described method of randomisation and
blinding was incorrect. Clinical trials scoring more than 3
are considered as high quality (refer Table 3).
Data analysis
Meta-analysis of the standardised mean differences
(SMDs), and their standard errors, in VAS scores was
performed between vitamin D-treated and placebo-
treated groups. SMD has several versions such as
Cohen’s d [23], Glass’s Δ [24] and Hedges’ g [25];
however, we have used the simple SMD which is the
ratio of the mean difference and the standard deviations.
The value SMD less than 0.5 is considered to be small
effect, from 0.5 to 0.8 medium effect and greater than
0.8 large effect [26]. Summary effect estimates were
calculated with the fixed effects models. Analysis was
performed in Stata, version 12.1, software (StataCorp
LP, College Station, TX) using the metan commands
[27]. The heterogeneity between studies was assessed
by computing the I2 statistics. A value of 0 inferred
no heterogeneity, and value above 50 % is recognised
as substantial heterogeneity [26]. Following Bailey [28],
we used fixed effects model, as the objective of this
study is to test whether the intervention has produced
an effect in a set of homogenous studies. In the fixed
effects model, we weighted the data by the amount of
information (inverse of the variance of the study) that is
captured by the study.
Results
The initial search located 101 studies from the databases
(PubMed 14, Embase 20, Web of Science 19, Cochrane
Library 45 and Scopus 9). After reviewing the title, the ab-
stract and removal of the duplicates, ten studies were identi-
fied for potential inclusion (Fig. 1). Full text of these articles
was reviewed and assessed. Of these ten articles, seven were
excluded because they did not meet our selection criteria of
study design, thus leaving us with only three studies, for
conducting the systematic review [29–31]. These three studies
used a RCTstudy design to investigate the effect of vitamin D
supplementation (treatment group) compared to a placebo
(control group) in CNMP patients.
The characteristics of the selected studies are described in
Table 2. The three studies included in the meta-analysis eval-
uated 492 participants in total. The participants were generally
adults with their mean ages ranging from 41 to 76 years. The
majority of participants in all studies were females. All studies
measured pain, and one study also measured functional mo-
bility and quality of life. Study sample sizes ranged from 84 to
288 subjects. All three studies used VAS to measure changes
in pain (outcome); in addition, studies also used the timed up
and go test (TUG) [29], functional pain scores (FPS) [31] and
Likert scales [30]. All studies used oral route for administering
vitamin D except Sakalli et al. study which, in addition. also
used intramuscular route for administering vitamin D. This is
reflected in the Fig. 2 which shows four studies namely study
A, Schreuder et al. study; study B1, Sakalli et al. oral vitamin
D supplementation group; study B2, Sakalli et al. intramuscu-
lar vitamin D supplementation group; and study C, Warner
Studies excluded aer: 
Inial screening of tle and abstract (n=77)
Studies idenfied from literature search (n=107) 
Full text of studies retrieved for further evaluaon (n= 30) 
 Duplicate studies excluded (n= 20) 
Full text of studies retrieved for further evaluaon (n= 30)
Studies excluded: 
Not RCT (n= 4), paent criteria unfulfilled (n = 3)
Total number of RCTs included (n=3) 
Fig. 1 Flow chart diagram of
study selection
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et al. study. We did this to test if the mode of administration
influenced the strength of the clinical effect. The trial period of
selected studies was 4 weeks [29] and 12 weeks [32, 33]. Of
the three included studies, only one study reported that none
of the participants experienced adverse events during the trial
or in the follow-up period [30]. In general, all studies scored
highly on methodological quality with two studies scoring 5
and one study scoring 4 (Table 3).
Out of the three selected studies, two showed reduction in
pain, following treatment with single mega-dose vitamin D
supplementation [29, 30], and one showed no effect on pain
following vitamin D supplementation [31].
Meta-analysis result
The results from meta-analysis are presented in the forest plot
(Fig. 2). The horizontal lines, depicting the length of confi-
dence intervals, for study A and study B1 are on treatment side
indicating a modest effect of the intervention on pain in
CNMP patients, while for study B2 and study C, the lines
are on control side representing no effect of intervention.
The overall effect (represented by black diamond in Fig. 2)
lies on the line of no effect, indicating that the average effect
size of the pooled analysis is 0. The I2 statistic is 62.4 %,
indicating a moderate level of heterogeneity in the pooled
analysis, which confirms that the variation is not due to
chance. The overall pooled SMD was 0 with confidence in-
terval (CI) ranging between −0.25 and 0.26, p value=0.97,
indicating that the intervention has no clinical effect on the
CNMP (Fig. 2). The test for overall effect is not statistically
significant.
To split the variance as within- and between-study vari-
ance, we also analysed data using random effects model
(Fig. 3). The overall pooled SMD was 0.05 with CI ranging
from −0.37 to 0.46, I2=61.4 and p value=0.05 reiterating no
statistical significance.
Discussion
We aimed to evaluate the evidence concerning the effect of
vitamin D supplementation, when compared in a RCT to a
placebo, on pain in people with CNMP. Our results are in
contrast to the prevailing clinical opinion [1, 17, 32] insofar
as they suggest that vitamin D supplementation does not de-
crease pain in CNMP, when compared to a placebo. Our re-
sults also show, however, that robust RCT data are perhaps
more limited than would be assumed: despite a comprehen-
sive search strategy, only three RCTs, with total of 492 partic-
ipants, satisfied our a priori criteria. The included trials com-
posed of participants aged between 41 and 76 years with vi-
tamin D levels of 20 nmol/L or less. A range of doses of
vitamin D were administered in each included trial, but there
was no evidence of a dose-response relationship.
The current study raises new questions for the investigation
of CNMP. Our results clearly suggest that vitamin D supple-
mentation is not helpful for CNMP. According to the Grading
of Recommendations Assessment, Development and
Evaluation (GRADE) [33], we suggest that there is low to
moderate evidence (one high-quality study or several studies
with some limitations but consistent results) [33] that vitamin
D supplementation is not helpful for people with CNMP.
It is notable that the proposed mechanisms by which vitamin
D deficiency might contribute to CNMP—disruption of calcium
homeostasis and a loss of anti-inflammatory, anti-apoptotic or
anti-fibrotic effects [13, 14]—imply that the primary cause of
CNMP lies within the tissues of the body. Although such mech-
anisms seem intuitive, they are not necessarily consistent with
Fig. 3 Forest plot using random
effects model
Fig. 2 Forest plot using fixed
effects model
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modern models of CNMP and other chronic pain conditions.
Although vitamin D deficiency, through disruption of immune
regulation [13, 14], could disrupt the neuroimmunological pro-
cesses that subserve pain [34], the assumption that this would
increase pain rather than decrease it remains to be properly tested.
The prevailing theories with regard to chronic pain place greater
emphasis on enhanced sensitivity within the nociceptive system
[35], increased contribution of non-nociceptive sensory inputs
and associative learning [36], and cognitive mechanisms that
emphasise perceived threat to body tissue and behavioural pro-
cesses linking fear of pain, activity avoidance and catastrophising
[37] and de-emphasise ongoing tissue pathology or damage
(with some exceptions, for example, seronegative arthropathies)
[38]. Indeed, CNMP is widely considered to be influenced by a
wide range of biological, physical, psychological and social fac-
tors [7] and management approaches reflect this biopsychosocial
framework [39, 40]. Perhaps, vitamin D supplementation might
play a more important role in painful conditions that more obvi-
ously relate to tissue inflammation, for example, rheumatoid ar-
thritis, although this remains to be determined.
The biological complexity of vitamin D effects leaves open
the possibility that supplementation could offer benefit for peo-
ple with CNMP and that the current research base is not suffi-
cient to detect it. That is, protocols of the RCTs may have led to
inadequate rise in serum vitamin D levels postsupplementation
[41] due to noncompliance, although one might argue that such
interventions are really Badvice to take a particular action^ rath-
er than the action itself [42]. Different effects may also relate to
heterogeneity of body mass index (BMI) between participants.
Alternatively, standard doses of vitamin D supplementation
may not always produce predictable increases in the vitamin
D levels [41] or predictable rates at which vitamin D level
changes [43], potentially masking positive effects. That other
study designs, for example, clinical studies [1], observational
[18], cross-sectional and case report studies [17], have demon-
strated moderate benefit following supplementation may reflect
an advantage of tailored supplementation regimes (although
considering the findings of such studies, one should remember
that these study designs are highly vulnerable and may overes-
timate true effects) [44].
The relative paucity of RCTs comparing vitamin D supple-
mentation to placebo is surprising, considering the widespread
clinical endorsement of the idea. The available data are also
not very generalisable to all ages because most studies have
investigated primarily postmenopausal women and compared
nonstandard doses for which there is little justification.
Estradiol is recognised as a physiological predictor of vitamin
D binding protein [45], and postmenopausal women show a
higher natural decline in vitamin D levels than premenopausal
women [46], suggesting that it would be important to investi-
gate the variance in vitamin D levels in premenopausal wom-
enwith depleting estradiol levels as well as in younger women
with normal estradiol levels. Furthermore, CNMP is highly
prevalent in children and adolescents, but this group has not
been investigated with regard to vitamin D.
There are several considerations, strengths and limitations
of the current study. We included the Warner et al. study [31]
even though they diagnosed participants with primary fibro-
myalgia, not CNMP. On closer appraisal, the participants in
their study did not satisfy the ACR criteria for fibromyalgia
but did satisfy criteria for CNMP. The strengths of this study
are its focus on CNMP and inclusion of meta-analysis, as was
recommended in a recent Cochrane review [19]; the absence
of language or publication restrictions, giving confidence that
we did not miss important studies; and the confinement of
included studies to those that used a RCT design, because they
provide the most rigorousmethod of verifying if a cause-effect
relationship exists between the intervention and outcome [47].
We used SMD score to evaluate the clinical relevance and CI
for inference because it focuses on the probability and signif-
icance of the intervention and helps to establish the clinical
and statistical significance of the findings [48]. There are also
limitations: the forest plot shows variability between the stud-
ies, and broad 95 % CIs show the imprecision of the results, a
common problem with small sample sizes [48]. The most
significant limitation is indeed the lack of source literature,
which is particularly pertinent to the field because it contrasts
with popular clinical belief.
This study shows that there is no proven effect of vitamin D
supplementation on pain in people with CNMP, when com-
pared to a placebo.We conclude that there is GRADE C (low)
to level B (moderate) evidence that vitamin D supplementa-
tion is not helpful for people with CNMP. Clearly, more robust
and nuanced RCTs might have an important impact on our
confidence in the estimate of effect [33].
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Background: It is widely recognized that both doctors and patients report discontent regard-
ing pain management provided and received. The impact of chronic pain on an individual’s life 
resonates beyond physical and mental suffering; equal or at times even greater impact is observed 
on an individual’s personal relationships, ability to work, and social interactions. The degree of 
these effects in each individual varies, mainly because of differences in biological factors, social 
environment, past experiences, support, and belief systems. Therefore, it is equally possible that 
these individual patient characteristics could influence their treatment outcome. Research shows 
that meeting patient expectations is a major challenge for health care systems attempting to 
provide optimal treatment strategies. However, patient perspectives and expectations in chronic 
pain management have not been studied extensively. The aim of this study is to investigate the 
views, perceptions, beliefs, and expectations of individuals who experience chronic pain on a 
daily basis, and the strategies used by them in managing chronic pain. This paper describes the 
study protocol to be used in a cross sectional survey of chronic pain patients.
Methods and analysis: The study population will comprise of individuals aged ≥18 years, 
who have experienced pain for ≥3 months with no restrictions of sex, ethnicity, or region of 
residence. Ethics approval for our study was obtained from Humans research ethics commit-
tees, University of Adelaide and University of South Australia. Multinomial logistic regression 
will be used to estimate the effect of duration and character of pain, on patient’s perception of 
time to recovery and supplement intake. Logistic regression will also be used for estimating 
the effect of patient-provider relationship and pain education on patient-reported recovery 
and pain intensity.
Discussion: Knowledge about the perceptions and beliefs of patients with chronic pain could 
inform future policies, research, health care professional education, and development of indi-
vidualized treatment strategies.
Keywords: chronic pain, pain management, patient perspectives, survey, time to recovery
Introduction
The International Association for the Study of Pain (IASP) defines chronic pain as “pain 
that persists beyond the normal tissue healing time, usually ≥3 months”, in the absence 
of an obvious underlying biological cause.1 With nearly 20% of the population affected 
worldwide, chronic pain has become a disease in its own right, rather than just being 
considered a symptom.2–5 Furthermore, chronic pain is often associated with numerous 
physical and psychological complications such as disability, sleep disturbances, fatigue, 
depression, and social isolation. The traditional approach for managing an injury or 
other illness of diagnosis and treatment offers little hope to individuals experiencing 
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chronic pain by trapping patients with chronic pain in a 
vicious cycle of trial and error treatments. Both patients and 
their doctors struggle with pain management with studies 
reporting a feeling of inadequacy about providing optimal 
treatment among physicians6–8 and dissatisfaction among 
patients concerning the treatments provided.9 
Studies show that between 40% and 60% of the general 
population use dietary supplements to promote health and 
manage conditions.10–12 Approximately 33% of those who 
use supplements quote pain as the primary reason.11 However 
little is known about their benefits as perceived by patients 
with chronic pain. Moreover, pain is a subjective sensory 
emotional experience,13 which may be influenced by an indi-
vidual’s biological, environmental, social, and psychological 
factors. Together with belief systems and expectations, these 
factors may also guide individual experiences, and influence 
treatment outcome(s). Even though studies report factors 
which predict chronic pain,14,15 their association with patients’ 
perspectives of chronic pain and its management has not been 
studied extensively. In addition, meeting patients’ expecta-
tions is an important objective for health care systems16 as it 
appears to improve treatment satisfaction between 8% and 
25%.17,18 Aligning patient expectations with a management 
plan can enhance treatment outcome and benefits.
Best practice insight recommends publishing a protocol 
prior to undertaking the study as it facilitates awareness of 
the research in progress.19 It also helps to maintain the trans-
parency in reporting of the study.20,21 This paper describes 
the protocol and the questionnaire used in a cross-sectional 
survey of individuals who experienced pain for ≥3 months. 
Aim and objectives
The aim of this study protocol is to investigate the views, 
perceptions, beliefs, and expectations of individuals who 
experience chronic pain on a daily basis, and the strategies 
used by them in managing this pain. The objectives of this 
study protocol are to investigate if pain-related factors (such 
as duration and characteristics) and pain education, affects 
chronic pain patients’ intake of supplements and perception 
of recovery. This study will also examine if health profes-
sionals support, and pain education to family and employer is 
related to pain intensity and perception of time for recovery 
in patients with chronic pain.
Methods
Design
An online survey method was selected for this study as it 
is cost-effective and easy to administer; unlike face-to-face 
interviewing, a survey provides a standardized approach 
allowing uniformity of questions asked to all participants. 
It also provides access to individuals without geographi-
cal dependency thus allowing the collection of rich data.22 
Although online surveys may limit participation from indi-
viduals without access to the internet23 the advantages of this 
method have been shown to outweigh the disadvantages in 
terms of external validity.24
A questionnaire was designed specifically for this study 
following the checklist for reporting results of internet 
e-surveys (CHERRIES) protocol25 for the ethical reporting of 
surveys and was administered online using Survey Monkey. 
Ethics approval for this study was obtained from the Human 
Research Ethics Committee of the University of Adelaide 
(approval no: HREC-2016-0712) and the University of South 
Australia (application id: 0000035791). 
Recruitment
The survey was advertised on multiple educational, basic, 
and clinical science websites and on social media in different 
countries, including Australia, Ireland, India, New Zealand 
and the US. Individuals accessing these websites were invited 
to participate in the study if they met the inclusion criteria. 
The survey was open for participants from all ethnicities and 
regions of residence. Data collection ceased by the end of 
October 2016. All participants activated an electronic consent 
prior to beginning the survey.
Inclusion criteria
Individuals for inclusion in the survey should be: 1) currently 
aged 18 years and above and 2) must have experienced pain 
≥3 months duration.
Exclusion criteria
Individuals are not eligible to participate in the survey if: 
1) their current age is below 18 years; 2) they suffer from 
acute pain of <3 months duration; and 3) they do not consent 
to be a part of the survey study.
Consent and confidentiality
Individuals who click the link to participate in the study are 
first taken to an information page. The information page 
describes the proposed study, its relevance and also outlines 
what type of information will be asked from the participants 
and the time required to complete the survey. The information 
page notifies the participants that the survey is voluntary and 
their choice of participating or not participating will have 
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Understanding patient perspectives on management of their chronic pain
provides the participants with information regarding whom 
to contact in case of distress or if they have a complaint. The 
information page also explains that the survey is completely 
anonymous – information that could disclose the participant’s 
identity is never asked at any stage during the survey.
Data storage and handling
The data was stored on a secure computer owned by Uni-
versity of Adelaide, with password-controlled access. Only 
the research team (all authors listed) had access to the data. 
Sample size 
Sample size calculations for estimation are based on three 
parameters, the variance or spread of the observations, the 














where n=sample size, P=estimated population proportion, 
d= precision of the estimate. 
For this sample size estimation, the values chosen were 
P=0.5 and d=0.05. Thus, it gives a sample size of 384 with 
95% confidence interval and 80% power. This is the simple 
random sampling approach.26 
Questionnaire development
Currently, there are very few studies examining the perspec-
tives and the expectations of individuals who experience 
chronic pain regarding their pain management. Due to the 
unavailability of validated scales of chronic pain patients’ 
perspectives, this questionnaire was developed by the team 
of authors through discussions and literature search. The 
questionnaire (Supplementary material) comprises of 5 sec-
tions and 39 items in total. A pilot study to verify the face 




All analyses will be performed using STATA 14.1 Statistical 
software Release 12. 
Multinomial logistic regression will be performed to esti-
mate the effect of duration and character of pain; education 
about pain and variation in supplement intake on chronic pain 
patients’ perception of time to recovery. Univariate logistic 
regression will be used to examine the effect of support 
received from health professionals, family, and employers on 
chronic pain patients pain levels, quality of life, and physical 
goals. The analysis will be adjusted for confounding factors 
such as age, sex, education, employment, and marital status.
Simple descriptive statistics such as mean, proportions, 
and variances will be described for the entire sample. Par-
ticipants will be described in terms of pain duration, average 
length of their consulting time and frequency of visits, and 




1. Patients’ perception of time to recovery. Information 
regarding participants’ perceived time to recovery from 
their current pain problem will be collected.   
2. Supplement intake. Information regarding each par-
ticipant’s intake of complementary medicines or dietary 
supplements (eg, calcium, magnesium, fish oil) and 
alternative medicines (eg, Chinese, herbal, Ayurvedic) 
will be collected, in addition to information regarding 
testing of vitamin D, vitamin D deficiency, and vitamin 
D supplementation. 
Independent variables/confounders
1. Demographic data. Information regarding each partici-
pants’ age, sex, area of residence, education, employment, 
and marital status will be collected.
2. Pain history. Information pertaining to each partici-
pants’ history of current pain problem such as diagnosis 
received, duration, character, and intensity of pain will 
be collected.
3. Pain education. Information regarding method of edu-
cation received, provider of education and influence of 
education on understanding, and management of pain 
will be collected.
4. Goals from pain management. The goals from pain man-
agement are classified into pain related outcomes; quality 
of life and physical functioning. Information pertaining 
to each classification will be collected.
5. Other variables. Information regarding each participant’s 
most recent health care consultation, as well as informa-
tion regarding provision of pain education to their family 
and employers, and its perceived impact on their recovery 
time will be collected. 
Dissemination
The results from this survey analysis will be included as 
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 scientific journals as well as used for conference presenta-
tions. The results of the study will be made available via the 
institutional websites.
Discussion
We aim to better understand whether patients’ perspectives, 
views, and beliefs about their chronic pain management 
are associated, with perception of time to recovery and 
particularly with reference to testing and prescription of 
supplements. Moreover, the study has been promoted inter-
nationally and it is anticipated that the analysis will capture 
the variability of patients’ perceptions and beliefs across 
countries (if the distribution of the sample obtained allows 
subgroup analysis). It is also expected that the results from 
the survey study will provide insight about what patients with 
chronic pain expect from their pain management and how 
these expectations are challenged by the duration of pain, 
the character of the pain, the quality of pain education, and 
support of health professionals. A deeper understanding of 
patients’ perceptions with regards to their pain management 
will enable researchers, policy makers, and health profession-
als to design policies, interventions and prevention strategies 
which are tailored to individual patient needs and are intended 
to improve the treatment outcome. 
This study will also provide information on intake of 
complementary and alternative medicines, dietary supple-
ments, nonpharmacological therapies, and educational 
sources most frequently used by the chronic pain patients for 
managing their pain. It is also anticipated that this evidence-
based knowledge will describe the self-management strate-
gies most frequently implemented by chronic pain patients. 
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1 Demographic Information 
1.1 Age (years) 
☐ 18-30     ☐  31-40      ☐  41-50     ☐ 51-60       ☐ 61-70      ☐  71-80   ☐ 81-90   ☐   90+        
1.2 Sex 
☐ Female                ☐ Male ☐ Prefer not to say 
1.3 Region of residence  
☐ Australia   ☐ North America        ☐ South America      ☐ Europe     
☐ Asia            ☐ Africa                    ☐ New Zealand       
☐ Other (please specify) 
1.4 Level of education  
☐  Primary                   ☐ Secondary     ☐ Tertiary    
☐ Post graduate            ☐ Other education    
1.5 Are you currently employed? 
☐ Yes                             ☐ No ☐ Prefer not to say 
1.6 What best describes your current work status? 
☐ Full time paid employment         ☐ Part time paid employment             ☐ Retired 
☐ Unemployed due to pain             ☐ Unemployed (not pain related)      ☐ Home duties 
☐ On leave from work due to pain   ☐ Studying        ☐ Other 
1.7 What is your marital status? 
☐ Married        ☐Partnered  ☐  Unmarried     ☐ Single      ☐  Prefer not to say 
 
2 Medical History 
 
2.1 Have you received any of the following diagnosis for your current pain problem (tick all 
that apply)? 
☐ Osteoarthritis            ☐ Rheumatoid arthritis            ☐ Fibromyalgia     





☐  Neck pain                 ☐  Migraines                           ☐  Headaches 
☐  Pelvic pain               ☐ No specific diagnosis but experience pain 
2.2 Do you take any of the following supplements for your current pain problem? 
☐ Calcium        ☐  Vitamin D          ☐   Fish oil    ☐ Magnesium      ☐   Ayurveda medicines   
☐ Chinese medicine      ☐  Herbal medicines           ☐ other 
2.3 Do you take any of the following supplements for any other reason? 
☐ Calcium        ☐  Vitamin D          ☐   Fish oil    ☐ Magnesium      ☐   Ayurveda medicines   
☐ Chinese medicine      ☐  Herbal medicines           ☐ other 
2.4 Do you take any of the following supplements because you were advised by a health care 
professional to do so? 
☐ Calcium        ☐  Vitamin D          ☐   Fish oil    ☐ Magnesium      ☐   Ayurveda medicines   
☐ Chinese medicine      ☐  Herbal medicines           ☐ other 
2.5 Have you ever been tested for Vitamin D levels? 
☐ Yes                      ☐ No 
2.6 If yes, have your test results for Vitamin D ever been deficient? 
☐ Yes                     ☐ No    ☐ not applicable 
2.7 If yes, have you ever been told that it may contribute to your current pain problem? 
☐ Yes                    ☐ No     ☐ not applicable 
 
3 The Pain Questionnaire 
 
3.1 Was your current pain problem triggered by an injury? 
☐   Yes                   ☐ No  
3.2 How long has the pain been present? 
☐ Less than 6 months           ☐    6- 12 months       ☐ >12 months  
3.3 What best describes the character of your pain? (tick all that apply) 
☐  Aching       ☐  Burning        ☐ Cold          ☐ Electric shocks   ☐ Dull             ☐    Hot                            
☐  Flushed      ☐   Lightning-like   ☐ Tingling   ☐  Numb     ☐  Pins & Needle ☐ Sharp   





3.4 Over the past 2 days what’s the average severity of your pain on a scale of 1-10 
(0= no pain, 10 = severe/ worst pain) 
☐ 0      ☐ 1       ☐ 2       ☐ 3          ☐ 4        ☐ 5       ☐ 6         ☐ 7           ☐ 8       ☐ 9  ☐ 10 
 
4. Pain experience 
 
4.1 How well do you understand the cause of your pain? 
(0 = I do not understand at all, 10 = I understand very well) 
☐ 0      ☐ 1       ☐  2       ☐  3     ☐  4      ☐  5        ☐  6      ☐  7     ☐  8      ☐  9      ☐  10 
4.2 Have you received any education about your pain? 
☐  Yes                                                      ☐ No  
4.3 If yes, was this education provided in person by any of the following professional?  
☐ General Practitioner ☐  Nurse Practitioner ☐  Pain Physician  ☐  Physiotherapist      
☐ Chiropractor              ☐  Massage therapist    ☐  Pharmacist     ☐other (please specify) 
☐ Not applicable  
4.4 Have you been referred to any of the following types of education material about pain? 
☐  Book     ☐  Website     ☐ video   ☐  YouTube ☐ Audio book   ☐  Smart phone App            
☐   Pamphlets/Brochure     ☐Not applicable 
4.5 What was the most helpful type of education? 
☐  Book     ☐  Website   ☐ video   ☐  YouTube ☐ Audio book   ☐  Smart phone App            
☐  Pamphlets/Brochure   ☐ Not applicable 
4.6 How helpful was this education? (0= not helpful; 5= very helpful) 
☐  0            ☐ 1               ☐ 2            ☐ 3           ☐ 4              ☐ 5 
4.7 Did the education change the way you think about your pain? 
 ☐  Yes                  ☐ No  
4.8 Did the education change the way you manage your pain? 
☐  Yes                  ☐ No  
4.9 Did you receive any information about your pain treatment options? 
☐  Yes                 ☐ No 





☐    0           ☐    1            ☐  2            ☐   3                ☐    4         ☐ 5 
4.11 How satisfied you were about your involvement in the decision about your pain treatment 
strategy? (0= not satisfied all, 10 = very satisfied) 
☐ 0      ☐ 1       ☐ 2       ☐ 3          ☐ 4        ☐ 5       ☐ 6         ☐ 7           ☐ 8       ☐ 9  ☐ 10 
4.12 Regarding the most recent health care consultation for your current pain problem, was the 
appointment duration? 
☐ Too long            ☐ Just right                 ☐ Not long enough   ☐ Not applicable 
4.13 How frequent are your consultations with medical health professional? 
☐Too frequent         ☐Just right              ☐Not frequent     ☐ Not applicable 
4.14 Do you use any non-medicine methods to relieve your pain? 
☐  Yes                                  ☐No 
4.15 If yes, which of the following methods have you used? 
☐Cold pack         ☐  Heat       ☐ Deep breathing      ☐  Meditation   ☐ Listen to music      
☐ Distraction (TV/reading)     ☐ Prayer    ☐ Relaxation ☐Imagery ☐ Visualization  
☐ Massage   ☐Walking           ☐Movement      ☐ Other                   ☐ Not applicable 
4.16 If yes, which have you found helpful? 
☐Cold pack         ☐  Heat        ☐ Deep breathing        ☐  Meditation   ☐ Listen to music      
☐ Distraction (TV/reading)  ☐ Prayer         ☐ Relaxation     ☐Imagery        ☐ Visualization  
☐ Massage      ☐Walking    ☐Movement      ☐ Other   option not applicable 
4.17 At your last consultation where any of the above non-medication methods recommended 
as a way to relieve pain? 
 ☐   Yes                                   ☐No 
4.18 At your last health care consultation, how did you feel? (tick all that apply) 
☐ Understood        ☐ Believed          ☐ Not taken seriously       ☐ Dismissed      ☐ Ignored  
 
5. Outcome expectation 
5.1 How long do you think it will take you to recover from your current pain problem? 
☐   >3 months      ☐   <6 months   ☐   >6 months   
☐   upto 1 year      ☐     >1 year   ☐  Never 





☐ More frequent doctor visits                       ☐ Longer duration of doctor visits       
☐ More education about pain                        ☐ Practical strategies for managing pain     
☐ Learning how to set realistic goals             ☐ More support from health care professionals   
☐ Having a team approach to management   ☐ Training in self-management of pain      
☐ Education about your pain for your family member’s     
☐ Education about your pain for your employer  
5.3 Choose the three top goals you want to achieve from your pain treatment? 
☐ Less Pain                              ☐ No pain                                 ☐ Improved quality of life  
☐ Increase movement              ☐ Improved activity levels       ☐ Improved sleep 
☐ Improved mood                   ☐ Less stress                             ☐ Going back to work 
☐ Increase in social activities   ☐ other 
Table 1 NHMRC Evidence Hierarchy: designations of ‘levels of evidence’ according to type of research question (including explanatory notes) 
 
Level Intervention 1 Diagnostic accuracy 2 Prognosis Aetiology 3 Screening Intervention 
I 4 A systematic review of level II 
studies 
A systematic review of level 
II studies 
A systematic review of level II 
studies 
A systematic review of level II 
studies 
A systematic review of level II 
studies 
II A randomised controlled trial A study of test accuracy with: 
an independent, blinded 
comparison with a valid 
reference standard,5 among 
consecutive persons with a 
defined clinical presentation6 
A prospective cohort study7 
 
A prospective cohort study A randomised controlled trial 
III-1 A pseudorandomised controlled trial 
(i.e. alternate allocation or some 
other method) 
A study of test accuracy with: 
an independent, blinded 
comparison with a valid 
reference standard,5 among 
non-consecutive persons with 
a defined clinical presentation6 
All or none8 All or none8 A pseudorandomised 
controlled trial 
(i.e. alternate allocation or 
some other method) 
III-2 A comparative study with 
concurrent controls: 
▪   Non-randomised, 
experimental trial9 
▪   Cohort study 
▪   Case-control study 
▪   Interrupted time series with a 
control group 
A comparison with reference 
standard that does not meet the 
criteria required for 
Level II and III-1 evidence 
Analysis of prognostic factors 
amongst persons in a single 
arm of a randomised 
controlled trial 
A retrospective cohort study A comparative study with 
concurrent controls: 
▪    Non-randomised, 
experimental trial 
▪    Cohort study 
▪    Case-control study 
III-3 A comparative study without 
concurrent controls: 
▪   Historical control study 
▪   Two or more single arm 
study10 
  ▪  Interrupted time series without a 
parallel control group 
Diagnostic case-control 
study6 
A retrospective cohort study A case-control study A comparative study without 
concurrent controls: 
▪    Historical control study 
▪    Two or more single arm 
study 
IV Case series with either post-test or 
pre-test/post-test outcomes 
Study of diagnostic yield (no 
reference standard)11 
Case series, or cohort study of 
persons at different stages of 
disease 
A cross-sectional study or 
case series 
Case series 
